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Abstract
Due to the importance of the antigen/ antibody reaction, all hos-
pitals and blood banks worldwide rely on routine blood group
phenotyping of samples. Using recombinant antigens removes
the disadvantage of the current antibody screening when using
the human red blood cells, which can complicate the detection of
antibody in different cases: in the case of multi-transfused indi-
viduals and in the case of weak antigens. Although constructing
recombinant antigens for some blood group antigens has been
achieved successfully, such as; Kell, Duffy and Lutheran blood
group antigens, no studies have been published describing suc-
cessful production of RH recombinant antigens in a prokaryotic
expression system. Rh proteins are conserved across many dif-
ferent species.
The aim was to construct a hybrid Rh protein comprised of a
Nitrosomonas europaea (N. europaea) Rh50 backbone contain-
ing different external loops of the human RhD protein.
Human RhD external loop 6 was the most suitable candidate
to start with due to its location between highly conserved do-
mains of the protein. The hybrid gene for the NeRH50”human
RHD was sub-cloned into an expression vector (pET) and trans-
formed in BL21 (DE3) competent E. coli. We constructed three
other hybrid genes with RhD human external loops on a NeRh50
backbone: loops 4, 6; loops 3, 4, 6 and loops 2, 3, 4, 6.
14
Hybrid recombinant constructs were successfully expressed in
the E. coli membrane as shown with western blot, flow cytome-
try, and transmission electron microscopy by the use of different
commercial/ customized monoclonal and polyclonal antibodies
against D epitopes in human RhD proteins and NeRh50 like
protein. Due to a lack of time, testing human sera against the
recombinant antigens was not possible. However, the approach
utilised in this study may lead to a new diagnostic assay whereby
the expression of human RhD external loops in E. coli may be
capable of detecting specific anti-Rh antibodies in patient serum.
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kb . . . . . . . . . . . . . . . . . . kilobases
LR-PCR . . . . . . . . . . . long-range polymerase chain reaction
mRNA . . . . . . . . . . . . . messenger RNA
MFI . . . . . . . . . . . . . . . . mean fluorescence intensity
NCBI . . . . . . . . . . . . . . National Centre for Biotechnology Information
NGS . . . . . . . . . . . . . . . next-generation sequencing
PCR . . . . . . . . . . . . . . . polymerase chain reaction
RBC(s) . . . . . . . . . . . . red blood cell(s)
RFLP-PCR . . . . . . . restriction fragment length polymorphism- poly-
merase chain reaction
RNA . . . . . . . . . . . . . . . ribonucleic acid
RT-PCR . . . . . . . . . . . real time PCR
SBT . . . . . . . . . . . . . . . . sequencing-based typing
SCD . . . . . . . . . . . . . . . sickle cell disease
SNPs . . . . . . . . . . . . . . single nucleotide polymorphisms
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SNV . . . . . . . . . . . . . . . single nucleotide variant
TEM . . . . . . . . . . . . . . . Transmission Electron Microscopy
TM . . . . . . . . . . . . . . . . Transmembrane
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Amino Acids List
Alanine . . . . . . . . . . . . Ala
Arginine . . . . . . . . . . . Arg
Asparagine . . . . . . . . Asn
Aspartic acid . . . . . . Asp
Cysteine . . . . . . . . . . . Cys
Glutamic acid . . . . . Glu
Glutamine . . . . . . . . . Gln
Glycine . . . . . . . . . . . . Gly
Histidine . . . . . . . . . . His
Isoleucine . . . . . . . . . . Ile
Leucine . . . . . . . . . . . . Leu
Lysine . . . . . . . . . . . . . Lys
Methionine . . . . . . . . Met
Phenylalanine . . . . . Phe
Proline . . . . . . . . . . . . . Pro
Serine . . . . . . . . . . . . . . Ser
Threonine . . . . . . . . . Thr
Tryptophan . . . . . . . Trp
Tyrosine . . . . . . . . . . . Tyr





1.1 Mammalian Red Blood Cells
Red blood cells (RBCs) are bright red, doughnut shaped, enu-
cleated eukaryotic cells present in the peripheral circulation and
circulate the body to supply oxygen (O2) to the organs and
transport carbon dioxide (CO2) to the lungs, and are the most
numerous cell type in the body. Moreover, RBCs able to trans-
port nutrients, waste products, and hormones. RBCs are pro-
duced in the Bone Marrow (BM) and stay in the circulation for
about 120 days (Yawata, 2003).
The plasma membrane or cell membrane of RBCs (erythro-
cytes), which is a thin semi-permeable membrane is easy to
isolate and use as a model to study the membrane structure
and to perform biochemical analyses for the membrane’s com-
ponent, due to the lack of both nuclei and internal membranes
(Gorter & Grendel., 1925).
The red cell membrane is highly dynamic and has a compli-
cated structure. It is composed of an asymmetrical lipid bi-
layer, which makes 40% of the red cell membrane, almost 10%
carbohydrates, and 50% are proteins both transmembrane pro-
teins, and a filamentous meshwork of proteins, which forms a
membrane skeleton along the entire cytoplasmic surface of the
plasma membrane.
The 40% lipids of the red cell membrane are classified into phos-
pholipids (PL) (60%), neutral lipids (30%) mainly cholesterol,
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and glycolipids (10%). Phosphatidylcholine (PC) (31%) is the
major phospholipid in the red cell membrane. However, phos-
phatidylethanolamine (PE) (29%), sphingomyelin (SM) (26%)
and Phosphatidylserine (PS) (13%) are presented in the red cell
membrane (Yawata, 2003).
The phospholipids play a role in the structure of the membrane
and are thought to be important in the maintenance of red cell
shape. The most important thing about phospholipids is that
PS is located in the inner leaflet of the membrane in normal
haemostasis, but it will switch to the outer leaflet of the mem-
brane in non-healthy conditions such as aged, infected, or sen-
sitised red cells (Pinder et al.,1978; Lang et al., 2012)
1.1.1 Major RBC Membrane Proteins
Due to the presence of the long twisted alpha and beta spectrin
strands and actin filaments, the plasma membrane is linked to
the RBC’s cytoskeleton (Pinder et al.,1978). Moreover, another
link is provided by band 4.1, which binds to the junctions of
spectrin and actin, as well as to glycophorin proteins.
The importance of the RBCs component interaction is to achieve
the critical functions of the RBCs such as; transporting elec-
trolytes from the RBCs to the plasma or vice-versa, and main-
taining the RBCs shape and their elasticity and stability.There
are two ways to show the interaction between the important
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RBCs proteins component on the cell membrane: vertical inter-
action, which mediated by protein 4.1R that couples the junc-
tional complex to Glycophorin C and horizontal interaction,
which is mediated by ankyrin that couple spectrin to Band 3
(Figure 1.1).
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Figure 1.1. Interaction between the Red Cell Membrane Components:
This figure shows how these proteins interact with each other to achieve the criti-
cal functions of the RBCs such as; transporting electrolytes from the RBCs to the
plasma or vice-versa, and maintaining the RBCs shape and their elasticity and sta-
bility. There are two types of interaction within the Red cell membrane; a vertical
interaction is the main reason for the extreme elasticity of the red cell membrane.
This type of a interaction occurs between Band 3, and the Rh core complex has
interactions with Ankyrin. The other kind is the horizontal interactions where
the spectrin dimers and protein 4.1R with phosphatidylserine, a cytoplasmically
localised phospholipid, also occur.
Adapted from Avent (2018).
To demonstrate the importance of the transmembrane proteins
and the interactions within the plasma membrane and the cy-
toskeleton components, any defect or mutation in them will af-
fect both the shape and the function of the RBCs and can lead
to many disorders, such as anaemia.
RBCs membrane proteins are classified into three different
categories based on their function. Firstly, integral proteins,
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these proteins are firmly attached to the membrane and act as
the main transport channel such as; Glycophorin and Band 3
protein.
Secondly, peripheral proteins, cortical cytoskeleton components,
which lie underneath the membrane and form a meshwork all
over the membrane and determines cell shape, the most abun-
dant; spectrin. Other peripheral membrane proteins of red blood
cells; actin, ankyrin, and band 4.1R.
Thirdly, the anchoring proteins, which maintain the mem-
brane structure such as Ankyrin (Von Heijne, 2006) (Figure 1.2).
1.1.1.1 Glycophorin
Glycophorin is a small integral glycoprotein, consisting of 131
amino acids with a molecular weight of about 30,000. Gly-
cophorins were one of the first identified transmembrane pro-
teins, they play important roles in maintaining and stabilizing
the membrane shape of RBCs. Moreover, glycophorin is rich of
sialic acid which gives the surface of RBCs a polar charge that
assists in the movement of RBCs.
Glycophorins A and B are single transmembrane α helix of 23
amino acids, it is heavily glyocosylated, with oligosaccharides,
which exposed on the plasma cell surface, attached to 16 sites
on the extracellular portion of the polypeptide chain.
Glycophorin C (GPC) and glycophorin D (GPD) interact with
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protein 4.1R, contributing stability to RBC membrane (Alloisio
et al, 1993; Marfatia et al, 1994).
1.1.1.2 Band 3 Complex
Band 3 is a glycoprotein and considered the major integral pro-
tein in the membrane and it is known as anion exchanger (AE1),
with a molecular mass of 100 kDa on SDS-PAGE. Band-3 is
composed of 911 amino acids and the gene (EPB3 ), which is
responsible for AE1, is located on chromosome 17.
There are 1-2 million copies of AE1 per red blood cell membrane,
it consists of three domains, an N-terminal domain, a short
C-terminal domain, and membrane-spanning domain acts as a
chloride/ bicarbonate exchange anion exchange channel (Bruce
et al., 2003).
Band 3 carries out the one to one exchange of bicarbonate
(HCO3-) for Chloride (Cl-) ions, transport of which can be re-
versed due to pH changes (Bohr shift). HCO3- is transported
into the red cell in metabolising tissues, and out of the red cell
in the lungs.
However, the band 3 complex not only attaches to the lipid bi-
layer membrane, but also interacts with other major membrane
protein such as Ankyrin, Spectrins, and Protein 4.1R to main-
tain the structure of RBCs.
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1.1.1.3 Ankyrin
Ankyrin is one of the primary anchoring membrane proteins in
the RBC membrane. There are 1.2 million copies in RBC. It
has a molecular weight of 206 kDa on SDS-PAGE. Ankyrin is
a polar protein and is involved in the local segregation of inte-
gral membrane proteins. It contains three domains; N-terminal
domain that is connected to AE1 while the heavily phospho-
rylated central domain is connected to spectrins and an acidic
C-terminal domain (Bennett & Baines., 2001).
Ankyrin plays an important role in linking the plasma mem-
brane with the cytoskeleton by binding to both spectrin and
band 3.
1.1.1.4 Spectrins
Spectrins are the largest proteins of the RBCs membrane skele-
ton, composing of 75% of the membrane skeletal proteins and
present at a concentration of about 200,000 copies per red cell.
Spectrins are composed of two subunits, α-Spectrin and β-Spectrin.
Each one of the spectrins is located on a different chromosome
and has a different gene. α-Spectrin gene is SPTA1 and located
on chromosome 1 at position 1q22-q23 while β-Spectrin gene
is SPTA 2 and located on chromosome 14 at position 14q23-
q24.2.
Spectrin proteins form the inner shell of the RBC membrane
and are considered to be one of the major determinants of RBC
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shape due to their flexibility, which can change the RBC mem-
brane shape and so, any defect in this protein, leads to abnormal
RBC membrane shape and some blood disorders.
1.1.1.5 Protein 4.1 R
Protein 4.1R is composed of 588 amino acids and is present at
the concentration of approx. 200,000 copies per red cell. Pro-
tein 4.1R is an essential phosphoprotein within cell membranes.
It has a molecular weight of 66 kDa, but on SDS-PAGE it mi-
grates to 80 kDa. Protein 4.1R gene (EPB41 ) is located on
chromosome 1p36.1 (Delaunay 1995; Yawata, 2003).
1.1.1.6 CD47
CD47 is also known as Integrin-associated protein (IAP). CD47
is a 47-52 kDa transmembrane receptor with five membrane
spanning segments. It is a member of the immunoglobin (Ig) su-
perfamily and has a highly glycosylated extracellular immunoglobin
variable domain (IgV) at the N-terminus and five isoforms at
the C-terminus. CD47 acts as a marker of self on the surface of
RBCs to prevent phagocytosis by binding to Signal Regulatory
Protein α (SIRPα). On senescent RBCs, CD47 levels drop and
the immune system engulfs these cells and clears them from the
circulation (Avice et al., 2001).
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Figure 1.2. Red Cell Membrane Protein Components:
This figure shows part of the important Red Cell membrane components and
membrane skeleton. The major RBC membrane components are Band 3 and
Glycophorin C (GPC) they appear to be in higher quantity (1,100,000 and
200,000 copies per red cell) respectively, than the other protein members. Next,
the Rh trimer complex, which consists of two RhAG and one RhD or RhCE, this
complex has approximately 100,000 copies per red cell.
Adapted from eClinPath.com, Cornell University,
http://eclinpath.com/hematology/physiology/erythrocytes/f2-large/
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1.2 Blood group antigens
In 1901, blood groups were identified by an Austrian scientist,
called Karl Landsteiner. Moreover, he developed a blood group
classification system based on the presence of agglutinin fac-
tors in the blood. This test was based on his observation of
clump formation in the individual isolated plasma, which iden-
tified later as ‘agglutination’ in a paper titled as Agglutination
phenomena of normal human blood, which led to identify three
antigens of the ABO blood group system (A, B, and O). Later in
1902, a fourth antigen (AB) was discovered by Decastello and
Sturli, respectively (Landsteiner, 1961, Levine, 1961, Schwarz
and Dorner, 2003, Giangrande, 2000). Furthermore, in 1937,
the blood transfusion patient’s death rate were reduced due to
the discovery of Rhesus factor by Landsteiner and the help of
another scientist, Alexander S. Wiener (Landsteiner & Wiener,
1940; Landsteiner & Wiener, 1941).
The blood group systems and their antigens are classified accord-
ing to The International Society of Blood Transfusion (ISBT)
nomenclature system. Currently, there are 39 blood group sys-
tems (Table 1.1).
Erythrocyte membrane components are critical in defining the
blood group systems, each of the blood groups are characterised
by specific antigens, which can be defined as inherited polymor-
phic markers present on the RBCs external membrane and can
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be detected serologically by specific antibodies. These antigens
can trigger an individual’s immune response by the synthesis of
corresponding antibodies, which occur normally after the indi-
vidual is exposed to antigens; either from the environment or
alloimmunisation during blood transfusion or pregnancy for in-
dividuals who lack these antigens (Reid et al., 2012, Daniels,
2013).
These antigens are either protein or carbohydrate molecules at-
tached to protein or lipid of the RBC membrane forming pro-
tein, glycoprotein, or glycolipid structures (Reid and Mohan-
das, 2004; Daniels, 2005). There are two major classifications
in order to define blood groups according to their antigens.
Firstly, the carbohydrate antigens, which are synthesised by
glycosyltransferases enzymes that are responsible for transfer-
ring a monosaccharide moiety from an active nucleotide sugar,
which is called a glycosyl donor to nucleophilic glycosyl accep-
tor molecule. Secondly, the protein antigens, where any alter-
ation or changing the sequence or configuration of the protein
or indeed the complete loss of RhD and Fy, which is the Duffy
antigen, is critical and causes recognition as an antigenic deter-
minant.
Five blood group systems are defined by carbohydrate structures
(ABO, H, P1Pk, I, GLOB); two are obtained from the plasma
(LE, CH RG). The remaining are characterised by the protein
sequence of the RBC membrane proteins. Moreover, major pro-
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teins are: (DI, RH, RHAG, MNS, GE, and CO) most of them
are expressed, and their function is membrane transporters, ex-
cept MNS and GE which function as sialic acid carriers and
membrane receptors (Table 1.1).
In the following section some of the major and minor blood
group antigens are discussed, given their importance in transfu-
sion and haemolytic disease.
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The first blood group system discovered and the most important
blood group in transfusion and transplantation. This system is
based on the carbohydrate antigens (N-Acetylgalactosamine and
galactose).
This system can be divided into four categories: A, B, AB,
and O. The individuals with B group have antibodies against
A present in their blood circulation, and individual’s with A
group have antibodies against B present in their blood circula-
tion. While people with group AB have both A and B antigens
but no antibodies in their serum. Moreover O individuals have
H antigens and have both antibodies in their blood circulation.
These antigens can be expressed on the RBCs membrane ad-
ditionally to some other cells (Anthea et al., 1993, Yamamoto,
2004, Storry and Olsson, 2009).
Anti-A and anti-B are produced in the early years of life. The
first explanation of presence for these antibodies, is as a conse-
quence of exposure to environmental substances, such as food,
bacteria, and viruses and the production of these antibodies is
due to the similarity of these environmental substance epitopes
to A and B glycoprotein antigens. Moreover, the other possible
explanation of the presence for anti-A and anti-B in individual’s
serum is due to the presence of A and B antigens in human gut
flora and, thus leading to the production of anti-A and anti-B
(Carel, 2004).
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Early 1980s, at the NewYork Blood Center, Goldstein and his
colleagues successfully created a H group antigen from blood
group A and B by using a specific exo-glycosidases capable of
removing the immunodominant sugar residues. Thus, able them
to reduce the mismatching error that happened after having an
incompatible blood transfusion, which lead to fatal transfusion
reactions, moreover, creating a universal blood supply.
In 2000, Kruskall and his colleagues were successfully utilizing
a recombinant enzyme-converted group-B-to-group-O (ECO).
They conclude that ECO RBCs were comparable to group O
cells for safety and efficacy.
1.2.2 RH System
The RH system is the second most important blood group sys-
tem after ABO system. It is based on protein antigens; most
major antigen is D. It can cause Haemolytic disease of the fe-
tus and newborn (HDFN) when the blood of the mother is in-
compatible with her fetus, and haemolytic transfusion reactions
(HTR). In this thesis we will discuss this blood group system in
more depth. See later in introduction.
1.2.3 Kell (KEL) System
In 1946, Kell blood group system was named after Mr. Kelleher,
who was the first producer of its antibody (Coombs et al., 1946).
Kell blood group system is considered to be the third most clin-
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ically important blood group system and the sixth blood group
system (006) according to the ISBT. The Kell glycoprotein is
a transmembrane, single-pass protein with an enzymatic func-
tion that carries the Kell antigens. This system is highly poly-
morphic, it consists of 35 antigens, which all expressed on the
surface of the Kell glycoprotein on the RBCs membrane, on
haematopoietic tissue and some other tissues such as; brain,
lymphoid organs, heart and skeletal muscle (Kaitaet al., 1959;
Russo et al., 2000; Daniels et al., 2007; Reid et al., 2012).
Anti-K (KEL1) causes severe HDFN and HTR (Vaughan et
al., 1998; Daniels et al., 2003). Additionally to other antigens
including; k (KEL2), Kpa (KEL3), Kpb (KEL4), Jsa (KEL6) and
Jsb (KEL7), which have the ability to stimulate the production
of haemolytic antibodies and causing HDFN (Daniels, 2002).
1.2.4 MNS Antigen System
In 1927, Landsteiner and Levine described the MNS Antigen sys-
tem, which consists of 48 antigens. The responsible genes are:
Glycophorin A and Glycophorin B. Anti-M and anti-N antibod-




Glycophorin C (GPC), 128 amino acid residues and glycophorin
D (GPD), 107 amino acid residues, which are both encoded by a
single gene. GYPC, is the responsible protein to express the Ger-
bich blood group system with 11 antigens. The high dominance
antigens are; Ge2, Ge3, Ge4, GEPL [Ge10*], GEAT [Ge11*],
GETI [Ge12*] (Alloisioet al., 1993; Reid& Spring, 1994; Marfa-
tiaet al., 1994).
Gebrich antigens act as receptors for the malarial parasite
Plasmodium falciparum. Anti-Ge2 and anti-Ge3 have caused
hemolytic transfusion reactions, and anti-Ge3 has produced HDFN.
1.2.6 Duffy System
The Duffy System is also known as Fy glycoprotein, CD234. It
presents and is expressed on the surface of RBCs and other tis-
sues such as; kidney, lung, liver, spleen, brain (Iwamoto et al.,
1996) and colon (Chaudhuri et al., 1997). Antigens Fya and Fyb,
which are located on the Duffy glycoprotein, can result in four
possible phenotypes, namely Fy(a+b-), a Fy(a+b+), Fy(a-b+),
and Fy(a-b-). The antibodies against this system are predomi-
nantly IgG subtype (Tournamille et al., 1995).
The Duffy glycoprotein is a receptor for cytokines, which are
chemicals that are secreted by white blood cells during inflam-
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mation. Moreover, it acts as a receptor for Plasmodium vivax,
a parasite causes malaria. RBCs with Duffy antigens deficiency
are relatively resistant to invasion by Plasmodium vivax.
Duffy blood group system antibodies can cause haemolytic trans-
fusion reactions (Boyland et al., 1982; Sosler et al., 1989) and
HDFN (Vescio et al., 1987; Goodrick et al., 1997).
Ridgwell et al, in 2007 successfully produced soluble recombi-
nant blood group antigens; Duffy blood group antigen was one
of them. In this study they prove that the soluble recombinant
blood group antigens can mimic blood group antigens and react
with human allogeneic antibodies.
1.2.7 Lutheran System
Lutheran (Lu, B-CAM, CD239) blood group antigens are car-
ried by membrane glycoproteins (Campbell et al., 1994), which
are a member of the immunoglobulin gene superfamily (IgSF)
(Parsons et al., 1995). It is expressed in RBCs membrane and
other tissues (Reid & Lomas-Francis, 2012).
Lutheran blood group antigens are involved in a mild type
of haemolytic transfusion reactions (Daniels, 2002) and rarely
involved in HDFN (Inderbitzen et al., 1982).
1.2.8 Kidd (JK) System
Kidd antigens, which are also known as Jk antigen is a glyco-
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protein. The Kidd protein is expressed on the RBCs membrane
and kidney tissues and acts as a urea transporter in RBCs and
renal endothelial cells. This system consists of 3 antigens: Jka,
Jkb and Jk3.
Although Kidd antibodies are rare, they can cause severe trans-
fusion reactions.
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1.3 History of Rh Blood Group
In 1939, the Rh system was clinically described in a historic
paper written by Levine and Stetson for a case of miscarriage,
where the fetus had been lost due to a haemolytic reaction after
a blood transfusion from her husband. They assumed that the
mother’s serum was immunised by her fetus, which had inher-
ited this newly described antigen from their father.
In 1940, Rhesus red cell factor was described by Landsteiner and
Wiener (Landsteiner & Wiener, 1940; Landsteiner & Wiener,
1941). It is considered as one of the most immunogenic and
polymorphic blood grouping systems (Levine et al., 1941). In
fact, Landsteiner & Wiener had described anti-LW which shows
different degrees of reactivity against RhD positive and negative
red cells.
The Rh system comprises 56 antigens, five of them are the most
important; (D, E, e, C, c) (Conroyet al., 2005). The presence
or absence of the D antigen from RBCs surface can distinguish
between Rh positive (in the presence of D antigen) or Rh nega-
tive (in the absence of D antigen) (Colin et al., 1991). Moreover,
the RHCE gene is related to C/c and E/e epitopes, and they
represent other polymorphisms of the Rh complex.
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1.4 Molecular Aspects of Rh
The Rh family includes three erythroid gene members: RHD,
RHCE, and RHAG (Matassi et al., 1999) and two non-erythroid
proteins RhBG and RhCG (Huang et al., 2000). The erythroid
genes are involved in forming the essential complex of Rh antigen
expression and red blood cell membrane integrity (Huang, 1998).
RHD and RHCE are located at the RH locus on chromosome
1p34-1p36 (Cherif-Zahar et al., 1991; Matassi et al., 1999), while
RHAG is present on chromosome 6p12- 6p21(Cherif-Zahar et al.,
1991; Matassi et al., 1999).
Three genes are expressed in the erythroid lineages (Van Kim
et al., 2006). RHD positive locus is composed of not only RHD
but also the RHCE gene (Van Kim et al., 2006). Both RHD
and RHCE genes have ten exons, share comparable exon/intron
organisation, and can encode different proteins (Matassi et al.,
1999; Westhoff, 2004). genes,
The differences between RHD and RHCE, although they are
located on the same chromosome, they are orientated in opposite
directions (RHD 5’ to 3’, RHCE 3’ to 5’). They carry different
antigens (D, CE), respectively (Van Kim et al., 2006) (Figure
1.3).
Moreover, Rh family include other two non-erythroid members,
which are RHBG and RHCG which are mainly expressed in the
liver and kidney, one of their functions is related to ammonia
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genesis and excretion (Avent et al., 2006; Van Kim et al., 2006).
Figure 1.3. RHD and RHCE genomic structure in different status:
RHD and RHCE genes are located on chromosome 1p36.11, with 10 exons of each
and opposed direction RHD 5’ to 3’ while RHCE is 3’ to 5’. A it shows both RHD
and RHCE genes in the D positive individuals. In B the RHD pseudo-gene (RHD
ψ) it shows a 37bp duplication insert between exon 3 and 4 of RHD. There are
three missense mutations in exon 5 and a nonsense mutation in exon 6, which stop
the protein being expressed. In this case, the individuals still have normal RHCE
gene. In C, D-negative shown where there is a complete deletion of the RHD gene
with normal RHCE gene. This case commonly appears in Caucasian.
Adapted from Avent, 2018
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In 2000, Singleton et al. studied 98 blood samples from a mixed
race of black African donors to screen for the RHD pseudogene
(RHDψ) (Figure 1.3). Three samples out of the 98 samples were
D-negative samples while the rest were D-positive samples. The
screening results show 14 samples out of the total number of
samples have the RHD ψ. Finding the difference between the
RHD and RHDψ, the exons and introns of both genes were se-
quenced.
The result of this sequencing of some D-negative Africans sam-
ples showed the existence of the RHD gene, but no mRNA was
produced due to an additional 37bp insertion, which causes a
stop codon at position 210. This 37 bp is a duplication of a
sequence spanning the intron3- exon 4 boundary.
Secondly, the sequencing of the RHD ψ exons 1, 3-7, and 10
showed more alterations within the RHD gene. For example
exon 4 has a mutation from point G to A at nucleotide 609.
Thirdly, the sequencing showed some missense mutations in ex-
ons 3 and 5 encoding Met 218 Ile, Phe 223 Val, and Ser 225 Phe
substitutions. Fourthly, in exon 6, the sequencing showed an
alteration in the nucleotide 807 from T to G, which translates
as a stop codon.
Finally, Singleton et al. concluded that the inactive RHD gene
would be referred to here as RHD ψ. Moreover, there are more
conclusions in this study such as; they found that about two-
thirds of D-negative Africans have an inactive RHD gene.
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While the remaining third is divided into two groups; one char-
acterised by homozygous RHD deletion and the other group is
characterised by having theRHD-CE-Ds hybrid gene, which is
capable of producing c, C, e but not D. Also, the D-negative
African Americans and South African people of mixed race are
having the same 3 genetic backgrounds, but with different per-
centage.
24% of African Americans have the RHD ψ, and 17% of South
African donors of mixed race have RHD ψ, while 81% of South
African donors of mixed race and 54% of African Americans,
81% of South African donors of mixed race have no RHD. Sin-
gleton et al., 2000 found that 66 percent of donors had the RHD
ψ, 18% completely lacked the RHD, and 15 percent had the hy-
brid RHD-CE gene that is linked to the positive and negative
phenotype.
Moreover, most RHD negative cases in Caucasians (Mourant et
al., 1976; Tills et al., 1983) are caused by a deletion of the RHD
gene with no molecular change in the RHCe gene (Colin et al.,
1991; Faas et al., 1995; Avent et al., 1997).
In non-Caucasians, the individuals can have the RHD negative
phenotype while they carry the entire RHD gene (Daniels et al.,
1997; Okudaet al., 1997).
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1.4.1 Rhnull Syndrome
Rhnull is an inherited haemolytic disease, where the RBCs look
abnormal morphologically and are dysfunctional (Schmidt et al.,
1967; Schmidtl et al., 1969). Rh null can cause some degree of
haemolytic anaemia due to the abnormality in the organisation
of their RBCs membrane phospholipids (Kuypers et al., 1984).
Rhnull RBCs membrane shows more cation permeability than
the normal RBCs (Lauf et al., 1976).
Rhnull has two types; Amorph type and Regulator type; and it’s
related to completely deficient in RhD and RhCE proteins. The
deficiency caused by molecular changes (silencing mutations) in
RHCE associated with deletion of RHD, which lead to the lack
of Rh proteins expression (Chown et al., 1972). However, RhAG
is still expressed in small amounts (Cherif-Zahar et al., 1998;
Huang et al., 1998). Regulator type is related to a molecular
defect in RHAG gene (Chérif-Zahar et al., 1996).
The importance of theRHAG in the regulator type is the asso-
ciation of the presence of this gene with the expression of Rh
antigens (Chérif-Zahar et al., 1996; Avent et al., 2000).
There is an interaction between the Rh protein complex and
other protein members of the RBC membrane such as Gly-
cophorin B (GPB), CD47 or integrin-associated protein (IAP),
and Landsteiner-Wiener glycoprotein (ICAM-4)(LW) (Cartron
et al., 1994).
Both Rhnull types have shown a reduction in GPB (Dahr et al.,
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1987; Avent et al., 1988), is considered as a major sialoglyco-
proteins RBCs membrane component can be linked to the MNS
and SC blood groups respectively.
According to Von dem Borne et al (1990), they noticed the
different in the Rh glycoprotein N-glycan chains size between
the the normal RBCs and the Rhnull RBCs by using anti-RhAG
MoAb 2D10 with co-precipitation techniques. In normal RBCs
that were GPB-deficient, the Rh glycoprotein N-glycan chains
size were increased while the size of this chain was reduced in the
Rhnull RBCs. The molecular weight difference is due to faster
moving of the Rh glycoprotein chain in the Rh null RBCs through
intracellular membranes to the cell surface. Moreover, they con-
firmed that both GPB and the Rh30 polypeptides interact with
the Rh glycoprotein during the biosynthesis of the Rh complex.
The RBC membrane of the Rhnull individual has shown a the
reduction of CD47 compared to healthy RBC membranes (Miller
et al., 1987; Avent et al., 1988; Lindberg et al., 1994). The
role of CD47 is associated with the prevention of phagocytosis
of RBCs. It functions as a self-marker by binding to signal
regulatory protein an alpha (SIRP a) on macrophages, to create
a negative signal that can reduce the “eat me” signal and protect
the RBCs from engulfment (Oldenborg et al., 2000).
According to some studies, in Rhnull patients, NH3 permeation
cannot be measured directly from the RhD and RhCE due to the
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absence of the RhAG; both RhD and RhCE cannot be expressed.
Furthermore, there are two different experiments show the role
of the RhAG in transporting the NH4
+ (Westhoff, 2006).
1.5 Rh Proteins
The Rh protein family is divided into two main categories; non-
glycosylated and glycosylated (Eyers et al., 1994).
Non-glycosylated protein group contains; RhD and RhCE with
417 amino acids (416 amino acid mature protein as the N-
terminal methionine is cleaved), which associate with another
protein located in the red blood cell membrane such as (RhAG)
(Conroy et al., 2005).
The molecular weight of RhD and RhCE proteins is 30 kDa,
while the (Rh-50) consist of RhAG glycoprotein which measured
40-100 kDa on SDS-PAGE with 409 amino acid residues (Eyers
et al., 1994). RhCe and RhD are very homologous; they differ
in just 35-36 amino acids (Avent et al., 1990; Cherif-Zahar et
al., 1990).
The important region in the RhD protein, which has the confor-
mational difference to the RhCE protein is, the predicted third,
fourth and sixth external loops of the RhD polypeptide (Liu et
al., 1999 a). The alteration on these amino acids will affect the
creation of the D epitopes.
The Rh complex (RhD, RhCE, RhAG, and CD47) is located
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embedded in the phospholipid bilayer of the RBCs membrane.
Rhnull cases were studied in order knowing the location and the
function of this complex (Cartron, 1999; Huang et al., 2000).
Moreover, it shows that the Rh complex is connected to the
actin-spectrin-based RBCs membrane skeleton, presumably via
RhD, RhCcEe, RhAG and/or CD47 (Figure 1.1).
In 1994, Eyers’s group proposed that erythrocyte Rh assembly
is a RhAG2 Rh-30 2 tetramer. The tetrameric model of Rh
complex is created by the interacting of RBCs membrane gly-
coproteins components such as LW, CD47 and GPB (Cartron,
1994).
In 2005, Conroy et al., proposed a model of the human Rh pro-
teins, RhD and RhAG by using one of the Escherichia coli am-
monia channel AmtB proteins (ammonia transporters) in bac-
teria as a template. Moreover, they used the predicted tertiary
structure of Rh proteins and the available biochemical data for
the Rh proteins.
The conclusion of this study leads to suggest that the erythro-
cyte Rh complex is trimeric (Figure 1.4).
According to the model, they suggested that RhAG and the ho-
mologous non-erythrocyte Rh glycoproteins, RhBG and RhCG,
have very similar channel architecture to AmtB.
According to Rh topology prediction, it is believed the Rh pro-
teins have 12 transmembrane spanning domains with intracellu-
lar N and C-termini, unlike the AmtB member family, which has
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Figure 1.4. The predicted trimeric structure of the Rh complex.
This structure was predicted based on the E. coli AmtB and human RhCG crystal
structures. It is composed of 2 molecules of RhAG and one molecule either RhD
or RhCcEe. The dimension of each monomer is around 46 A. The red residues
show the critical amino acid in the epitope of external loop 4, while the purple
residues show them in external loop 6. The transmembrane -helices are numbered
from (M0 to M11).
Adapted from Callebaut et al., (2006).
11 transmembrane domains (Cherif-Zahar et al., 1990; Avent et
al., 1992) (Figure 1.5).
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Figure 1.5. Topology of the human RhD protein:
Twelve transmembrane domains are shown with six external loops, the arrows
show the 2, 4, 6 (left to right) external loops of the human RhD and their critical
amino acid. The black coloured circle shows the equivalent residues to the His
those present in the AmtB (Tyr173, Phe316). The red circle at position (353Gly)
is representing the proteolytically susceptible area. The cyan coloured circles are
related to the critical position residues in the channel. The yellow coloured circle
is for the surface exposed (Cys). The orange, purple, green, and blue coloured
circles show the epitopic residues. Adapted from Conroy et al.,(2005).
In RBCs, the most important probable function of RhAG is to
detoxify the organs: such as the liver and the kidney by trans-
porting NH3 and/or NH4
+.
The role of RhAG in the non-erythroid tissues would be to reg-
ulate the acid-base balance (Van Kim et al., 2006). Comparing
the Rh proteins models: the RhAG protein model has a central
region occupied by histidine amino acids. Although, in both
RhD and RhCE proteins, these histidines are replaced by other
amino acids (tyrosine and phenylalanine); histidine number 185
is substituted with tyrosine and histidine number 344 is replaced
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by phenylalanine (Javelle et al. 2006).(Figure 1.6).
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Figure 1.6. The 2-Dimensional structure of the human RhD and RhCE proteins.
The blood group active Rh proteins, RhD and RhCcEe both have 12 membrane
spanning segments. It shows the similarity between them and the difference. Both
of them comprise of 10 exons, and they share similar amino acid except for (35 or
36 depending on RhCE status) changes between RhD and RhCcEe. The yellow
circles in RhCcEe protein show the critical amino acids, which can distinguish
between the (Rh C and Rhc) / (RhE and Rhe).
Adapted from Avent (2018).
The role of the first histidine pore is a prerequisite in transport-
ing the methylammonium (Javelle et al., 2006). RhD and RhCE
are not involve in ammonia transport but may be evolving a new
function in the RBC membrane (Westhoff & Wylie, 2006).
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1.6 RH polymorphisms
The Rh system has two related genes, the RHD gene that en-
codes the RhD protein, which expresses the D-antigen while the
RHCE gene that encodes RhCE protein, which is carrying mul-
tiple specific (C, c, E, and e) antigens (Mouro et al., 1993). All
Rh system antigens arise from either RhD and RhCcEe polypep-
tides or hybrid molecules caused by an exchange between the
RHD and RHCE genes.
There are two nomenclature systems for the Rh system: Fisher
and Race developed the first one while Wiener developed the
second one. Both systems were named after their discoverers,
and they reflect the inheritance theories (Fisher & Race, 1944;
Wiener 1949).
The Fisher-Race system is more frequently in use in blood bank-
ing, it is based on CDE nomenclature while the Wiener system
uses the R, r nomenclature (Table 1.2).
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Table 1.2. The haplotype nomenclature of RHD and RHCE genes:
According to The Fisher-Race and Wiener systems and it shows the D positive
nomenclature is shown in the first 4 lines and the D negative nomenclature is
shown in the rest. Rosenfield et al., (1973)
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The primary antigens in the Rh system are D, C or c, and E or e.
They were written in alphabetical order (C, D, E) but recently
they have changed the order to become (D, C, E) according
to Fisher-Race system to reflect gene order. The RHD, RHCE
haplotypes are shown in Table 1.2 with the corresponding let-
ter from Wiener system. d is used to represent the D-negative
genotype. They are also referred as R and r depending on D-
antigen case if it is expressed or not, respectively (Rosenfield et
al., 1973) (Table 1.2).
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1.6.1 D-epitopes Models
There are two different predicting models for the D-epitopes
called single footprint and the D epitope cluster model (Figure
1.7). In 1998, Chang and Siegel suggested the single footprint
model to study the Rh (D) epitopes and the Rh D antibod-
ies. They propose a model that reconciles the serological di-
versity between the anti-Rh (D) antibodies and the topological
constraints imposed by the Rh (D) antigen. Their data were
proven that there are a genetic homology between antibodies
and D epitopes. It was based primarily on the sequence analy-
sis of monoclonal anti-D.
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Figure 1.7. Predictive models of D epitope configuration.
This figure is comparing between the D epitope cluster model by Liu and the single
footprints model by Chang and Siegel In the first model it shows the external loops
by cross-hatched rectangles, numbered circles indicate12 domains and intracellular
loops by black rectangles. This model is based on expression mutant’s Rh cE
proteins with different combinations of RHD loops recombinant (3 + 4; 4 + 6,
6, and 3 + 4 + 6), which was generated by site-directed mutagenesis. Studying
the D epitope they used specific antibodies, the results was that the loop 4 are
the critical loop. The single footprint model of D epitope, it shows the external
loops by cross-hatched rectangles, 12 domains are shown by numbered circles and
intracellular loops by black rectangles. This model argued that D epitopes are close
and similar to each other and the only difference is the number and arrangement
of the amino acid residues that can be D-specific, which shows as black circles or
D/CcEe common protein residues, which shows as white circles.
Adapted from Avent (1999).
Moreover, Rh (D) epitopes classically defined by panels of Rh
(D) variant cells are not spatially discrete. The data showed that
there is a wide genetic homology between antibodies against dif-
ferent Rh (D) epitopes. In spite of the specificity differences of
the RhD epitopes, these antibodies, which share a high degree of
structural relatedness and have the ability to inhibit the binding
between each one of them (Chang& Siegel, 1998).
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Furthermore, in 1999, Liu et al. suggested the second model,
which is the D epitope cluster model. In this study, they sug-
gest 6 clusters model for the D epitope. This study was based
on replacing the external loops of RhCE by the external loops
of RhD (loop3, loop4, and loop6) they have used each loop in-
dividually and then all loops simultaneously. At the end, they
construct RhCE with external loops (3, 4, and 6) of RhD. They
used the Site-directed mutagenesis (SDM) technique. A human
myelogenous leukaemia cell line K562 cell was used to see the
constructed gene expression; where RHD-derived amino acids
were expressed on chimeric RhCcEe cDNAs.
The purpose of these constructs was to study the expression of
individual D epitopes, which led to the prediction of the ex-
ternal loop-loop interactions of the RhD protein and predicted
the molecular topology of Rh antigen epitopes. Flow-cytometry
was used with a total of 50 MAb anti-D to analyse the different
expression pattern of D epitopes (Liu et al., 1999 a; Liu et al.,
1999 b).
Each model was claiming about different points: the single foot-
prints model was arguing that D epitopes are similar, and the
only difference is about the number and the arrangement of the
amino-acid in the paratope-epitope contact area or the common
protein residues. Moreover, they believed that any RhD anti-
body could bind to the different D epitope at the same time re-
gardless of the distance between these epitopes. Chang & Siegel
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moreover did not sequence antibodies that react with the 6th
exofacial loop of the RhD protein. While the D epitope cluster
model was arguing about the distance between each loop, which
must be at least 20A apart, and therefore, the Rh D protein
monomer is more than 50A in diameter.
According to the X-ray crystallography of the antibody-antigen
interaction it shows that the approximate diameter of the paratope
is 20 A. Commonly the paratopes make contact with a minimum
of 15 to 20 amino acids in the corresponding epitope (Davies &
Cohen, 1996). The distance between each external loop of the
RBCs membrane protein is around 20-30 A (Walz et al., 1997;
Cheng et al., 1997).
Thus, the paratope of the antibody is capable of contacting with
up to 3 external loops. Therefore, that lead to disagree with the
footprint model because it is based on using the one antibody
to react with all the different epitopes at the same time, which
is impossible due to the distance. So, these models are conflict-
ing with each other in the manner of the distance between each
epitope and the number of epitopes that anti-D can bind to at
any one time.
1.7 D-Variant Phenotypes
Although the phenotypes of RHD in most people are either D+
or D-, there are other two types of D-variants, which are known
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as weak D and partial D.
There are two systems to classify the D-epitopes; one uses a
nine-epitope model, and the other represents 30 different epi-
topes. Anti-D is present in the sera of D-positive individuals.
Therefore, by using the same anti-D in the D-negative people
and comparing the reactivity of the D-negative to D-positive
sera, it was possible to determine the different D-variants (D II
to DVII) (Tippett & Sanger, 1962, 1977).
Using a monoclonal anti RhD, demonstrated the variety of RhD
epitopes due to the alteration of the RhD protein structure and
defined those lacking on partial D phenotype red cells. The phe-
notypes of the partial D are DIIIb, DIllc, D1Vb, D Va, D VI,
DFR, and DBT (Flegel et al., 1996), but over 100 have now been
described (http://www.rhesusbase.info/).
A loss of one or more of the nine D epitopes can lead to Partial-D
phenotypes (Lomas et al., 1989, 1993). By discovering the other
classification system for the D-epitope (30 epitopes system) the
reason of having partial D-epitope was changed to be related to
the loss of RHD exon and replaced it by RHCE exon (Jones
et al., 1995) or point mutations in RHD affecting externalised
regions of the molecule.
DNU and DII phenotypes are based on a single mutation in exon
7 on the RHD gene. DNU phenotype the amino acid residue
number 353 on the RhD sequence substitute from Gly to Arg
while in the DII phenotype an amino acid change in the RhD se-
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quence in position 354 from Ala to Asp, which is responsible for
the lacking of epD4 and epD9 (Avent et al., 1997). (Rhesus base
website, http://www.uni-ulm.de/ fwagner/RH/RBhttp://www.uni-
ulm. de/ fwagner/RH/RB) provides an up to date resource of
all known partial and weak D phenotypes.
1.8 Rh in Various Species
Mammals appear the only species able to express RhD and
RhCE proteins, while the RhAG- related protein seems to be
present in different species, including marine sponges, insects,
nematodes, slime moulds and fish (Huang & Liu, 2001). RhAG
protein in RBCs shows to accelerate ammonium transport (Ripo-
che et al., 2004). Furthermore, it has the same function in yeast
(Marini et al., 2000; Westhoff et al., 2004). Moreover, in Xeno-
pus oocytes RhBG and RhCG both work to facilitate the am-
monium transport (Bakouh et al., 2004; Ludewig, 2004).
The RhD and RhCE proteins are different functionally to RhAG,
as they don’t transport ammonium (Westhoff et al., 2002; Ripo-
che et al., 2004).
The RhAG protein shows a similar structure and a similar three-
dimension structure of other Rh proteins, and that’s attributable
to the trans-membrane helix (TMH) regions (Liu et al., 2000;
Conroy et al., 2004; Khademi et al., 2004; Zheng et al., 2004).
Moreover, the RhD and RhCE proteins are identical to each
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other with a tiny difference. The RhCG molecule (Figure 1.8)
has been crystallised and shows similar topology to that pre-
dicted by Conroy et al., 2005. Furthermore, Rh proteins show
sequence homology to ammonium transport proteins (Marini et
al., 1997).
According to Conroy 2005, predicted topology model of hu-
man RhD and RhAG proteins (Figure 1.5) and Escherichia coli
(E.coli) ammonia channel AmtB model (Figure 1.9) (Khademi
et al., 2004; Zheng et al., 2004) with multiple sequence align-
ments of the unknown Rh family member. Also, using of the
ClustalW2 Multiple Sequence Alignment
(http://www.ebi.ac.uk/Tools/msa/clustalw2/) (Thompson et al.,
1997) as an alignment tool, Avent (unpublished data, 2015)
aligned the 13 Rh proteins, including human RhD, RhCE, RhAG,
RhCG, Murine RhAG, Murine RhBG, Murine RhCG, Geodia
cydonium, Caenorhabditis elegans Rh 1, Caenorhabditis elegans
Rh 2, and Nitrosomonas europaea NeRh50. Their accession
numbers from the GenBank are: ( ALM96707, ANT95300, AH-
Y04440, NP 057405, NP 035399.1, NP 067350, NP 062773.2,
C-AA73029, AAF97864.1, AAF97865.1 and WP 011111083 )
(Figure 1.10). These elements combined help in mapping the
sequence of interest in this project.
All known Rh-related proteins from bacteria, plants, insects and
animals that share an equivalent structure of the conserved re-
gions, which are located in the central subunit pore. The most
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important conserved regions are The Phenylalanine Gate, The
Twin-His Motif, and ammonium transporter fold.
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Figure 1.8. Secondary structure of RhCG protein.
Adapted from Gruwitz et al., (2010).
Figure 1.9. Crystal structure of AmtB:




Figure 1.10. Sequence alignment of the Rh protein family members.
A total of 13 proteins from the Rh family is aligned using ClustalW2 Multiple
Sequence Alignment (Thompson a et al., 1997). The green highlighted amino
acids are referring to s a Consensus Rh protein family Homology. The purple
highlighted amino acids are referring to Human Rh glycoprotein vs. G. Cydonium
/C.Elegans homology. The cyan highlighted amino acids are referring to Human
Rh glycoprotein Vs. Human Rh polypeptide homology. The yellow highlighted
amino acids are referring to differences, human Rhce vs. Rhd polypeptides.
Adapted from Avent (2015).
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1.8.1 Escherichia coli (E.coli)
In 1885, Escherichia coli (E. coli) was discovered in a healthy
individual’s feces by a German-Austrian paediatrician called
Theodor Escherich, who firstly named it as Bacterium coli refer
to presence place (colon) and he was able to determine the mor-
phology features and the properties of this bacteria. Later in
1919, after Theodor Escherich passed a way the bacteria name
was changed to reflect Theodor Escherich name.
E. coli is a rod shaped, anaerobic, Gram-negative bacterium,
which is naturally found in the human body. Although most E.
coli strains are harmless there are some harmful strains, which
can cause a food poisoning to the host body. E. coli has a ben-
efit to the human host by producing vitamin K2 (Bentley &
Meganathan, 1982). Due to the simplicity of using, growing E.
coli in the laboratory, it consider to use widely as a model or a
host organism in biotechnology and microbiology specially when
work with recombinant DNA (Lee,1996; Makrides 1996).
E. coli is surrounded with lipopolysaccharide (LPS) layer, which
forms the cell wall membrane. E. coli also surrounded with an
outer membrane and work as a selective barrier to provide the
E. coli with high protection against antibiotics such as penicillin
(Raetz,1996; Gerard, 2010).
E. coli is reliant on ammonium as a source for nitrogen (Kleiner,
1985) via ammonium transporter (AMT) family, which are in-
tegral membrane proteins (Von & Merrick, 2004). The E. coli
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AmtB was the first Amt protein to be purified (Blakey, 2002). It
has a stable homotrimer in the cytoplasmic membrane. Topol-
ogy of E. coli ’s AmtB shows to have 11 transmembrane domains
with 5 external loops N-terminus out and C-terminus inside the
cytoplasm (Thomas et al.,2000; Berne‘che et al., 2004; Khademi
et al., 2004; Scanlon & Merrick,2006).(Figure 1.11)
Figure 1.11. Topology structure of E. coli AmtB Channel:
This figure shows the AmtB amino acid sequence arrangement within the mem-
brane. It has 11 membrane domains label as M1-M11. These domains bind to-
gether to create 5 external loops facing preplasm side. Red circle residues con-
tribute to the substrate contacting walls of the channel. Blue circle residues con-
tribute to the inter-monomer contacts.
Adapted from Khademi et al., 2004
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1.8.2 Nitrosomonas europaea
Nitrosomonas europaea (N. europaea) are Gram-negative bac-
terium; their genome is a single circular chromosome of 2,812,094
bp. These bacteria exists in several places such as; soil, sewage
(McTavish et al., 1993). They can derive their energy from the
oxidation of ammonia to nitrite by using a hydroxylamine oxi-
doreductase enzyme, which catalyses the oxidation of hydroxy-
lamine to nitrite (Arp et al., 2002).
Studies of the expression of the NeRh50 protein on Saccha-
romyces cerevisiae ∆ mep bacteria strain proved the function of
NeRh50 protein (Figure 1.12). In this study, the Rh50 protein
of N. europaea and Nitrosospira multiformis (N. multiformis)
was used to replace the lack of MEP gene in the Saccharomyces
cerevisiae ∆ mep, and to restore the NH+4 uptake, which is crit-
ical to bacterial growth. That indicates NeRh50 proteins can
replace Amt proteins to aid ammonium uptake. This process is
not presently well understood, although Rh50 could potentially
play a role (Marini et al., 2000; Cherif-Zahar et al., 2007; Wei-
dinger et al., 2007). Moreover, there were many studies done to
explore the Rh proteins possible role in CO2 transport, but the
results of these studies were impeded by the lack of a reliable
biochemical assays (Peng & Huang 2006).
According to the topology prediction of the Rh50 like protein,
it shows that it has 12 membrane domains. The 1.85-Å reso-
lution was used to determined this structure. Thus, choosing
71
this kind of bacteria to construct the hybrid recombinant gene
was the similarity between the human Rh protein and the N. eu-
ropaea in the topology aspect. Both proteins have 12 membrane
domains.
Figure 1.12. The trimer structure of the Rh-like protein in Nitrosomonas europaea
(NeRh50 ).
The yellow circle in the left monomer face surface structure shows the extracellular
pore entry. At the right, ribbon representation it shows the side view.
Adapted from Lupo et al., (2007).
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Figure 1.13. Topology structure of NeRh50 protein in N. europaea:
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1.9 The Immunogenicity of Rh Blood Group
Due to the clinical significance of an incompatible blood trans-
fusion, which can lead to severe or even fatal cases of damaging
organs and cells specifically RBCs, the importance of knowing
the correct compatible blood and how to treat patients in case
of any blood group mismatching was raised.
Transfusion reactions are caused by antibodies against blood
group antigens. These antibodies may be naturally existing; for
example, antibodies, mostly IgM, against the absent antigens of
the ABO system are naturally present in blood. On the other
hand, alloimmunisation with immunoglobulin G (IgG) antibod-
ies occurs as a consequence of the exposure to blood group anti-
gens absent in an individual, which generally occurs via trans-
fusion or foeto-maternal haemorrhage during pregnancy. Anti-
bodies (Abs) against RhD in the cases of D negative persons
will not appear in their plasma. Unless this person has been
exposed to D positive blood type, for example, in the case of a
D-negative mother with a D-positive foetus as in HDFN (Molli-
son et al., 1987; Daniels, 2013). The Rh blood group system is
clinically relevant, because antibodies against Rh antigens are
involved in HDFN, HTR, and autoimmune haemolytic anaemia
(Mollison et al., 1987; Eyers et al., 1994).
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1.9.1 Haemolytic Transfusion Reactions
Haemolytic transfusion reactions (HTR) are relatively rare con-
ditions due to incompatible blood transfusion. HTR is caused
by alloimmunisation, which is an immune response to any for-
eign antigen from different cells or tissues. So it occurs in blood
transfusion and organ transplantations. HTR happens due to
the incompatible blood group between the donor and recipient
(Sloand et al., 1994). The recipient immune system starts to at-
tack the donor RBCs. This kind of reaction can happen during
or after the transfusion.
The complications related to the transfer of an incompatible
blood group are ranging from mild reactions to severe reac-
tion due to the short lifespan of the transferred RBCs and thus
lead to have high levels of bilirubin and lactate dehydrogenase.
Milder reactions are; fever, chills and anaemia, while the se-
vere reactions are; coagulation, renal failure and death (Eder &
Chambers, 2007).
1.9.2 Haemolytic Disease of the Foetus and Newborn
The historical story of this disease was begun in 1609. It was
firstly described by a midwife called Louise Bourgeois when she
first saw the hydrops foetal is in a twin baby’s case (Bowman,
1988). Then, in 1939 Levine and Stetson found an antibody
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that caused HDFN (Levine & Stetson, 1939).
HDFN occurs in subsequent pregnancies of the RhD negative
mother carries RhD positive foetus, which means, the foetal
RBCs contain the D antigens while the mother’s RBCs have
not. In this case, the mother must have been previously sensi-
tised to RhD positive blood (Pollack et al., 1968; Bowman 1988).
The sensitization happens when a woman with RhD negative
blood is exposed to RhD positive blood, usually during a previ-
ous pregnancy during mainly delivery with a RhD positive baby.
Blood exchange can occur between the foetus and the mother,
which activates the mother’s immune system to form antibodies
against this foreign D-antigen. The woman’s body responds to
the D+ blood by producing antibodies that destroy the foreign
blood cells (Urbaniak et al., 2000).
The woman’s immune system will have IgM against anti-D af-
ter the first sensitisation. Furthermore, if she is exposed to RhD
positive blood again through a RhD positive foetus, her body
will respond immediately by producing IgG antibodies, which
are capable of crossing the placenta (Alberts et al., 2002). The
antibodies can continue attacking the baby’s red blood cells for
a few months after birth. The consequence of antibody crossing
the placenta can cause jaundice in mild cases (Picchiassiet al.,
2015) and may lead to foetal death in severe cases (Bowman,
1998; Anstee et al., 2010). The incidence of the mortality of the
babies from this disease in the era between 1940 and 1970 has
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shown a dramatic reduction, from 50% to 5–9% of all prenatal
deaths (Bowman 1988). Over the next 20 years, HDFN deaths
caused by immune anti-D were dropped from 46 per 100,000
pregnancies to 1.6 per 100,000 (Pilgrim et al., 2009).
In 1968, there was a clinical trial by Pollack et al., on the effective
dose of the RhoGAM, Rh0 (D) Immune Globulin anti-D. This
treatment was given to the pregnant women and administrated
as intramuscular injection. In order to prevent the primary Rh-
immunization of those pregnant mothers with an Rh-negative
fetus, who had giving birth to ABO-compatible Rh-positive in-
fants. The result of this clinical trial of intramuscularly admin-
istered RhoGAM in the maternal women showed the best dose
of this treatment, which was 300 g and it, was given a great
result against the Rh-immunization (Pollack et al., 1968).
The most efficient treatment is avoidance of the initial RhD al-
loimmunization by prophylactic administration of passive anti-D
immunoglobulin. Prophylaxis is given against Rh-immunisation
using anti-D Ig for pregnant Rh-negative mothers. These moth-
ers should have anti-D prophylaxis injection during 28 to 30
weeks of her pregnancy and at birth. This treatment does not
have a life-long effect, so, the mother with RHD negative needs
to have this injection in each pregnancy (Urbaniak et al., 2000).
HDFN disease is uncommon in the UK because it can usually be
prevented using injections of anti-D immunoglobulin. It is rec-
ommended that all maternal mothers have a blood test in the
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early stage of their pregnancy to determine their blood type.
Directly before delivering the baby, there is some necessary test
has been done to the fetus such as; newborn blood group. Direct
anti-globulin test and checking the haemoglobin concentration,
should be taken from the cord blood. Moreover, bilirubin level
should be monitored in the first days of the neonatal period.
All D-negative pregnant women have an antibody screen to de-
tect anti-D and other clinically significant antibodies. Recombi-
nant Rh antigens could readily be used in these cases.
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1.10 Aims and Objectives
Currently, regular blood tests to define the blood phenotype of
the patient are able to detect only the D and ABO antigens, but
for identifying the other antigens further serological tests are re-
quired. Moreover, in cases such as alloimmunisation, extended
serological testing to unknown antibodies is costly. To detect
rare antibodies needs lots of reagents and rare red cells which
may or may not be available to the serologist.
Recombinant DNA (rDNA) is based on joining DNA molecules
from different sources to create a new DNA by using a molecular
cloning technique. The importance of this approach is related to
biotechnology, medicine and research purposes. This technique
is advantageous due to the similarity in the chemical structure
between all organisms (Watson 2007).
Recombinant Rh antigens may become an extensive protocol
to use at the blood banks and laboratories because of the af-
fordability, and the specificity of using bacterial cell membrane
comparing to the human RBCs, which have a short shelf-life and
low specificity especially in the case of multi-transfused patients.
Therefore, the objective of this project was to develop Rh hy-
brid recombinant genes in bacteria, and it will be capable of
detecting the D antigen with affordable price and much faster
technique, and with unlimited supplies of antigens. Moreover,
to generate the Rh-antigens in the bacterial membrane, these
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cells will have no other human antigens on their surface, that
means in the case of patients who have multiple antibodies we
can use a mono-specific antigen to detect and to sort out which
antibody they have.
The aims of this research were:
1- Constructing a hybrid N. europaea- human RHD gene by
using the available synthetic cDNA of N. europaea will be the
first step to achieve this goal, choosing the E. coli membrane
to study the expression of the human RhD external loops (2, 3,
4, and 6), due to the simplicity of manipulating E. coli in the
laboratory.
2- Cloning of these recombinant genes in the appropriate host
will be confirmed by using several techniques such as synthetic
cDNA, cloning, flow-cytometry and Western blotting to detect
bacterial proteins. Moreover, to detect the expressing RhD pro-
tein in the E. coli membrane, specific antibodies will be ob-
tained.
3- Generate a new, fast, and affordable diagnostic assay based
on hybrid recombinant N. europaea- human RHD gene.
4- Demonstrate that the recombinant RhD protein can mimic
the Rh blood group antigen (D) and be used to screen human
sera for their antibodies. This diagnostic assay will be capable
of detecting anti-D and other Rh antibodies in patient serum.
By using human RhD loops (6, 4, 3 and 2), which may be ex-
pressed in the E. coli membrane and if successful in generating
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D-epitopes, further recombinant Rh antigens may be produced.
5- This E. coli may be commercially available and could replace
the use of red blood cells to detect patient antibodies. This E.
coli will express just one Rh antigen and no others, although







Tissue culture supernatant monoclonal antibody (mAb) anti-
D 2.2B9, raised against a synthetic peptide corresponding to
the fourth external domain of the human RhD protein (Skin-
ner, Musherns & Avent, unpublished) and it was produced in
conjunction with the International Blood Group Reference Lab-
oratory (IBGRL), NHSBT, Bristol, U.K.
Tissue culture supernatant mAb anti-D MS-26, raised against a
synthetic peptide corresponding to EpD23 of the RhD protein
(Scott M,1996). It was purchased from Plasmatec Company,
Bridport, U.K.
Several purified anti-D mAb were purchased from IBGRL, NHSBT,
Bristol, U.K.: BIRMA-D6, BIRMA-D10, BRAD-3, HAM-A,
RUM-1, and MAD-2.
MAb anti-E. coli DH5 α (HRP) was purchased from Biorbyt
Company, Cambridge, U.K.(Table 2.1).
2.1.2 Custom Primary Antibodies
Several antibodies were customized in our lab and produced by
Dundee Cell Products, Dundee, U.K.: mAb anti-D (2A4/5G9),
raised against a synthetic peptide corresponding to the sixth
external domain (NH2-CLVLDTVGAGNGMC-COOH) of the
human RhD protein.
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MAb Anti-NeRh50 (1917), raised against a synthetic peptide
corresponding to the first external domain (CSSWASAVAPAEIN-
EAR) of the NeRh50 wild type.
Polyclonal antibody anti-NeRh50 (1918), raised against syn-
thetic peptides corresponding to the first external domain (CSS-
WASAVAPAEINEAR) and C-terminus (CEFIHLAGPED) do-
main of the NeRh50 wild type protein.
For producing these antibodies there was a two phase proce-
dure. Phase one included: synthesis of stable and water soluble
peptides that were coupled to carrier proteins (KLH and BSA)
Following this the quality of the peptide sequence was confirmed
by mass spectrometry and HPLC analyses.
The second phase included: immunisation of four mice for six to
eight weeks with 3-5 injections of 50 µg antigen based on their
response to this antigen. After the cell-fusion of splenocytes and
myeloma cells, which took around 9 weeks a screening test was
performed for hybridomas to select the positive clones. Then, in
week 11 propagation of hybridomas, cryopreservation and pro-
duction of cell bank took place. Between weeks 11-13 positive
clones were recloned and the Ig isotypes were characterized. Fi-
nally, in weeks 14 and 16 a cell bank and 25 ml of supernatant
from each positive clone were produced (Table 2.1).
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Table 2.1. Polyclonal(P)/ monoclonal(M) Anti-D and Anti-NeRh50 antibodies
List shows polyclonal(P)/ monoclonal(M) antibodies with the target protein in
the Human RhD external loops and the target proteins in the NeRh50 and their





ated rabbit anti-mouse secondary polyclonal antibody (1:1000)
and horseradish peroxidase-conjugated swine anti-rabbit sec-
ondary polyclonal antibody (1:1000) catalogue numbers (P 0260;
P 0399), respectively were purchased from Dako Agilent Pathol-
ogy Solutions, U.K.
Goat Anti-Mouse IgG H&L (FITC)(ab6785) and Goat Anti-
Rabbit IgG H&L (FITC) (ab6717) were purchased from Ab-
cam, U.K. FITC Mouse Anti-Human CD43 1G10 (RUO) was
purchased from BD Biosciences, U.K.
Goat anti-Mouse IgG (whole molecule)–Gold antibody and Goat
anti-Rabbit IgG (whole molecule)–Gold antibody were purchased
from Sigma-Aldrich, Gillingham, U.K.
2.1.4 Plasmids and Bacterial Strains
2.1.4.1 Plasmids and Expression vectors
pUC57 (GenScript, UK) was used as a carrier vector for the re-
combinant genes and was used for the initial cloning. Plasmids
pESV2 was constructed at Department of Molecular Microbi-
ology, John Innes Centre, Colney Lane, Norwich NR4 7UH,
United Kingdom by Mike Merrick et al., (Cherif-Zahar et al.,
2007). pET-9a DNA - Novagen (Merck Millipore, UK) used for
expressing the recombinant gene constructs.
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2.1.4.2 Bacterial Strains
E. coli DH5α competent cells (Thermo Fisher Scientific, Paisley,
U.K.) were used for cloning and BL21(DE3) (New England Bio
Labs, Hitchin, UK) were used for expressing the recombinant
gene constructs.
2.1.5 Erythrocyte samples
Ethylenediaminetetraacetate acid (EDTA) tubes containing at
least 5 ml of whole blood for IP experiments were obtained from
random blood donors. All samples were with complete aware-
ness of ethical donor consent form from National Health Service
Blood and Transplant (NHSBT), Filton Bristol, UK. For each
sample, serology information was provided. The blood was spun
at 1500 rpm for 10 minutes, and the plasma was removed, and
packed red blood cells were added to 1.5 mL Eppendorf tubes.
2.1.6 Producing Luria Bertani Media (LB Media)
The LB media (Sigma –Aldrich, U.K.) was produced according
to the manufacture. Once dissolved the solution was autoclaved
and kept at room temperature until needed. Filter sterilized
ampicillin (AMP) (100 µg/ml) / kanamycin (Kn) (50 µg/ml)
(Sigma-Aldrich, U.K) were added as needed.
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2.1.7 Producing Luria Bertani Agar Plates (LB Agar)
LB Agar, (Sigma –Aldrich, U.K.) was prepared according to the
manufacturer’s instructions. The solution was autoclaved and
kept at room temperature until needed. In cases where the mix-
ture had solidified before use it was reheated in a boiling water
bath for 1 hour. Once the temperature of LB agar had reduced
to 55 ◦C, filter sterilized AMP (100 µg/ml) / Kn (50 µg/ml)
(Sigma-Aldrich, U.K) were added as needed. Working near an
opened Bunsen burner, 25 mL of the LB agar containing appro-
priate antibiotic was added per 10cm polystyrene Petri dish (2̃5
plates in total/ 500 mL). Each plate was covered with a lid and




2.2.1 Alignment of Rh for different species
This step was started by comparison of the human RhD protein
and 12 Rh proteins from different species. The amino acid se-
quences of 13 Rh proteins were aligned with ClustalW2 Multiple
Sequence Alignment (http://www.ebi.ac.uk/Tools/msa/clustalw2/)
(Figure 1.10). This alignment was done by Avent (unpublished
data, 2015); it shows the regions of high homology between these
proteins, and the different regions.
2.2.2 Mapping of the Human RhD external loops and
Designing of the Recombinant Gene
Moreover, the alignment helps to predict the mapping the hu-
man RhD external loops and match it with the corresponding
external loops of the Rh50 like protein Nitrosomonas europaea
(NeRh50 ) in order to construct the hybrid recombinant gene of
interest.
By comparison with Conroyet al., 2005, it was possible to iden-
tify each amino acid in the external loops of the human RhD
protein through the predicted RhD protein model as shown in
(Figure 1.5).
The aim was to create a hybrid sequence with the NeRh50 back-
bone with the human RhD sixth external loop inserted. So,
to do this, the codon usage table of E. coli (Table 3.1), Gen-
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Script website (2002-2019) GenScript Codon Usage Frequency
Table(chart) Tool. [online] Available at: http://www.genscript.
com /tools/codon-frequency-table [23-06-2019] was used to trans-
late the amino acid sequence back to nucleotide level.
The final DNA sequence was sent to GenScript Company, USA
to synthesise the cDNA of the Construct recombinant gene con-
struct of N. europaea RH50 with a human RHD loop 6 (NeRh50”6 ).
2.2.3 Cloning
2.2.3.1 Cloning NeRh50”6 Construct in pESV2 vector
2.2.3.1.1 Polymerase Chain Reaction (PCR)
2.2.3.1.1.1 Primers and Generation of NeRh50”6 Recombinant
amplicon
The primer sequences of AD1 and AD2 (Table 2.2), were ob-
tained from Cherif-Zahar et al., (2007), these HPLC primers
were purchased from Eurofins Genomics, Germany. AD1 and
AD2 were used to add new enzyme restriction sites in the NeRh50”6
sequence to simplify the ligation with the pESV2 vector:
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Table 2.2. Primer sequences to add NdeI enzyme restriction site in the recombinant
gene NeRh50”6.
These primers were obtained from Cherif-Zahar et al., (2007), these primers
were purchased from Eurofins Genomics. The underlined parts of the primers
indicate the restriction sites. In AD1 the first part of the primer indicate the XbaI
restriction site while the second underline section indicates the NdeI restriction
site. In AD2, the first part of the underlying sequence of the primer (GGATCC)
indicates the restriction site of BamHI.
2.2.3.1.2 PCR Amplification of the Recombinant Gene
Q5 Hot Start High-Fidelity 2x Master Mix (from Eurofins
Genomics) was used for the 50 µL PCR reaction, the final con-
centrations were 1x Q5 Hot Start High Fidelity Master Mix and
0.5 µM forward primer and 0.5 µM reverse primer. Then, 5
µL of DNA and nuclease free water was added to complete the
volume to 50 µL. After that, PCR were conducted as a Veriti
Thermal Cycler (Thermo Fisher Scientific, U.K.), at the follow-
ing conditions; 98 ◦C for 30 s (initial denaturation); 35 cycles of;
98 ◦C for 10 s (denaturation phase); 68 ◦C for 30 s (annealing
phase); 72 ◦C for 60 s. Then, the 35 cycles were then followed
by 2 minutes at 72 ◦C (extension phase) and a 72 ◦C.
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2.2.3.1.3 Agarose Gel Electrophoresis
PCR amplicons were analysed using agarose gel electrophore-
sis. Samples were run on 1% (w/v) agarose gels, which were
produced by mixing 1 x TAE buffer (40 mM Tris-acetate, 1
mM EDTA [pH 8.0]) with 1X GelRed Nucleic Acid Stain (Cam-
bridge Bioscience, Cambridge, UK). 10 µL of the PCR Ranger
100bp and 5 µL of The Quick-Load R© 1 kb Extend DNA Lad-
der (New England BioLabs, U.K.) DNA Ladder was purchased
from Geneflow, United Kingdom suppliers of Molecular Biology
Product, UK were loaded as a marker for the gel electrophoresis
run.
Electrophoresis was carried out at 120V for 80 mins in 1 xTAE
buffer. Following the run, gels were removed and placed in the
EC3 imaging 104 system (UVP BioImaging system, Cambridge,
UK) and results were analysed using the Launch Vision Work-
sLS program (Chemi Doc 410).
2.2.3.2 Enzymatic Digestion
0.5 µL of BamHI and NdeI (Promega Corporation, Southamp-
ton, UK.) restriction enzymes were used with pESV2 vector
and with the recombinant amplicons PCR product following
of NeRh50”6 with AD1/AD2 primers to create cohesive ends,
which made the cloning into any pESV2 expression vector easier.
The digestion step was 20 min at 37 ◦C. Finally, inactivation of
enzymes was achieved by heating to 70 ◦C for 10 min.
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2.2.3.3 Purification of Digested DNA
2.2.3.3.1 Desalting the Recombinant amplicon
In this step, the digested recombinant amplicons NeRh50”6*ˆ
were purified without losing their DNA. one tenth volume of am-
monium acetate and 2 volume 100% (v/v) cold ethanol. Samples
were incubated in low-temperature condition −20 ◦C for 30 min
to precipitate the recombinant amplicons DNA. The DNA was
resuspended in 40 µL nuclease-free water.
Finally, Nano-Drop 2000 UV-Vis Spectrophotometer (Thermos
Scientific, UK.) was used to estimate the DNA concentration in
these samples.
2.2.3.3.2 Gel Extraction of Digested pESV2 expression vector
In the previous step, the restriction enzymes (BamHI and
NdeI ) cut the expression vector (pESV2) to give two fragments.
These were run on 1% (w/v) agarose gel and following separa-
tion, the fluorescent band of the DNA fragments of the pESV2
vector were excised from the agarose gel using a clean sharp
scalpel on the EC3 imaging system (UVP BioImaging system)
under UV light rays the gel slices were weighed and the DNA
was purified using the QIAquick gel extraction protocol (QIA-
GEN, Hilden, UK) according to the manufacturer’s instructions,
as detailed below.
Three volumes of buffer QG were added to one volume of gel
93
and the mix was incubated at 50 ◦C for 10 mins, with vortexing
every 2-3 mins until the gel was completely dissolved. Then, one
gel volume of isopropanol was added to increase the concentra-
tion of the DNA. Samples were moved to QIAquick spin columns
and centrifuged for 1 minute at maximum speed at room tem-
perature. 500 µL of buffer QG was used to remove all traces of
agarose and the samples were centrifuged for 1 minute at max.
speed at room temperature. 750 µL of Buffer PE was added to
the QIAquick column and centrifuged for 1 min at max. speed
at room temperature. The flow through was discarded after each
step. The QIAquick spin columns with a clean 1.5 mL micro-
centrifuge tube and the samples were eluted in 30 µL of Buffer
EB (10 mM Tris-Cl, pH8.5). Finally, the DNA samples were
quantified using the NanoDrop 2000 UV-V is Spectrophotome-
ter (Thermos Scientific, UK.) and the purified DNA of pESV2
plasmid was stored at 4 ◦C for later use in cloning step.
2.2.3.4 Molecular cloning into pESV2
The molecular cloning process was conducted near a Bunsen
Burner. The purified digested pESV2 plasmid and purified di-
gested recombinant amplicon NeRh50”6*ˆ were used to create
pESV2/ recombinant NeRh50”6 gene. LigaFast
TM
Rapid DNA
Ligation system (Promega Corporation, UK) was used to ligate
the pESV2 vector with the amplified digested recombinant gene
NeRh50”6*ˆ.
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The following equation was used to calculate how many nano-
grams of the insert should used, and from these numbers, the
volumes that should be used can be determined.
The recombinant PCR product NeRh50”6*ˆ (insert) to plasmid
DNA pESV2 (vector) size is 5Kb, and the insert size is 1349
bp. The ratio of 2:1 and 5:1 (Insert: Vector) was used in the
equation above.
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The reaction mixture was then gently mixed, followed by in-
cubation for 5 minutes at room temperature.
2.2.3.5 Transforming in DH5α E. coli competent cells
Following ligation, the plasmids were transformed in to DH5α
E. coli competent cells. This step was conducted near a Bunsen
Burner. The transformation was performed by adding the fol-
lowing reacgents into a 0.5 mL sterilized eppendorf tube, in the
indicated order: 100 µL of the thawed DH5 α E. coli competent
cells (Thermo Fisher Scientific, UK) was mixed gently with 6 µL
of the cloning mixture. The mixture was incubated on ice for
30 minutes, then, the mixture was heat shocked at 42 ◦C for 45
sec and then the mixture was immediately replaced on ice for 2
min.
Next, 0.9 mL of (Super Optimal Broth) S.O.C media (provided
in the kit and equilibrated to room temperature) was carefully
added to the mixture, which was then placed horizontally into
a shaking (170 rpm) incubator at 37 ◦C for 1 hour.
Finally, different volumes of the transformation mixture were
spread over pre-warmed selective plates (LB plates containing
100 µg/ml with AMP). Plates were incubated overnight at 37 ◦C.
Next day, master plate (LB plate with AMP) was prepared by
inoculating single colonies from the transformed plate. These
plates were incubated at 37 ◦C for overnight (see results sec-
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tion).
Next day, a number of single colonies from the master plate
were picked by sterilized plastic disposable loops and incubated
individually in tubes containing 5mL medium (LB medium con-
tacting 100 µg/ml AMP) overnight at 37 ◦C in shaking (170rpm)
incubator.
Then, the cultured colonies with cloning expression vector (pESV2)
and a recombinant DNA (NeRh6*”) were isolated and purified
using the Wizard (R) Plus SV Minipreps DNA Purification Sys-
tem (Promega, UK) (Figure 2.1).
Figure 2.1. Cloning and Transformation.
Diagram shows transformation step, where the vector with the recombinant gene
was transformed into the DH5α E. coli (host cells) by the heat shock process.
Cloning step, where the transformed host cells were able to replicate. Amp resis-
tance bacteria are selected and will only grow in the presence of the NeRh50”6*ˆ
/pESV2 plasmid.
97
2.2.3.6 Isolation and purification of plasmid DNA
Wizard (R) Plus SV Minipreps DNA Purification System (Promega,UK)
was used to isolate and purify the plasmid DNA. 5 mL LB-AMP
overnight broth, was centrifuged at 4500 xg for 10 mins at room
temperature, the supernatant was removed gently, without dis-
turbing the pellet, and discarded.
The pellet was resuspended by adding 250 µL of Cell Resuspen-
sion Solution and pipetted to completely resuspend. Then, the
mixture was moved to a sterilised eppendorf tube, followed by
adding 250 µL of Cell Lysis Solution and mixed by inverting the
tube 4 times. To inactivate endonucleases and other proteins re-
leased during bacterial cell lysis which can adversely affect the
quality of the isolated DNA, 10 µL of Proteinase K was added
to the mixture then mixed well by pipetting before incubation
for 5 mins at room temperature. 350 µL of Neutralization So-
lution was added and immediately mixed by inverting the tube
4 times, followed with centrifugation of the mixture at 4500 xg
for 10 mins at room temperature.
Clear solution were moved (around 800 µL each time) to the
Spun Column, which was provided with the kit. The columns
were spun at 4500 xg for 1 min at room temperature, the flow-
through was discarded from the collection tube, and this pro-
cess was continued until all the supernatant was centrifuged.
Then, 750 µL of Column Wash Solution was added, followed
by centrifuging the supernatant at 4500 xg for 1 min at room
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temperature, and then the flow-through was discarded from the
collection tube. Then, spun column was re-washed by 250 µL
of column Wash Solution then centrifuged the spin column at
4500 xg for 2 mins at RT, the flow-through was discarded.
The Spin Column was transferred to a new, sterile 1.5 mL micro-
centrifuge tube, followed by elution of the plasmid DNA by
adding 30 µL of Nuclease-Free Water to the Spin Column. The
plasmid DNA was eluted by spinning at maximum speed for 1
minute at room temperature.
Finally, the eluted sample was stored at −20 ◦C until required.
2 µL purified plasmid DNA was quantified using the Qubit R©2.0
Fluorometer and the Qubit R© dsDNA Broad range (BR) assay
Kit (Life Technologies, UK), according to the manufacturer’s
instructions.
During this procedure, 500 µL of LB-culture broth was stored
together with 50% (v/v) sterile glycerol at −80 ◦C for future use.
2.2.3.7 Confirmation tests
2.2.3.7.1 PCR Screening
After 16 hours of incubation for the two different ratios of the
ligation step (2:1 and 5:1), PCR screening was done to confirm
if the recombinant gene (NeRh50”6*ˆ) was inserted correctly in
the expression plasmid without contamination. Steps in (See
2.2.2.3.1) were followed with AD1 forward primer, and AD2 re-
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verse primer.
In 0.2 mL sterilised nuclease free tubes (BIOplastics, Land-
graaf, the Netherlands) 50 µL of PCR reaction mix were added.
Using sterilized filter tips (Fisher Scientific, Loughborough, UK)
single colonies from the transformation plate were picked and in-
oculated on a selective LB Agar master plate, which was divided
by numbers (each number indicating a different single colony).
Then, the same tip was moved into a PCR tube, which con-
tained PCR master mix and was gently mixed, followed by brief
spinning prior to thermo-cycling (Figure 2.2).
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Figure 2.2. Screening process.
Using a sterilised tip to pick a single colony from the transformation plate (example
colony number 11) move the tip to a divided agar plate with AMP and do a small
line with each tip alone (inoculate). Then move the same tip to PCR tube, which
contains the mixture of Q5 -Hot Start High-Fidelity 2x master mix, primers (AD1
forward and AD2 reverse), Use the tip just once with each colony.
The PCR tubes were run on Veriti Thermal Cycler (Thermo
Fisher Scientific, U.K.) according to the conditions in (2.2.3.1.2
). Gel visualisation was made by running these samples on 1%
(w/v) Agarose gels to check the size of the PCR amplicons.
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Plus gDNA Fragment Library Preparation (Thermo-
fisher scientific, UK) was used for sequencing. In a 1.5 mL Ep-
pendorf LoBind
TM
Tube the following reagents were added in
the indicated order 100 ng of purified genomic plasmid DNA
from both the original sample (pESV2-G1000) and the pESV2-
(NeRh50”6*ˆ), 5 µL of Ion Shear
TM
Plus 10X Reaction Buffer
followed by adding Nuclease-free Water to increase the volume
up to 40 µL. The mixture was by vortexed for 5 sec at room
temperature.
10 µL of Ion Shear
TM
Plus Enzyme Mix II was added to the
sample and immediately mixed by pipetting up and down. To
fragment the DNA in 450 bp, samples were incubated in a heat
block at 37 ◦C for 5 mins and immediately following this 5 µL of
Ion Shear
TM
Stop Buffer was added, and mixed thoroughly by
vortex. The reaction tube was stored on ice.




XP Reagent was added to the sample, then the mixture of sam-
ple and beads was mixed by pipetting up and down 5 times,
then the mixture was incubated at room temperature for 5 mins.
Tubes were spun and placed in a magnetic rack (Thermo Fisher
Scientific, Paisley, UK) for 3 mins until the solution was clear
of brown tint when viewed at an angle. The supernatant were
removed and discarded carefully without disturbing the bead
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pellet.
0.5 mL of 70% ethanol was freshly prepared and added to the
tube whilst keeping the tube in the magnetic rack followed by
incubation for 30 seconds and turning the tube around twice in
the magnetic rack to move the beads around. Then, the super-
natant was discarded without disturbing the pellet. The wash
step was repeated twice.
The tube was spun and placed back in the magnetic rack and
any remaining supernatant was carefully removed this was to
ensure all ethanol was removed without disturbing the pellet.
The beads were air dried at room temperature for 5 mins whilst
keeping the tube in the magnetic rack. Then, the tube was
moved from the magnetic rack, 25 µL of Low TE was added di-
rectly to the pellet to disperse the beads and to elute the DNA.
The suspension was mixed thoroughly by pipetting up and down
5 times, and then the sample was vortexed for 10 seconds.
After that, the tube was pulse-spun and placed back in the mag-
netic rack until the solution was clear. The clear supernatant
was moved into a sterelized 0.2 mL PCR tube, without dis-







High Sensitivity DNA Kit were used to check the
fragment size.
Next step was to ligate the adapters and to purify the ligated
DNA. In a 0.2 mL sterilized PCR tube, the DNA and other
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reagents were added according to Table 2.3 followed by pipet-
ting up and down.
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Table 2.3. Reaction Setup for Barcoded Libraries
The tube was placed in a thermal cycler and run following these
conditions; 25 ◦C for 15 min, 72 ◦C for 5 min then 4 ◦C.
The mixture was moved to a new, sterilized 1.5-mL Eppendorf
LoBind
TM





XP Reagent was added to the mix-
ture followed by pipetting the mixture of fragmented DNA and
beads up and down 5 times.
Afterword, the tube was pulse-spun and incubated for 5 min-
utes at RT. The tube was placed in the magnetic rack until the
solution was clear, the supernatant was carefully removed and
discarded without disturbing the pellet.
0.5 mL of freshly prepared 70% ethanol was added to the tube
whilst the tube was still in the magnetic rack followed by incu-
bating the mixture for 30 seconds at RT with moving the tube in
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the magnetic rack. Next the clear solution was discarded care-
fully without disturbing the pellet. This step was repeated for
a second wash.
The beads in the tube were air dried by leaving the tube in the
magnetic rack at RT for 5 mins. 20 µL of Low TE was added
directly to resuspend the pellet and to elute the DNA, then,
the mixture was mixed thoroughly by pipetting the suspension
followed by vortexing the sample for 10 seconds. The tube was
removed from the magnetic rack and pulse-spun then replaced
in the magnetic rack until the solution was clear.
Clear supernatant was transferred to a new sterilized 1.5-mL
Eppendorf LoBindr TM Tube without disturbing the pellet.
Pippin Prep
TM
instrument manual for100–300-base-read libraries
was followed to run the size-select the library step.




XP Reagent was added to the mixture followed by pipetting
the mixture of fragmented DNA and beads up and down 5 times.
Afterward, the tube was pulse-spun and incubated for 5 minutes
at RT. Tube was placed in the magnatic rack until the solution
was clear, the supernatant was carefully removed and discarded
without disturbing the pellet.
Add 0.5 mL of freshly prepared 70% ethanol while the tube still
in the magnetic rack followed with the same steps were done
before. Air dry beads in the tube by leaving the tube in the
magnetic rack at RT for 5 mins.
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After that, the tube was removed from the magnetic rack and
0.5 mL of Platinum
TM
PCR SuperMix High Fidelity (black cap)
and 2 µL of Equalizer
TM
Primers were added to the bead pellet
followed by pipetting the mixture up and down. The tube was
placed back on the magnetic rack for 2 mins, then carefully 50
µL of supernatant was transferred to a new, sterilized 0.2 mL
PCR tube, without disturbing the pellet. The tube was sealed
and placed in the thermal cycler, and run on the following pro-
gram. Dr Michele Kiernan of the Genomics Facility Systems
Biology Centre at the University of Plymouth conducted the
chip loading and sequencing steps. Finally, De-novo assembly
software was used to align results against bacterial genome.
2.2.3.8 Cloning NeRh50”6 Recombinant in pET expression vec-
tor
2.2.3.8.1 Enzymatic Digestion of pUC57-Recombinant gene
0.5 µL of BamHI and XbaI (Promega Corporation, UK.) re-
striction enzymes were used to cut the recombinant gene from
pUC57 vector and to confirm if we have the right hybrid recom-
binant gene. Moreover, these restriction enzymes were used to
cut the expression vector (pET) to create cohesive ends, which
make the cloning into any expression vector easier (pET). En-
zyme inactivation was done for 10 min at 70 ◦C.
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2.2.3.9 Purification of Digested DNA
2.2.3.9.1 Desalting the Digested pET Expression Vector
In this step, the digested pET expression vector was purified
by adding 1/10 volume of ammonium acetate and 2 volumes of
100% (v/v) cold ethanol. The sample was incubated at −20 ◦C
for 30 min to precipitate the pET DNA. The DNA was resus-
pended in 40 µL nuclease-free water.
Finally, Nano-Drop 2000 UV-Vis Spectrophotometer (Thermos
Scientific, UK.) was used to estimate the DNA concentration in
these samples.
2.2.3.9.2 Gel Extraction of Digested Hybrid Recombinant
DNA
In the previous step, the restriction enzymes (BamHI and
XbaI ) cut the pUC57 vector containing the hybrid recombinant
construct gene. These samples were run on a 1% (w)̌ agarose gel.
The DNA fragments for the hybrid recombinant construct gene
(1275 bp) were excised from the agarose gel using a clean sharp
scalpel on the EC3 imaging system (UVP BioImaging system)
under UV light rays and then weighed. DNA was purified using
the QIAquick gel extraction protocol (QIAGEN, Hilden, UK)
according to manufacturer’s instructions. 2.2.2.3.3.2 for more
information about gel extraction steps.
Finally, DNA samples were quantified using the NanoDrop 2000
UV-V is Spectrophotometer (Thermos Scientific, UK.) and the
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purified DNA of the hybrid recombinant construct was stored
at 4 ◦C for later use.
2.2.3.10 Molecular cloning into the pET Expression Vector
The molecular cloning process was conducted near a Bunsen
Burner. The purified digested pET expression vector and the
purified digested recombinant DNA NeRh50”6ˆ were used to
create the pET/ recombinant NeRh50”6 gene. Liga Fast
TM
Rapid
DNA Ligation system (Promega Corporation, UK.) was used to
ligate the pET expression vector with the digested recombinant
gene NeRh50”6ˆ. Followed the same equation in 2.2.3.4.
The recombinant PCR product (insert) to plasmid DNA(vector)
size is 3Kb, and the insert size is 1349 bp. The ratio of 2:1 and
5:1 (Insert: Vector) was used in the equation (2.2.3.4). The re-
action mixture was then gently mixed, followed by incubation
for 5 minutes at room temperature.
Using BamHI and XbaI restriction enzymes in the digestion
step for the pET plasmid and constructs recombinant DNA was
facilitating the ligation step.
Finally, the cloning reactants were transformed into BL21(DE3)
E. coli competent cells.
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2.2.3.11 Transforming in BL21(DE3) E.coli competent cells
This step was conducted near a Bunsen Burner. The reaction
was performed by adding the following reagents into a 0.5 mL
sterilized eppendorf tube, in the indicated order: 100 µL of the
thawed BL21(DE3) E. coli competent cells (New England Bio-
labs, UK) was mixed gently with 6 µL of the cloning mixture.
The mixture were incubated on ice for 30 minutes, then, the
mixture was heat shocked at 42 ◦C for 10 sec, followed by imme-
diately, replacing the mixture on ice for 2 min.
Next, 0.9 mL of (Super Optimal Broth) S.O.C media (provided
in the kit and equilibrated to room temperature) was carefully
added to the mixture, which was then placed horizontally into
a shaking (170 rpm) incubator at 37 ◦C for 1 hour.
Finally, different volumes of the transformation mixture were
spread over pre-warmed selective plates (LB plates containing
50 µg/ml Kn). Plates were incubated overnight at 37 ◦C.
Next day, master plate (LB plate with Kn) was prepared by inoc-
ulating single colonies from the transformed plate.These plates
were incubated at at 37 ◦C for overnight (see results section).
Next day, a number of single colonies from the master plate
were picked by sterilized plastic disposable loops and incubated
individually in tubes containing 5mL medium (LB medium con-
tacting 100 µg/ml Kn) overnight at 37 ◦C in shaking (170 rpm)
incubator.
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Then, the cultured colonies with cloning pET expression vec-
tor and a recombinant DNA (NeRh50”6ˆ) were isolated and pu-
rified using the Wizard (R) Plus SV Minipreps DNA Purification
System (Promega,UK).
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2.2.3.12 Isolation and purification of plasmid DNA
See 2.2.3.6 section
All previous steps: See 2.2.3.8; 2.2.3.9; 2.2.3.10; and 2.2.3.11
were followed for the other constructs: NeRh50”4, 6, NeRh50”3,
4, 6, and NeRh50”2, 3, 4, 6.
2.2.3.13 Confirmation tests
2.2.3.13.1 Sanger Sequencing
Purified plasmid DNA samples were sent to Eurofins Ge-
nomics (Ebersberg, Germany) for sequencing. Primer sets shown
in Table 2.4, which were purchased from Eurofins Genomics were
used to confirm: the human RhD external loops; NeRh50, and
the pET expression vector were these primer sets cover the en-
tire plasmid with the recombinant gene.
Samples were diluted to 10 ng/ µL and then 15 µL of each di-
luted sample was added to 10 mM forward and reverse primers in
separate serial numbers barcoded labelled tube followed by cov-
ering them with a yellow cap which was provided with Mix2Seq
kit (Eurofins MWG Operon).
Results were analysed using CLC Genomics workbench 9 soft-
ware for alignment against expected reference sequence.
2.2.3.13.1.1 Primer Design
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Several software packages were utilised to design the oligonu-
cleotide primers for RhD/NeRh50/ pET expression vector. Primer
3 software (http://primer3.ut.ee/) was initially used to design
the primers; the NCBI BLAST database (http://www.ncbi.nlm.
nih.gov/). was used to confirm the specificity of primers; the
UCSC Genome Browser database 66 (http://genome.ucsc.edu)
was also used to analyse the specificity of the primers. In ad-
dition, visualisation of the location of the amplicons within the
genome was done using the in-silico PCR (virtual PCR). Primers
were designed to cover the entire plasmid and each human RhD
external loop to confirm the presence of all human RhD exter-
nal loops. The primers were received as lyophilised from Eu-
rofins Genomics (Ebersberg, Germany) in a High Performance
Liquid Chromatography purity (HPLC), and were re-suspended
by addingnuclease-free water (Ambion R©, Applied Biosystems,
Thermo Fisher Scientific, USA) as indicated by the manufac-
turer.
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Table 2.4. Primer sequences to amplify regions in pET-NeRh50”2, 3, 4, 6
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2.2.3.13.2 Enzymatic Digestion of pET-Recombinant gene
plasmids
0.5 µL BamHI and XbaI (Promega Corporation, UK.) re-
striction enzymes were used at 37 ◦C for 30 min to cut the re-
combinant gene from pET vector and to confirm if we have the
right hybrid recombinant gene.
Enzyme inactivation step was achieved by heated up the sam-
ple to 70 ◦C for 10 min. Then, the samples were run on a 1%
(w/v)agarose gel to check the band sizes.
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2.2.3.13.3 Electron Microscopy Imaging
Most of the sample preparation steps of this test was done
with the help of Plymouth Electron Microscopy Centre (PEMC).
In particular Dr. Alexander Strachan and Glenn Harper are
thanked for their support and assistance in this work.
10 ml overnight LB broth with 50 µg/ml Kn at 37 ◦C were har-
vested on a 4500 xg at room temperature for 10 min, then, the
supernatant was discarded. Pellets were washed with 1 ml of 1x
PBS. After that, samples were centrifuged at 2100 xg at room
temperature for 2 min and the supernatant was discarded. This
step was repeated two times.
After that, 500 µL mixture of fixation solution (2.5% (v/v) Glu-
turaldehyde and 4% (v/v) Formaldehyde in 0.1 M Phosphate
buffer) was added to the samples to fix bacterial cells and to
stabilize the protein structure.
Due to the fact that incident electrons need to penetrate through
the sample, so that transmitted electron signals would be col-
lected for imaging, the sample thickness needs to be limited
(e.g. 50 to 250 nm for biological samples). Therefore specified
sample preparation is necessary before staining them with an-
tibodies. Steps include; cutting the specimen to fit the Gatan
disc grinder by using ultrasonic disk-cutter. Then, low melting
point wax was used to glue the specimen to the disc in order
to have a plane view imaging. Next, these Grid were heated at
120 ◦C to bind slices rigidly. Then, it was glued for a second
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time. Followed by polishing the specimen with Silicon Carbide
Grinding Paper (SiC) paper to fix the specimen on a rotating
polishing machine.
The specimen thickness were adjusted by controlling knob of the
grinder with 10 µm until the specimen is flush with the polish-
ing surface followed with another glue step. Then, Precision Ion
polishing System (PIPS) was used to create high-quality TEM
specimens with a plane-view observation.
Then, the grid was submerged in a blocking buffer (1x PBS-
Tween 20 and 5% (w/v) of bovine milk powder) were used to
wash the grid membrane for an hour at room temperature. After
that, the blocking buffer was washed off and the primary anti-
bodies (2.2B9, 2A4, and 1918) were added either neat or diluted
in the blocking buffer, to the grid membrane as the manufac-
turer’s instructions recommended. Then, it was stored at 4 ◦C
for overnight.
On the next day, three washes with 1x PBS-T has been done to
the grid membrane each wash was 5 min long at room temper-
ature. Then, secondary antibody: Goat anti-Mouse IgG (whole
molecule)–Gold antibody and Goat anti-Rabbit IgG (whole mole-
cule)–Gold antibody was prepared with a ratio of (1:20) ac-
cording to manufacturer’s instructions. It was added to the grid
membrane after discarding the 1x PBS-T solution. Next, grid
membrane was incubated for 1 hour at RT followed by washing
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for three times with 1x PBS-T and then one wash with 1x PBS.
Each wash was 5 min long at room temperature.
Finally, images from the grid membrane was taken with Trans-
mission Electron Microscope (TEM) with a 0.38 nm resolution
and Gatan Orius camera.
2.2.3.14 Protein Extraction
2.2.3.14.1 Bacterial Protein Extraction from Broth Media
This step was based on using BugBuster Master Mix protein
extraction reagent (Merck Chemicals Limted) 1.5 ml of overnight
broth culture was centrifuged at 45000 xg for 10 min at RT. All
supernatant were discarded, then, 300 µL of BugBuster protein
extraction reagent was mixed gently, prior to incubating these
pESV2-NeRh50”6 samples for 10 min at RT in the shaking in-
cubator. These samples were centrifuged at 45000 xg for 20 min
at 4 ◦C. The pellets and the supernatants were stored at −20 ◦C
for quantification test and stored at −80 ◦C for long periods.
2.2.3.14.1.1 Qubit R© Protein quantitation assay:
To estimate the concentration of the protein in the samples,
quantification QubitTM Protein Assay Kit (Thermo Fisher Sci-
entific, UK) was used. First, the Qubit working solution was
prepared at a ratio of 1:200. Three standards were prepared
according to the manufacturer’s instructions, the recommended
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ratio for each standard and each sample is 1:200. Next, stan-
dards and samples were incubated at room temperature for 15
mins.
Finally, the samples were measured by using Qubit R© Fluorome-
ter 2.0. To calculate the concentration of the protein this equa-
tion was followed:
conc= QF value X 200/(x),
where (x) represent the number of µL from the sample that has
been used.
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2.2.3.14.2 Erythrocyte Ghost Membrane Preparation
Fresh red blood samples were centrifuged at 15000xg for 10
mins to get rid of plasma and the buffy coat and precipitate the
red blood cells (RBCs). After that, 5 mL of the RBCs were
incubated with 3mg/ml as a final concentration of bromelain at
37 ◦C for 1 hr to cleave the 6th external loop of RhD protein on
the RBC membranes.
Then, samples were washed three times with 0.15 M NaCl solu-
tion. 0.2 M Monobasic and 0.2 M Dibasic solution were prepared
by dissolving NaH2PO4.2H2O and anhydrous Na2HPO4 respec-
tively in 1 L of distilled water. To prepare the stock solution of
phosphate buffer (0.1M Na2PO4 pH8.0) monobasic and dibasic
solutions were mixed together.
The samples were washed with 0.1M Na2PO4 pH8.0 until the
supernatant was clear followed by incubating the pellet for 10
mins at 4 ◦C. Samples were transferred into centrifuge tubes.
Samples were mixed thoroughly and were incubated for 5 mins
at 4 ◦C with 5M 0.1M Na2PO4. After that, these samples were
centrifuged at 16000xg at 4 ◦C for 5 mins, the supernatant was
removed. This step was repeated until the membranes were
creamy pink. Membranes were transferred to 1mL Eppendorf
tubes.
1 mL of 5 mM phosphate buffer was added and membranes were
centrifuged at 22 xg for 10 mins. Clear supernatant was dis-
carded followed by adding 100 µL 5mM phosphate along with 10
120
µL 2mM phenylmethylsulphonyl fluoride (Sigma-Aldrich, UK)
to the membrane to prevent proteolysis of samples during long
term storage. Samples were stored at −80 ◦C until required.
2.2.3.15 Sodium Dodecyl Sulphate-polyacrylamide Gel Electrophore-
sis (SDS-PAGE)
5 µg of the protein per sample from bacterial protein and 10 µg
from the human ghost membrane samples were used. To pre-
pare the samples in order to load them into a gel, samples were
mixed with 4x loading sample buffer (50% (w/v) glycerol, 5%
(w/v) lithium dodecyl sulphate, 5% (w/v) Tris(hydroxymethyl)
aminomethane, 1.0% (v/v) hydrochloric acid) (BioRAD, U.K)
by a ratio of 3:1, sample: loading dye.
Then, 2 µL of XT reducing agent (BIO-RAD, UK) were added
(BioRAD, U.K) to each sample. Next, the samples were heated
in a hot block at 95 ◦C for 5 mins prior loading them onto the
gel. Samples were loaded into pre-cast gel XT Bis-Tris 4-12%,
12+2 well, 45 µL , Criterion Cell (BioRad, U.K). BluEye Marker
(GeneFlow, U.K) and Precision Plus ProteinTM WesternCTM
Standards were used as a marker to determine the protein molec-
ular weight. Then, 3-(N-morpholino)propanesulfonic acid run-
ning buffer 1x XTMOPS (BIO-RAD, UK) was prepared (1:20).
Gels were run at 150V for 90 mins or until the dye went to the
lowest point of the gels. Gels were either stained or immunoblot-
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ted (Western blotted).
2.2.3.15.1 Instant Blue Staining
To test the quality control of the gel electrophoresis and to
check the presence of the proteins in samples, the gel was im-
mersed overnight at room temperature on a shaker in Instant
Blue stain (Expedeon, U.K). Next day, the gel was washed and
was imaged by a phone camera.
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2.2.3.15.2 Western Blotting
Polyvinylidene fluoride (PVDF) membrane with 0.45 um pore
size (Merck Millipore, U.K) was activated by submersing the
membrane in Methanol for 20 sec followed by 2 min in dH2O
then in cold transfer buffer (190 mM glycine, 25 mM Tris base,
and 20% (v/v) Methanol).
To prepare the sandwich of the membrane, layers of the sponge,
filter paper, gel peice (which contain proteins and the marker),the
prepared PVDF membrane, second filter paper, and finally the
second sponge layer then this was placed into the cassette of the
wet transfer blotting Bio-Rad system for 60 minutes at 100 V.
After the proteins were transferred from the gel to the PVDF
membrane, this membrane was placed in sterilized plastic tray
with lid, blocking solution (1x PBS-Tween 20 and 5% (w/v) of
dried milk powder) was used to block the membrane for an hour
at room temperature on the shaker. After that, the blocking
buffer was discarded and the primary antibodies were added ei-
ther neat or diluted in the blocking buffer with (1:6) ratio, to
the membrane as the manufacturer’s instructions recommended.
Then, it was stored on a shaker in the cold room for overnight.
On the next day, three washes with 1x PBS-T were to the PVDF
membrane each wash was 10 min long at room temperature on a
shaker. Secondary antibody was prepared with a ratio of 1:1000
according to manufacturer’s instructions. It was added to the
membrane after discarding the 1x PBS-T solution. Next, PVDF
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membrane was incubated for 1 hour at RT followed by washing
three times with 1x PBS-T and then, one wash with 1x PBS;
each wash was 10 min long at room temperature on a shaker.
Finally, Pierce
TM
ECL Plus Western Blotting Substrate (Thermo
Fisher, U.K) was prepared according to manufacturer’s instruc-
tions and added to the PVDF membrane before taking the im-
ages of the membrane by using PXi6 Imaging System (Syngene)
to enhance the membrane chemilumescent visualization.
However, 10 µg of protein from ghost membrane with differ-
ent Rh phenotypes and 5 µg of protein from all constructs and
wild types samples were run using 1D gel electrophoresis prior
to transfer them onto PVDF membrane. Moreover, cultural su-
pernatant 2.2B9 were used at the concentration 1:6 as a primary
antibody followed by rabbit anti-mouse horse radish peroxidase
as a secondary antibody.
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2.2.3.16 Flow cytometry
2.2.3.16.1 Flow cytometry for Blood Samples
RhD+, RhD- blood samples were ordered from National Health
Service (NHSBT) and were used as a control to test the ef-
ficiency of our Human antibodies; 2.2B9 which reacts against
human RhD external loop 4, BIRMA-D6 which reacts against
human RhD external loops 4, and 6, and MS-26, which reacts
against human RhD external loops 3, 4, and 6.
Whole blood was washed in 30 ml of 1x PBS and it was cen-
trifuged for 5 min at 15000 xg then the supernatant were dis-
carded, this step was repeated three times. 20 µL of the final
pellet from the blood samples was used and were diluted in 30 ml
of 1x PBS. Then, 200 µL of this mixture was used to mix it with
100 µL of tissue culture supernatant human antibodies (2.2B9
and MS-26) and 10 µL of the purified human antibody(BIRMA-
D6). These samples were incubated for 1 hour at 4 ◦C in dark.
PBS were added followed by centrifuge samples for 5 min at
15000 xg at room temperature, this step was repeated for two
times. Then, 200 µL of 1x PBS was used to resuspended the
pellet. 10 µL of secondary FITC antibody was added and in-
cubated with samples for 30 min at 4 ◦C in dark. Samples were
washed with 1x PBS and centrifuged at 4 ◦C for two times at
15000 xg. 300 µL of 1x PBS was used to resuspend the samples.
Finally, samples were transferred into FACS tubes and analysed
by FACS ARIA II Flow cytometer/Cell Sorter (BD, U.K)
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2.2.3.16.2 Flow cytometry for E. coli Broth
5 ml of LB broth with 50 µL Kn were grown overnight at
37 ◦C at 200 rpm for the positive colonies from the last transfor-
mation of PET vector/ NeRh50 with human external loop (6/
4,6/ 3,4,5/ 2,3,4,6). 5 ml LB broth with Kn for BL21 ED3 com-
petent cells, 5 ml LB broth with Kn for Nitrosomonas europaea
ATCC 19718 were used as a positive control.
All broth were harvested on 22000 xg at room temperature for
10 min, then, supernatant were discarded. Pellets were washed
with 1 ml of cold 1x PBS. After that, samples were centrifuged
at the maximum speed at room temperature for 10 min, the su-
pernatant were discarded. This step was repeated for two times.
700 µ L of resuspending mixture [5% (w/v) Triton X-100, 0.15
(v/v) NaCl, 10mM Tris-HCl, and 1mM EDTA pH 8.0] were used
to resuspend pellets.
50 µL of 10 mg/ml of freshly prepared Lysozyme were added
to the previous mixture and vortexed for sec. The final mix-
ture were incubated for cell wall lysis step for 30 min at 37 ◦C.
Followed with spinning at 1500 xg at room temperature for 10
min, supernatant were discarded. Then, all pellets were resus-
pended with 1 ml of cold 1x PBS. This mixture were divided in
to 4 main tubes; unstain sample, only secondary, only secondary
with blocking buffer and primary Abs.
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100 µL of culture supernatant Abs, 10 µL of purified Abs; Anti-
D (2.2B9, BIRMA-D6, MS-26)/ Anti-NeRh50 (1918, 1755, 1917)
and Anti-E. coli were added to the right tube. Then, these tubes
were incubated in dark at 4 ◦C for 45 min. Samples were cen-
trifuged at the maximum speed at room temperature for 10 min,
the supernatant were discarded. Pellets were washed with 1 ml
of cold 1x PBS. This step was repeated two times.
500 µL of 1% BSA (blocking buffer) were added to the right
tubes while 500 µL of cold 1x PBS were added to the other
tubes. Then, these tubes were incubated in the dark on shaker
at 4 ◦C for 1hr. Samples were centrifuged at 22000 xg at room
temperature for 10 min, supernatant were discarded. Pellets
were washed with 1 ml of cold 1xPBS. This step was repeated
two times.
10 µL of the suitable secondary- FITC conjugated Ab (Mouse
anti human FITC, Goat anti mouse FITC, and Goat anti rabbit
FITC) were added and incubated in dark at 4 ◦C for 1hr then,
washing step was repeated twice.
Finally, 1 ml of cold 1x PBS were used to resuspend pellets to
prepare the sample to be read by BD FACS Aria II - Flow cy-







Blood groups were discovered in 1901 and there are plenty of
studies in this area, reflecting the importance of this science
in the Immuno-haematology field. The antigen/antibody reac-
tion is one of the most significant features in serology. Due to
the importance of this approach, all hospitals and blood banks
worldwide rely on the phenotyping of blood groups as one of the
routine blood tests.
The disadvantage of the current antibody screening and identi-
fication methods is the use of human red blood cells, as these
can complicate the detection of antibody in different cases for
example, if more than one antibody specificity is present, in the
case of multi-transfused individuals and in the case of having
weak antigens. Moreover, using human red blood cells, that
have a limited shelf life, is another barrier to study rare blood
phenotype cases.
Thus, to overcome the downsides of using human red cells, in
this project, the aim was to construct recombinant Rh antigens.
The concept was that if bacteria can express Rh antigens, they
may reduce the need for human red cells in complicated cases.
The principle of using blood group recombinant antigens to iden-
tify blood group antibodies in human serum is well affirmed, and
has been achieved for many blood group systems but not for Rh
blood group system (Ridgwell et al., 2007).
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The Rh blood group system is the second most important blood
group system in transfusion medicine (Westhoff, 2004). Anti-Rh
system antibodies are major causes of transfusion reactions and
haemolytic disease of the fetus and newborn (Van Kim et al.,
2006). Despite the great importance of Rh blood group system,
there has not been any successful production of recombinant Rh
antigens in prokaryotic cells (Conroy et al., 2005, (Ridgwell et
al., 2007).
Rh blood group system has five genes, the blood group active
RHCE and RHD, the erythroid ammonium transporter RHAG
and two non-erythroid counterparts, RHBG and RHCG. Rh-
related proteins are expressed in all animals, humans, bacte-
ria (including AmtB) having a highly conserved membrane do-
main, termed the Ammonium transporter fold (Marini et al.,
2000). The Rh recombinant antigens would produce a fast, lower
bio-hazard, affordable technique depending on the expression of
RhD protein in the bacterial membrane.
The recombinant gene is composed of NeRh50 backbone and
multiple combinations of human RhD external loops. Firstly, we
attempted proof of concept by designing a NeRh50”6 construct,
with the location of loop 6 being between two highly conserved
transmembrane domains (11-12), which increases the probabil-
ity of this gene sequence being expressed on the E. coli inner
membrane.
Choosing to work with the external loops (6, 4, and 3) to cre-
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ate the recombinant gene constructs was based on the successful
work of (Liu et al., 1999 a, 1999 b). These studies achieved Rh
expression by constructing the recombinant RHCE RHD cD-
NAs by replacing the human RHCE external loops 3, 4, and 6
with the corresponding human RHD external loops 3, 4, and 6
sequences to construct a cDNA expressing a hybrid form of Rh
protein, which has a backbone of RhCE and external loops from
human RhD. Besides these results, in 1997, there was another
study by Avent et al., where they were able to determine the 9
critical amino acids (AA) for expression of the D epitopes, which
are located on the predicted external loops 3, 4, and 6 of the
RhD protein. These critical amino acid are: Met169, Metl70,
Ile172, Phe223, Ala226, Glu233, Asp350, Gly353, and Ala354.
Furthermore, in 2005, Conroy et al., have successfully constructed
homology models of RhD and RhAG based on using the pre-
dicted secondary structure of Rh proteins (Figure 1.8) and the
structure of E. coli AmtB (Figure 1.9) as a template. These
models predicted the human RhD external loops, which assessed
constructing the hybrid NeRh50”human RhD external loops (2,
3, 4, and 6). The entire Rh complex comprising one Rh protein
monomer and two RhAG subunits form a trimer arranged in a
cloverleaf configuration (Conroy et al., 2005; Callebaut et al.,
2006).
Choosing the N. europaea Rh50 like protein to be the backbone
of the constructed gene instead of another bacterial species such
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as E. coli AmtB is due to the similar topology of the NeRh50 like
protein to human Rh proteins. NeRh50 has 6 external domains
with 12 membrane domains (Figure 1.13) like human Rh pro-
teins, while E. coli AmtB protein has 5 external loops with 11
membrane domains (Figure 1.11). The similarity in the topol-
ogy between human RhD and N. europaea Rh50 like protein is
more likely to allow the human RhD epitopes to be expressed.
Moreover, N. europaea was also chosen because it was a prokary-
ote, before this study no successful expression of eukaryote Rh
cDNAs have been described in prokaryotic cells.
3.1.1 Aim of the study
Aims of this chapter will be divided in two main section based
on the results of this project,
A) Aims for generating constructs:
- Map the human RhD external loops (2, 3, 4, and 6) with the
corresponding domains in the NeRh50 protein.
- Generate a recombinant gene composed of NeRh50 backbone
and human RhD external loops (2, 3, 4, and 6) to create; NeRh50”6,
NeRh50”4, 6, NeRh50”3, 4, 6, and NeRh50”2, 3, 4, 6.
- Clone these constructs in to a suitable expression vector.
- Produce these constructs in a prokaryotic expression system,
which is E. coli.
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- Confirm the presence of all constructs in the pET vector by
enzymatic digestion.
B) Aims for confirming the presence of constructs and their
efficiency by testing for proteins expression:
- Confirm the presence of the hybrid recombinant genes at
the protein level by detecting their protein expression on the
inner E. coli membrane.
- Use Several polyclonal and monoclonal antibodies (Table 2.1).
- Use different techniques; Western blot, Flow-cytometry, immuno-
gold staining and Transmission electron microscopy (TEM) (Ta-
ble 3.2) to assess the presence of the NeRh50”human RhD ex-
ternal loops in the E. coli membrane.
So for that, the aim of this project is to generate Rh recombi-
nant antigens by constructing hybrid recombinant N. europaea-
human RH genes in order to prove that the recombinant RhD
proteins can mimic the Rh blood group antigen (D) as a novel
approach.
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3.2 Constructing RH recombinant genes for
expression in E. coli membrane.
3.2.1 Mapping human RhD 6th external loop
Mapping and alignment of the various 13 Rh homologous pro-
teins shows a high degree of variation between the 6th external
loop sequence (Figure 3.1).
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Figure 3.1. Clustal X alignment of the Transmembrane Domain (TM) (11-12) region of
13 Rh proteins from different species.
The yellow highlighted sequence shows the external loop 6, while the green high-
lighted AA residues are showing the consensus AA in the Rh protein family ho-
mology. This alignment shows that the transmembrane domain (11-12) is highly
conserved between the Rh protein family in different species, while loop 6 has
different AA sequences between these species.
This alignment shows a massive variation in loop 6 structure
between different species, but the 6th loop, which is located be-
tween two highly conserved transmembrane domains; 11 and 12.
Therefore, this doesn’t necessarily follow but as the TM domains
are conserved, we had hoped the replacement of the loop part
would not disrupt expression of hybrid Rh protein from NeRh50
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and human RhD loop 6 in E. coli.
GenScript Codon Usage Frequency Table (chart) Tool. [online]
Available at: http://www.genscript.com/tools/codon-frequency-
table [23-06-2019] was used to reverse translate the AA sequence
of human RhD external loops; loop 6 [LVLDTVGAGNGM] (Fig-
ure 3.2), loop 2 [FPSGKVVIT] (Figure 3.7), loop 3 [NIFNTDYH
MNMM] (Figure 3.8) and loop 4 [ALLRSPIERK] (Figure 3.9),
back to the most likely nucleotide sequence.
Therefore, minimizing the mutation incidence in the bacteria by
using the highest frequency codons, which will make the recom-
binant protein sequences more likely to be successfully expressed
by the E. coli (Table 3.1).
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The AA sequence of external loop 6 of the human RhD (Fig-
ure 3.2) was used to replace the corresponding loop 6 sequence
in NeRh50 (Figure 1.13) to generate the predicted NeRh50”6
topology (Figure 3.3).
The loop 6 amino acid sequence was reverse translated to nu-
cleotides by using the E. coli codon usage table website, Gen-
Script. (2002-2019). GenScript Codon Usage Frequency Ta-
ble(chart) Tool. [online] Available at: http://www.genscript.
com/tools/codon-frequency-table [23-06-2019].
These nucleotides were added to the NeRh50 backbone. The
nucleotide sequence was sent to GenScript Company, USA to
synthesis the cDNA of the first construct: hybrid recombinant
gene of N. europaea Rh50 with a human RhD external loop 6
(NeRh50”6 ).
Figure 3.2. Amino acid sequence of Human RhD external loop 6 and the corresponding
nucleotide sequence based on E. coli codon usage.
Red numbers on the above show the order of this AA in the 6th loop of human RhD
protein sequence. Bottom box shows the reverse translation of this AA sequence
back to the nucleotide level based on the E. coli codon usage table.
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Table 3.1. List of human RhD external loops AA and E. coli nucleotide codons of these
AA.
This table shows codon of each AA in human RhD external loops (2, 3, 4,
and 6) based on the codon usage table of E. coli website, GenScript. (2002-
2019). GenScript Codon Usage Frequency Table(chart) Tool. [online] Available
at: http://www.genscript.com/tools/codon-frequency-table [23-06-2019].
The yellow highlighted codons show the highest frequency and those were used
to reverse translate the AA.
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Figure 3.3. Predicted membrane topology and amino acid sequence of NeRh50”6 construct.
This figure depicts the hypothetical membrane orientation of the recombinant NeRh50”6 in which predicted externalized amino acids are
numbered. The recombinant protein was derived initially from a cDNA of a wild type NeRh50 combined with a human RhD external loop 6
polypeptide sequence. The predicted extracellular loop of the human RhD amino acids [LVLDTVGAGNGM] are shown as solid circles with
a blue single letter amino acid code inside each circle. The yellow arrow point to the external loop 6.
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NeRh50”6 hybrid recombinant gene size was 1766 bp and it was
inserted in the pUC57 vector (Figure 3.4). Thereafter, pUC57
plasmid-NeRh50”6 was transformed into DH5 α E. coli compe-
tent cells.
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Figure 3.4. pUC57 vector with the recombinant gene (NeRh50”6 ) circular sequence map.
Is a circular sequence of the full pUC57 vector with the recombinant gene (NeRh50”6 ), it shows all the restriction enzymes sites. By CLC
Genomics Workbench 12.0 programme.
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The sequence in Figure 3.5 was used to map the AD1/ AD2
primers and BamHI and XbaI restriction sites in the pUC57-
recombinant gene (NeRh50”6 ) plasmid sequence. BamHI and
XbaI restriction enzymes were used to digest the hybrid recom-
binant gene NeRh50”6 from the pUC57 vector. The digestion
plasmid shows 2 bands (1.7 and 3 kb). The lower band (1.7 kb)




Figure 3.5. pUC57 linear vector sequence with the recombinant gene (NeRh5026 ).
A linear nucleotide sequence of part of the pUC57 vector with the recombinant gene
(NeRh50”6 ). Blue highlighted nucleotides sequence refers to XbaI restriction site.
Green highlighted nucleotides sequence refers to Nitrosomonas europaea Rh50.
Red nucleotides sequence refers to human RhD loop 6. Red highlighted nucleotides
sequence shows BamHI restriction site. Yellow highlighted nucleotides sequence is
AD1 forward primer. Purple highlighted nucleotides sequence is an AD2 reverse
primer.
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Figure 3.6. BamHI andXbaI digestion of pUC57-NeRh50”6.
Lane numbers (1, 3, and 5) are representing three colonies of transformed pUC57
plasmid with the recombinant gene NeRh50”6, (non-cut sample), which is the
samples not treated with the BamHI and XbaI restriction enzymes. Lane numbers
(2, 4, and 6) are representing the digested pUC57 plasmid (the cut sample) with
restriction enzymes (BamHI andXbaI ) cut the plasmid. Band sizes are 3 kb and
1.7 kb. The lower band (1.7 kb) represents the constructed recombinant gene.
Products were run on a 1% (w/v) Agarose gel alongside a DNA marker (M).
Shown to the right of the figure are marker sizes in base pairs.
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After testing NeRh50”6, same steps were followed to replace
other external loops of the NeRh50 wild type with human RhD
corresponding external loops; human RhD loop 2 (Figure 3.7),
human RhD external loop 3 (Figure 3.8), and human RhD ex-
ternal loop 4 (Figure 3.9) were used to replace the corresponding
loop in wild type NeRh50 (Figure 1.13) to generate the other
constructs of NeRh50 wild type backbone with different hu-
man RhD external loops topology; NeRh50”4, 6 (Figure 3.10),
NeRh50”3, 4, 6 (Figure 3.11), NeRh50”2, 3, 4, 6 (Figure 3.12).
NeRh50”4, 6, NeRh50”3, 4, 6, and NeRh50”2, 3, 4, 6 hybrid
recombinant genes size were 1275 bp and they arrived inserted
in the pUC57 vector from GenScript (Figure 3.13).
Thereafter, all the constructs [pUC57 plasmid-NeRh50”4, 6 /
pUC57 plasmid-NeRh50”3, 4, 6 / pUC57 plasmid-NeRh50”2,
3, 4, 6 ] were transformed into DH5 α E. coli competent cells.
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Figure 3.7. Amino acid sequence of Human RhD external loop 2 and the corresponding
nucleotide sequence based on E. coli codon usage.
Red numbers on the above show the order of this AA in the 2nd loop of human
RhD protein sequence. Bottom box shows the reverse translation of this AA
sequence back to the nucleotide level based on the E. coli codon usage table.
Figure 3.8. Amino acid sequence of Human RhD external loop 3 and the corresponding
nucleotide sequence based on E. coli codon usage.
Red numbers on the above show the order of this AA in the 3rd loop of human
RhD protein sequence. Bottom box shows the reverse translation of this AA
sequence back to the nucleotide level based on the E. coli codon usage table.
Figure 3.9. Amino acid sequence of Human RhD external loop 4 and the corresponding
nucleotide sequence based on E. coli codon usage.
Red numbers on the above show the order of this AA in the 4th loop of human
RhD protein sequence. Bottom box shows the reverse translation of this AA
sequence back to the nucleotide level based on the E. coli codon usage table.
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Figure 3.10. Predicted membrane topology and amino acid sequence of NeRh50”4, 6 construct.
This figure depicts the hypothetical membrane orientation of the recombinant NeRh50”4, 6 in which predicted externalized amino acids
are numbered. The recombinant protein was derived initially from a cDNA of a wild type NeRh50 combined with a human RhD external
loops 4 and 6 polypeptide sequences. The predicted extracellular loops of the human RhD amino acids loop 6 [LVLDTVGAGNGM]/ loop
4 [ALLRSPIERK] are shown as solid circles with a blue single letter amino acid code inside each circle. The yellow arrows point to the
external loop 4 and loop 6 respectively.
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Figure 3.11. Predicted membrane topology and amino acid sequence of NeRh50”3, 4, 6 construct.
This figure depicts the hypothetical membrane orientation of the recombinant NeRh50”3, 4, 6 in which predicted externalized amino acids
are numbered. The recombinant protein was derived initially from a cDNA of a wild type NeRh50 combined with a human RhD exter-
nal loop 3, loops 4 and 6 polypeptide sequences. The predicted extracellular loops of the human RhD amino acids loop 6 [LVLDTVGAG-
NGM]/ loop 4 [ALLRSPIERK]/ loop 3 [NIFNTDYHMNMM] are shown as solid circles with a blue single letter amino acid code inside
each circle. The yellow arrows point to the external loops 3, 4 and loop 6 respectively.
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Figure 3.12. Predicted membrane topology and amino acid sequence of NeRh50”2, 3, 4, 6 construct.
This figure depicts the hypothetical membrane orientation of the recombinant NeRh50”2, 3, 4, 6 in which predicted externalized amino
acids are numbered. The recombinant protein was derived initially from a cDNA of a wild type NeRh50 combined with a human RhD ex-
ternal loop 3, loops 4 and 6 polypeptide sequences. The predicted extracellular loops of the human RhD amino acids loop 6 [LVLDTV-
GAGNGM]/ loop 4 [ALLRSPIERK]/ loop 3 [NIFNTDYHMNMM] and loop 2 [FPSGKVVIT] are shown as solid circles with a blue single
letter amino acid code inside each circle. The yellow arrows point to the external loops 2, 3, 4 and loop 6 respectively.
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Figure 3.13. pUC57 vector with the recombinant gene (NeRh50”2, 3, 4, 6 ) circular sequence map.
A circular sequence of the full pUC57 vector with the recombinant gene (NeRh50”2, 3, 4, 6 ), it shows all the restriction enzymes sites. By
CLC Genomics Workbench 12.0 programme.
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3.2.2 Purifying DNA
The pUC57 plasmid with NeRh50”6 DNA was purified using
Wizard(R) Plus SV Minipreps DNA Purification System from
Promega. The DNA concentration was assessed using Nano-
Drop 2000 UV-Vis Spectrophotometer (Thermos Scientific, UK).
3.2.3 PCR amplifying the NeRh50”6
The hybrid recombinant gene (NeRh50”6 ) was amplified using
PCR in the presence of AD1 forward and AD2 reverse primers
to generate NeRh50”6* (amplicon) with a new restriction site
(BamHI/ NdeI ) and an amplicon size of 1349 bp. These sam-
ples were run on a 1% (w/v) agarose gel to check the size of the
recombinant gene NeRh50”6* (Figure 3.14).
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Figure 3.14. Amplicons of pUC57 plasmid - NeRh50”6*
Lane numbers (1 / 2) are representing 2 amplicons of the pUC57 plasmid -
NeRh50”6*, which were transformed in DH5 α E. coli. Using AD1 forward/ AD2
reverse primers formed amplicons; the amplicon size is 1349 bp. Lane number
(3) is representing the negative control of the PCR product (nuclease free water).
Products were run on a 1% Agarose gel (w/v) alongside DNA markers [M1(1 Kb)
and M2(100 bp)]. Shown to the right of the figure are marker sizes in base pairs.
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3.3 Expression Vectors
3.3.1 pESV2 expression vector
pESV2 expression vector is the second vector used in this project
after pUC57 plasmid because it is useful in downstream tech-
niques to detect the recombinant protein NeRh50”RhD human
external loops expression on the E. coli. pESV2 is an E. coli
expression vector which was used by Cherif-Zahar et al., 2007,
it was used to study the expression of the NeRh50 protein in E.
coli.
3.3.1.1 Digestion of pESV2-NeRh50”6
Following digestion of the pESV2-NeRh50”6 plasmid with re-
striction enzymes NdeI and BamHI (See 2.2.3.2), the prod-
ucts were run on a 1% (w/v) agarose gel and two bands were
seen. The lower band (1.7 kb) represents the digested insertion
NeRh50”6 and the upper band 3 kb represents the pESV2 plas-
mid (Figure 3.15).
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Figure 3.15. BamHI / NdeI digestion of pESV2- NeRh50”6.
Lane (1) the digested pESV2 plasmid, which shows 2 bands where the 2 restriction
enzymes (BamHI and NdeI ) cut the plasmid. Bands size are 3 Kb represent
the digested pESV2 plasmid and 1.7 Kb represents the insertion. Lane (2) the
non-digested plasmid, which is the untreated sample with the (BamHI and NdeI )
restriction enzymes shows many bands due to the multiple constructing processes
that the pESV2 vector has been through (see 2.2.2.3.2). Products were run on a
1% (w/v) agarose gel alongside a DNA marker (M). Shown to the right of the
figure are marker sizes in base pairs.
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3.3.1.2 Cloning of pESV2-NeRh50”6ˆ Human RHD in DH5α E.
coli Competent Cells
Following the ligation of the mixture of purified pESV2 with the
purified digested amplicon (NeRh50”6*ˆ) with two different ra-
tio (see 2.2.3.4), the product was transformed in DH5α E. coli
competent cells. After that, master plate was prepared. PCR
screening for single colonies with different ligation ratio were
run on a 1% (w/v) agarose gel. The 2:1 ratio (Figure 3.16) (A)
showed a single band with high intensity a round 1.3 kb in all
colonies, which represent the right size of NeRh50”6*ˆ in pESV2
expression vector after amplified with AD1 / AD2 primers. The
5:1 ratio (B) showed lower band intensity than 2:1 and in some
colonies it showed multiply bands.
The PCR screening was done to check if each colony contained
the positive plasmid, which has the correct insertion while the
master plate was done to keep a stock from each positive colony
for later use.
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Figure 3.16. PCR screening of positive pESV2-NeRh50”6* plasmid colonies, which am-
plified with AD1 / AD2 primers.
Amplicon samples of the single colonies: from the transformation plate of the
[pESV2 with cDNA (NeRh50”6 )] with DH5 α E. coli competent cells with differ-
ent ligation ratio. A) Lane (1-16) shows amplicon samples of [pESV2 with cDNA
(NeRh50”6* )] transformed with DH5 α E. coli competent cells with (2:1) ligation
ratio insert: vector. B) Lane (1-17) shows amplicon samples of [pESV2 with cDNA
(NeRh50”6* )] transformed with DH5 α E. coli competent cells with (5:1) ligation
ratio insert:vector. Products were run on a 1% (w/v) Agarose gel alongside DNA
markers (M1 and M2). Shown to the right of figure are marker sizes in base pairs.
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3.3.1.3 Sequencing of pESV2 expression vector
pESV2 vector was constructed from pACYC184 and pSU18 vec-
tors and it was combined with sequence from other vectors (Fig-
ure 3.18) as described in Javelle et al., 2003.
Figure 3.17. pESV2 vector constructed process.
Javelle et al., 2003
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Snap Gene program was used to produce a pESV0 vector map,
which is part of this process of constructing the pESV2. This
vector contains the AmtB Shine Dalgarno sequence (5-AGGAGGU-
3), which is a (6-8) base sequence located upstream of the start
codon of the bacterial mRNA, that has an importance in ribo-
some alignment for efficient translation. Moreover, other critical
sequences were placed in the promoter sequence of the vector to
make sure that the vector will work in E. coli.
The problem was the unavailability of either the vector map or
the sequence of some vectors (provided by Prof Mike Merrick),
which were used to construct the pESV2 vector. Therefore, we
sequenced one of the original samples from Prof. Merrick’s lab
(Figure 3.18) and one of the clones, which has the vector from
Prof. Merrick’s lab combined with NeRh50”6* (Figure 3.19)
by next generation sequencing (See 2.2.2.3.7.3). So, a total of
2 samples, were sequenced using Ion PGMTM in one run. The
data was then processed, and a summary was produced by the
Torrent SuiteTM Software Version 4.4 (Figure 3.18 and 3.19).
The total reads produced from the original sample was 460,133,
while the total reads from the vector combined with NeRh50”6*
was 397,704. In the first report (Figure 3.18), the Ion Sphere
Particle (ISP) loading density was 90%, while 10% of the 314R
chip wells were empty. Moreover, in the second report (Figure
3.19), the Ion Sphere Particle (ISP) loading density was 85%,
while 15% of the 314R chip wells were empty. A brief sequencing
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report of the original sample sequencing run is displayed in Fig-
ure 3.18. For downstream analysis, there were around 460,133
usable reads in total, which is 41% of the total reads. These
reads were thoroughly processed by well classification and read
filtering to ensure their quality. Clonal ISPs (in which single
template fragments were amplified) made up 52% of the reads,
while 48% were polyclonal ISPs. After filtering out 1% of test
fragments and 22% of low-quality reads, the final percentage
of the final library was 77% with a mean read length of 180
bp (Figure 3.18). Furthermore, Figure 3.19 shows a brief se-
quencing report for the sample containing the vector combined
with NeRh50”6*. For downstream analysis, there were around
397,704 usable reads in total, which is 37% of the total reads.
These reads were thoroughly processed by well classification and
read filtering to ensure their quality. Clonal ISPs (in which sin-
gle template fragments were amplified) was made up 51% of
reads, while 49% were polyclonal ISPs. After filtering out 1% of
test fragments and 27% of low-quality reads, the final percent-
age of the final library was 72% with a mean read length of 177
bp (Figure 3.19).
The outcome of the NGS work confirmed that; the original vec-
tor from Prof. Merrick’s lab was, pUC57 vector after the se-
quence were Blasted to vector databases (https://blast.ncbi.
nlm.nih.gov/Blast.cgi?PROGRAM=blastn&PAGE TYPE=
BlastSearch&LINK LOC=blasthome) because there were no ref-
161
erence sequence to compare it with (see appendix A). The se-
quence from our NGS data (100%) similarity alignment of the
nucleotides to the pUC57 vector sequence, provided by Gen-
Script. Moreover, appendix B shows the alignment of the NeRh
50”6* sequence in pESV2 vector provided from Prof. Merrick’s
lab to the NeRh50”6 sequence in pUC57 vector, provided by
GenScript.
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Figure 3.18. The report of single sequencing run of the original (pESV2) vector sample library
A) The percentage of ISP loading density of the ISP shown by the 314R chip wells was 90%. Different colours represent the loading percentage
of ISP through the physical 314R chip plate surface (red is highest; blue is lowest).
B) The total number of usable reads is 460,133, after trimming and filtration from empty wells, non-templated and polyclonal reads. The
percentage 41% is obtained by dividing these reads by the number of reads containing the library ISPs (1,138,496). The live/enrichment
percentage is 100%, which indicates that ISPs contain a strong sequence signal from test fragment and library (templated).
C) Histogram shows a mean reading length of 180 bp. The read count is displayed in the y-axis, while the read length, in bp, is shown on
the x-axis.
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Figure 3.19. The report of single sequencing run of the pESV2- NeRh50”6 sample library
A) The percentage of ISP loading density of the ISP shown by the 314R chip wells was 85%. Different colours represent the loading percentage
of ISP through the physical 314R chip plate surface (red is highest; blue is lowest).
B) The total number of usable reads is 397,704, after trimming and filtration from empty wells, non-templated and polyclonal reads. The
percentage 37% is obtained by dividing these reads by the number of reads containing the library ISPs (1,079,309). The live/enrichment
percentage is 100%, which indicates that ISPs contain a strong sequence signal from test fragment and library (templated).
C) Histogram shows a mean reading length of 177 bp. The read count is displayed in the y-axis, while the read length, in bp, is shown on
the x-axis.
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Therefore, due to the sequencing results of the vector provided
from Merrick’s lab, which came as a pUC57 vector instead of
pESV2 vector, it was no longer used and it was replaced with
pET-a9 expression vector, which is widely used for expression
work.
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3.3.2 pET-a9 expression vector
pET-a9 expression vector (Figure 3.20) is a vector, which
carries an N-terminal T7•Tag R© sequence and BamHI cloning
site. It is one of the best system for cloning and expressing
recombinant proteins in E. coli.
Figure 3.20. pET-9a expression vector map showing all restriction enzyme sites
adapted from Novagen
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3.3.2.1 Cloning of pET- NeRh50/Human RhD external loops in
BL21 (DE3) Chemically Competent Cells
BL21 (DE3) competent cells are chemically competent E. coli
cells used for high-level protein expression with T7 RNA poly-
mer
ase-based expression systems, which is a derivative of T7 expres-
sion E. coli strain.
The mixture of purified digested pET with the purified digested
NeRh50”human RhD external loops from ligation step (see 2.2.2.
3.4) was transformed in BL21 (DE3) E. coli chemically compe-
tent cells; it was incubated for 16 hours at 37 ◦C. After that,
master plate was prepared. Thereafter, an enzymatic digestion
with BamHI and XbaI step was run on each single colony from
the master plate to check the positive colony, which has the cor-
rect insertion (NeRh50”human RhD external loops); NeRh50”6
with 1766 bp, NeRh50”4, 6 with 1275bp, NeRh50”3, 4, 6 with
1275 bp, and NeRh50”2, 3, 4, 6 with 1275 bp, as shown in Fig-
ure 3.21. Therefore, according to the band size (Figure 3.21)
prove that the ligation step was successful and the insertion of
NeRh50”RHD with different constructs were successfully cloned
in pET expression vector.
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Figure 3.21. Digested positive colonies of pET vector with the NeRh50”6, NeRh50”4, 6, NeRh50”3, 4, 6, NeRh50”2, 3, 4, 6 constructs.
Lane (1, 2) non-digested pET- NeRh50”6 gene and pET- NeRh50”4, 6 gene respectively, shows band around 5Kb. Lane(3) Digested pET-
NeRh50”4, 6ˆ, which shows 2 bands where the 2 restriction enzymes (BamHI and XbaI ) cut the plasmid. Bands size around 4 Kb and
1275 bp. Lane(4) Digested pET- NeRh50”6”, which shows 2 bands where the 2 restriction enzymes (BamHI and XbaI ) cut the plasmid.
Bands size around 4 Kb and 1766 bp. Lane (5) non-digested pET- NeRh50”2, 3, 4, 6 gene, shows band around 5Kb. Lane(6-8) Digested
pET-NeRh50”3, 4, 6ˆ, which shows 2 bands where the 2 restriction enzymes (BamHI and XbaI ) cut the plasmid. Lane(9-13) Digested
pET-NeRh50”2, 3, 4, 6ˆ, which shows 2 bands where the 2 restriction enzymes (BamHI and XbaI ). Bands size around 4 Kb and 1275 bp.
Products were run on a 1% (w/v) agarose gel alongside a DNA marker (M). Shown to the right of figure are marker sizes in base pairs.
Arrows point to the band of interest.
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3.3.2.2 Sanger Sequencing of NeRh50”human RhD external loops
to confirm the presence of the human RhD external loops Sanger
sequencing was used to sequence cDNA clones of each construct:
NeRh50”6, NeRh50”4, 6, NeRh50”3, 4, 6, and NeRh50”2, 3, 4,
6, to confirm restriction digestion results (Figure 3.21) using spe-
cific primer sets (Table 2.4). Primers were designed to amplify
the sequences around each human RhD external loops, more-
over, there were two primer sets to amplify the region before and
after the hybrid sequence NeRh50” human RhD external loops
in the pET expression vector sequence (Figure 3.22). The only
primer sets that worked were the sets around the hybrid gene
in the pET expression vector sequence (Figures 3.23, 3.24, 3.25,
and 3.26), while other primer sets gave unusable sequence or
some of them did not amplify at all (see Appendices C-I for full
alignment of all the constructs against each primer). However,
Sanger sequencing data were aligned against pET- NeRh50”2,
3, 4, 6 sequence. F1 forward primer (Figure 3.23) and R1 re-
verse primer (Figure 3.24) which aligned with the sequence be-
fore the hybrid gene by using CLC Genomics Workbench 12.0
programme. Moreover, F7 forward primer (Figure 3.25) and R7
reverse primer (Figure 3.26) were used to amplify the region on
the pET expression vector after the insertion location. The se-
quence data confirmed that we have the pET expression vector
and the cloning process was successful, though the coverage of
these primers (F1, F7, R1, and R7) was not enough to read
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entire hybrid recombinant sequence.
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Figure 3.22. pET-NeRh50”2,3,4,6 vector map
pET-NeRh50”2,3,4,6 vector map showing all restriction enzyme sites and all primer sets(F1-F7) with green dots, (R1-R7) with red dots.
Blue part shows recombinant NeRh50”2,3,4,6 DNA.
by SnapGene.
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Figure 3.23. Sanger sequencing data with electropherogram of all constructs cDNAs against (F1) forward primer.
Sanger sequencing data for all constructs: NeRh50”6, NeRh5024, 6, NeRh50”3, 4, 6, and NeRh50”2, 3, 4, 6 were aligned by CLC Genomics
Workbench 12.0 programme against: F1 forward primer which cover the sequence in the pET expression vector before insertion. Moreover,
that were aligned against the reference sequence, which is pET-NeRh50”2, 3, 4, 6.
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Figure 3.24. Sanger sequencing data with electropherogram of all constructs cDNAs against (R1) reverse primer.
Sanger sequencing data for all constructs: NeRh50”6, NeRh50”4, 6, NeRh50”3, 4, 6, and NeRh50”2, 3, 4, 6 were aligned by CLC Genomics
Workbench 12.0 programme against: R1 reverse primer, which cover the sequence in the pET expression vector before insertion.
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Figure 3.25. Sanger sequencing data with electropherogram of all constructs cDNAs against (F7) forward primer.
Sanger sequencing data for all constructs: NeRh50”6, NeRh50”4, 6, NeRh50”3, 4, 6, and NeRh50”2, 3, 4, 6 were aligned by CLC Genomics
Workbench 12.0 programme against: F7 forward primer which cover the sequence in the pET expression vector after insertion.
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Figure 3.26. Sanger sequencing data with electropherogram of all constructs cDNAs against (R7) forward primer.
Sanger sequencing data for all constructs: NeRh50”6, NeRh50”4, 6, NeRh50”3, 4, 6, and NeRh50”2, 3, 4, 6 were aligned by CLC Genomics
Workbench 12.0 programme against: R7 forward primer which cover the sequence in the pET expression vector after insertion.
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3.4 Three-Dimensional Protein Model
SWISS-MODEL is a fully automated protein structure homology-
modelling server. The purpose of this server is to create protein
models (https://swissmodel.expasy.org/).
This program was used to create the 3-dimensional protein model
for construct; NeRh50”2, 3, 4, 6 (Figure 3.30). Moreover, the
software tool was used to compare the three-dimensional protein
module for the construct to the human RhD wild type protein
(Figure 3.28) and NeRh50 wild type protein (Figure 3.29). The
construct was compared to the external loops of the human RhD
wild type protein and to the backbone of NeRh50 wild type pro-
tein in order detecting changes in these aspects.
In the NeRh50”2, 3, 4, 6 (Figure 3.27) there are light blue cir-
cles which are present in the NeRh50 wild type protein (Figure
3.29) that represent the backbone of the construct. Moreover,
the dark blue circles represent human RhD external loop 2, or-
ange circles represent human RhD external loop 3, green rep-
resent human RhD external loop 4, and cyan represent human
RhD external loop 6 that have the same colour as the external
loops in the human RhD wild type (Figure 3.28).
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Figure 3.27. Predicted 3D protein model of NeRh50” 2, 3, 4, 6.
Predicted 3D protein model of NeRh50”2, 3, 4, 6. The colour (dark blue light blue
green cyan orange red) represents the amino acid sequence. The arrows show the
human RhD external loops (2, 3, 4, 6). Dark blue represents human RhD external
loop 2, cyan represents human RhD external loop 6. Orange represents human
RhD external loop 3, and green represents human RhD external loop 4. Arrows
show external loops of the human RhD. By SWISS-MODEL
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Figure 3.28. Predicted 3D protein model of the human RhD wild type
Predicted 3D protein model of human RhD wild type. The colour; (dark blue light
blue green cyan orange red) represents the amino acid sequence. The arrows show
the human RhD external loops (2, 3, 4, 6). Dark blue represents human RhD
external loop 2, cyan represents human RhD external loop 6. Orange represents
human RhD external loop 3, and green represents human RhD external loop 4.
Arrows show external loops of the human RhD. By SWISS-MODEL
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Figure 3.29. Predicted 3D protein model of NeRh50 wild type
By SWISS-MODEL
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3.5 Confirming the presence of the Rh Re-
combinant proteins
Table 3.2. Anti-D and Anti-NeRh50 antibodies list against different techniques.
List shows Anti-D and Anti-NeRh50 antibodies, which were used in western blot,
flow-cytometry and TEM techniques. Asterisk mark used to show each antibody
were used.
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3.5.1 Western Blot Results
Seven antibodies (Table 2.1, 3.2) were tested against ghost mem-
brane samples with (Rh+, Rh-) phenotypes, and the four differ-
ent constructs expressed in E. coli ; NeRh50”6, NeRh50”4, 6,
NeRh50”3, 4, 6, and NeRh50”2, 3, 4, 6, human RhD30 wild
type and NeRh50 wild type to confirm that these antibodies
bind to the human RhD external loops and N.europaea external
loop 1 and C-terminus by western blot.
3.5.1.1 Comparison of Bacterial Protein Extraction Methods
Two different buffers were used; the lysis buffer and BugBuster
master mix protein extraction reagent (see 2.2.2.4.7.1) to assess
which resulted in a higher protein concentration for the sam-
ples. Following use of the Qubit assay for protein quantitation
of these samples, it was shown that use of BugBuster master
mix protein extraction reagent to have a higher protein concen-
tration in the cell lysates (Table 3.3), also easier and faster than
the lysis buffer.
Following this comparison, lysis buffer was no longer used and
bacterial proteins for samples from all constructs were extracted
by BugBuster master mix protein extraction reagent.
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Table 3.3. Qubit protein quantitation results of three different colonies of pESV2-
NeRh50”6
Qubit results of pESV2-NeRh50”6 colonies after lysing them with lysis buffer
or Bug Buster protein extraction reagent. Protein concentrations were higher
with the Bug-Buster Master Mix than with the lysis buffer. Moreover, A tube
(the pellet samples) has shown much higher results than B tubes (supernatant
samples) (see 2.2.2.4.7.1 )
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3.5.1.2 Detection of human RhD external loop 4 by 2.2B9 anti-
body by western blotting
2.2B9 a monoclonal antibody (see 2.1.1) was used to detect the
expression of human RhD external loop 4 in all constructs and
control samples. It was raised against a synthetic peptide cor-
responding to the fourth external domain of the RhD protein
(Figure 3.30) (Skinner, Mushens & Avent, unpublished).
NeRh50 wild type, which was used as a negative control for
2.2B9, shows an immunostaining band close to 37 kDa.
A ghost membrane sample with an Rh- phenotype, was used as
a second negative control to 2.2B9, and shows only one faint
band around 34 kDa.
On the other hand, a ghost membrane sample with an Rh+ phe-
notype, was used as a positive control to this antibody, and
shows clear double band around 32-34 kDa. Moreover, human
RhD30 wild type sample shows a clear double band around 32-
34 kDa similar to the ghost membrane sample with Rh+ pheno-
type.
pETNeRh50”6 sample, shows only one faint band around 37
kDa compared to other constructs; pET NeRh50”4, 6, pET
NeRh50”3, 4, 6, and pET NeRh50”2, 3, 4, 6 all react simi-
larly and show a clear double band around 37-36 kDa.
The lower band, which is the band of interest has a band size
approximately 36 kDa (Figure 3.30).
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Figure 3.30. Immunostaining of RBC membranes and E. coli protein extractions to detect human RhD external loop 4 by using 2.2B9 antibody.
Immunostaining of RBC membranes from different Rh phenotype erythrocytes and E. coli protein extractions using 2.2B9. Lane (1)
is representing a bacterial recombinant protein extraction of E. coli NeRh50”2, 3, 4, 6 construct. Lane (2) is representing a bacterial
recombinant protein extractions of E. coli NeRh50”3, 4, 6 construct. Lane (3) is representing a bacterial recombinant protein extractions
of E. coli NeRh50”4, 6 construct. Lane (4) is representing a bacterial recombinant protein extractions of E. coli NeRh50”6 construct. Lane
(5) E. coli protein extractions for NeRh50 wild type. Lane (6) RhD30 wild type. Lane numbers (7) is representing RBC ghost membrane
with Rh+ phenotype. Lane (8) is RBC ghost membrane with Rh- phenotype. 10 µg of RBC membrane proteins and 5 µg of E. coli protein
extractions were used in all samples under reducing conditions. Rh+ (lane 7) and the wild type human RhD (lane 6) samples show higher
density bands of the human RhD external loop 4. Human RhD external loop 4 was observed around 32 kDa as a double bands, while in
NeRh50”4, 6, NeRh50”3, 4, 6, and NeRh50”2, 3, 4, 6 samples (lanes 3, 2, 1 respectively), showed a clear double bands around 37 kDa.
Furthermore, NeRh50 wild type (lane 5) and NeRh50”6 lane (4) show a similar faint band around 37 kDa. Rh- lane(8) shows a one band
around 32 kDa. Products were run on a 4-12 % acrylamide gel alongside a protein marker (M). Shown to the right of the figure are marker
sizes in kDa. The primary antibody concentration was 1:6 and the secondary antibody was rabbit anti-mouse. Arrows are pointing to the
bands of interest.
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3.5.1.3 Detection of human RhD external loop 6 by 2A4 / 5G9
antibodies by western blotting
2A4 / 5G9 are two clones of a culture supernatant monoclonal
antibody (see 2.1.1) and were used to detect the expression of
human RhD external loop 6 in all constructs and control sam-
ples (Figure 3.31 and 3.32).
NeRh50 wild type, which was used as a negative control for both
2A4 and 5G9 antibodies, shows no obvious band. Ghost mem-
brane sample with Rh- phenotype, which was used as a second
negative control, shows no band.
On the other hand, ghost membrane sample with Rh+ pheno-
type, which was used as a positive control for this antibody,
shows a faint band around 32 kDa.
Moreover, all constructs; pETNeRh50”6 sample, pET NeRh50”4,
6, pET NeRh50”3, 4, 6, and pET NeRh50”2, 3, 4, 6, react simi-
lar and show a clear band around 37 kDa (Figure 3.31 and 3.32).
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Figure 3.31. Immunostaining of RBC membranes and E. coli protein extractions to detect human RhD external loop 6 by using 2A4 antibody.
Immunostaining of RBC membranes from different Rh phenotype erythrocytes and E. coli protein extractions using 2A4. Lane (1) is
representing a bacterial recombinant protein extraction of E. coli NeRh50”2, 3, 4, 6 construct. Lane (2) is representing a bacterial recombinant
protein extractions of E. coli NeRh50”3, 4, 6 construct. Lane (3) is representing a bacterial recombinant protein extractions of E. coli
NeRh50”4, 6 construct. Lane (4) is representing a bacterial recombinant protein extractions of E. coli NeRh50”6 construct. Lane (5) E.
coli protein extractions for NeRh50 wild type. Lanes (6), (7) is representing RBC ghost membrane with Rh+ phenotype and RBC ghost
membrane with Rh- phenotype respectively. 10 µg of RBC membrane proteins and 5 µg of E. coli protein extractions were used in all
samples under reducing conditions. Rh+ lane (6) shows a faint band for the human RhD external loop 6. Human RhD external loop 6 was
observed around 32 kDa as single band, while in NeRh50”6, NeRh50”4, 6, NeRh50”3, 4, 6, and NeRh50”2, 3, 4, 6 samples (lanes 4, 3, 2, 1
respectively), showed a clear band around 37 kDa. Furthermore, NeRh50 wild type lane (5) showed no band. Rh- lane (7) shows a no band.
Products were run on a 4-12 % acrylamide gel alongside a protein marker (M). Shown to the right of the figure are marker sizes in kDa. The
primary antibody concentration was 1:10 and the secondary antibody was rabbit anti-mouse. Arrows are pointing to the interested bands
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Figure 3.32. Immunostaining of RBC membranes and E. coli protein extractions to detect human RhD external loop 6 by using 5G9 antibody.
Immunostaining of RBC membranes from different Rh phenotype erythrocytes and E. coli protein extractions using 5G9. Lane (1) is
representing a bacterial recombinant protein extractions of E. coli NeRh50”2, 3, 4, 6 construct. Lane (2) is representing a bacterial
recombinant protein extractions of E. coli NeRh50”3, 4, 6 construct. Lane (3) is representing a bacterial recombinant protein extractions
of E. coli NeRh50”4, 6 construct. Lane (4) is representing a bacterial recombinant protein extractions of E. coli NeRh50”6 construct. Lane
(5) E. coli protein extractions for NeRh50 wild type. Lanes (6), (7) is representing RBC ghost membrane with Rh+ phenotype and RBC
ghost membrane with Rh- phenotype respectively. 10 µg of RBC membrane proteins and 5 µg of E. coli protein extractions were used in all
samples under reducing conditions. Rh+ lane (6) shows a faint band for the human RhD external loop 6. Human RhD external loop 6 was
observed around 32 kDa as a single band, while in NeRh50”6, NeRh50”4, 6, NeRh50”3, 4, 6, and NeRh50”2, 3, 4, 6 samples (lane 4, 3, 2,
1 respectively), showed a fade band around 37 kDa. Furthermore, NeRh50 wild type lane (5) shows no band. Rh- lane (7) shows no band.
Products were run on a 4-12 % acrylamide gel alongside a protein marker (M). Shown to the right of the figure are marker sizes in kDa. The
primary antibody concentration was 1:10 and the secondary antibody was rabbit anti-mouse. Arrows are pointing to the interested bands
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3.5.1.4 Detection of human RhD external loops 4, 6 by BIRMA-
D6 antibody by western blotting:
BIRMA-D6 is a purified monoclonal antibody (see 2.1.1), which
was used to detect the expression of human RhD external loops
4, 6 in all constructs and control samples (Figure 3.33).
NeRh50 wild type, which was used as a negative control for
BIRMA-D6, it shows no band. Ghost membrane sample with
Rh- phenotype, which was used as a second negative control for
BIRMA-D6, shows no obvious band.
On the other hand, ghost membrane sample with Rh+ pheno-
type, which was used as a positive control to this antibody,
shows a clear band around 32 kDa.
Furthermore, all constructs; pETNeRh50”6, pET NeRh50”4, 6,
pET NeRh50”3, 4, 6, and pET NeRh50”2, 3, 4, 6, react similar
and show a band around 37 kDa (Figure 3.33).
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Figure 3.33. Immunostaining of RBC membranes and E. coli protein extractions to detect human RhD external loops 4, 6 by using BIRMA-D6 anti-
body.
Immunostaining of RBC membranes from different Rh phenotypes erythrocytes and E. coli protein extractions using BIRMA-D6. Lane
(1) is representing a bacterial recombinant protein extractions of E. coli NeRh50”2, 3, 4, 6 construct. Lane (2) is representing a bacterial
recombinant protein extractions of E. coli NeRh50”3, 4, 6 construct. Lane (3) is representing a bacterial recombinant protein extractions
of E. coli NeRh50”4, 6 construct. Lane (4) is representing a bacterial recombinant protein extractions of E. coli NeRh50”6 construct. Lane
(5) E. coli protein extractions for NeRh50 wild type. Lanes (6), (7) is representing RBC ghost membrane with Rh+ phenotype and RBC
ghost membrane with Rh- phenotype respectively . 10 µg of RBC membrane proteins and 5 µg of E. coli protein extractions were used in all
samples under reducing conditions. Rh+ lane (6) shows a clear band for the human RhD external loop 6. Human RhD external loops 4, 6
were observed around 32 kDa as single band, while in NeRh50”6, NeRh50”4, 6, NeRh50”3, 4, 6, and NeRh50”2, 3, 4, 6 samples (lanes 4, 3,
2, 1 respectively), showed a clear band around 37 kDa. Furthermore, NeRh50 wild type lane (5) showed no band at the same size. Rh- lane
(7) shows a no band. Products were run on a 4-12 % acrylamide gel alongside a protein marker (M). Shown to the right of the figure are
marker sizes in kDa. The primary antibody concentration was 1:2500 and the secondary antibody was goat anti-human. Arrows are pointing
to the band of interest.
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3.5.1.5 Detection of human RhD external loops 3, 4, 6 by MS-26
antibody by western blotting:
MS-26 is a culture supernatant monoclonal antibody (see 2.1.1)
was used to detect the expression of human RhD external loops
3, 4, 6 in all constructs and control samples (Figure 3.34).
It was raised against a synthetic peptide corresponding to EpD23
of the RhD protein (Scott,1996).
NeRh50 wild type, which was used as a negative control for
MS-26, shows no band. Ghost membrane sample with Rh- phe-
notype, which was used as a second negative control to MS-26,
shows no obvious band, reflecting that this MAb may recognise
a conformation- dependent antibody, not detectable by western
blotting. On the other hand, ghost membrane sample with Rh+
phenotype, and all constructs; pETNeRh50”6, pET NeRh50”4,
6, pET NeRh50”3, 4, 6, and pET NeRh50”2, 3, 4, 6, show no
band at any size (Figure 3.34).
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Figure 3.34. Immunostaining of RBC membranes and E. coli protein extractions to detect human RhD external loops 3, 4, 6 by using MS-26 antibody.
Immunostaining of RBC membranes from different Rh phenotypes erythrocytes and E. coli protein extractions using MS-26. Lane (1)
is representing a bacterial recombinant protein extractions of E. coli NeRh50”2, 3, 4, 6 construct. Lane (2) is representing a bacterial
recombinant protein extractions of E. coli NeRh50”3, 4, 6 construct. Lane (3) is representing a bacterial recombinant protein extractions
of E. coli NeRh50”4, 6 construct. Lane (4) is representing a bacterial recombinant protein extractions of E. coli NeRh50”6 construct. Lane
(5) E. coli protein extractions for NeRh50 wild type. Lanes (6), (7) is representing RBC ghost membrane with Rh+ phenotype and RBC
ghost membrane with Rh- phenotype respectively .
Products were run on a 4-12 % acrylamide gel percentage alongside a protein marker (M). Shown to the right of the figure are marker sizes
in kDa. 10 µg of RBC membrane proteins and 5 µg of E. coli protein extractions were used in all samples under reducing conditions. All
controls and constructs were shown no obvious bands. The primary antibody concentration was 1:2500 and the secondary antibody was
Rabbit anti-mouse.
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3.5.1.6 Detection of NeRh50 external loop 1 and C-terminus by
1918 antibody by western blotting:
1918 is a purified polyclonal antibody (see 2.1.1) was used to de-
tect the expression of NeRh50 external loop 1 and C-terminus
in all constructs and control samples. It was raised against a
synthetic peptide corresponding to the first external loop and
C-terminus domains of the NeRh50 protein (Figure 3.35).
Ghost membrane samples with Rh- and Rh+ phenotypes, which
were used as a negative control to 1918 antibody, shows no ob-
vious band.
By contrast, NeRh50 wild type, which used as a positive control
to this antibody, shows a clear band around 37 kDa.
Furthermore, all constructs; pETNeRh50”6, pET NeRh50”4, 6,
pET NeRh50”3, 4, 6, and pET NeRh50”2, 3, 4, 6, react simi-
lar to the positive control NeRh50 wild type and show a band
around 37 kDa (Figure 3.35).
192
Figure 3.35. Immunostaining of RBC membranes and E. coli protein extractions to detect NeRh50 external loop 1 and C-terminus by using 1918 anti-
body.
Immunostaining of RBC membranes from different Rh phenotypes erythrocytes and E. coli protein extractions using 1918.
Lane (1) is representing a bacterial recombinant protein extractions of E. coli NeRh50”2, 3, 4, 6 construct. Lane (2) is representing a bacterial
recombinant protein extractions of E. coli NeRh50”3, 4, 6 construct. Lane (3) is representing a bacterial recombinant protein extractions
of E. coli NeRh50”4, 6 construct. Lane (4) is representing a bacterial recombinant protein extractions of E. coli NeRh50”6 construct. Lane
(5) E. coli protein extractions for NeRh50 wild type. Lanes (6), (7) is representing RBC ghost membrane with Rh+ phenotype and RBC
ghost membrane with Rh- phenotype respectively . 10 µg of RBC membrane proteins and 5 µg of E. coli protein extractions were used in
all samples under reducing conditions. Rh+, Rh- lanes (6, 7) shows no band. NeRh50 external loop 1 and C-terminus were observed around
37 kDa as single band as appear in; NeRh50 wild type NeRh50”6, NeRh50”4, 6, NeRh50”3, 4, 6, and NeRh50”2, 3, 4, 6 samples (lanes 5,
4, 3, 2, 1 respectively), showed a clear band around 37 kDa. Products were run on a 4-12 % acrylamide gel percentage alongside a protein
marker (M). Shown to the right of the figure are marker sizes in kDa. The primary antibody concentration was 1:2500 and the secondary
antibody was swine anti-rabbit. Arrows are pointing to the band of interest.
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3.5.1.7 Detection of NeRh50 external loop 1 by 1917 antibody by
western blotting:
1917 is a purified monoclonal antibody (see 2.1.1) was used to
detect the expression of NeRh50 external loop 1 in all constructs
and control samples. It was raised against a synthetic peptide
corresponding to the first external domains of the NeRh50 pro-
tein (Figure 3.36).
Ghost membrane samples with Rh- and Rh+ phenotypes, which
were used as a negative control to 1918 antibody, shows no ob-
vious band.
By contrast, NeRh50 wild type, which used as a positive control
for this antibody, shows a clear band around 37 kDa. Further-
more, all constructs; pETNeRh50”6, pET NeRh50”4, 6, pET
NeRh50”3, 4, 6, and pET NeRh50”2, 3, 4, 6, react similar to
the positive control NeRh50 wild type and show a band around
37 kDa (Figure 3.36). 1917 blots with wild type NeRh50/
NeRh50”6/ NeRh50”4, 6/ NeRh50”3, 4, 6 / NeRh50”2, 3, 4,
6, samples, which showed a clear band around 37 kDa com-
pared to Rh+, wild type human RhD samples and Rh- sample,
which shows nothing around the same size.
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Figure 3.36. Immunostaining of RBC membranes and E. coli protein extraction using 1917.
Immunostaining of RBC membranes from different Rh phenotypes erythrocytes and E. coli protein extractions using 1917. Lane numbers
(1-4) are E. coli protein extraction for constructs (NeRh50”2, 3, 4, 6 NeRh50”3, 4, 6/ NeRh50”4, 6 /NeRh50”6), lane(5) E. coli protein
extraction for wild type NeRh50, which shows no band. Lane numbers (6, 7) are representing RBC membranes for Rh+, Rh- respectively.
10 µg of RBC membrane proteins and 5 µg of E. coli protein extractions were used in all samples under reducing conditions. Rh+, Rh- lanes
(6, 7) shows no band. NeRh50 external loop 1 and C-terminus were observed around 37 kDa as single band as appear in; NeRh50 wild type
NeRh50”6, NeRh50”4, 6, NeRh50”3, 4, 6, and NeRh50”2, 3, 4, 6 samples (lanes 5, 4, 3, 2, 1 respectively), showed a clear band around 37
kDa. Products were run on an acrylamide gel 4-12% alongside a protein marker (M). Shown to the right of the figure are maker sizes in
kDa. The primary antibody concentration was 1:2500 and the secondary antibody was rabbit anti-mouse. Arrows are pointing to the band
of interest.
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3.5.2 Flow cytometry Results
Flow cytometry was completed using a total of 11 different mon-
oclonal anti-D and anti-NeRh50 antibodies shown in Table 2.1
and using the methods outlined (See 2.2.2.4.9) to analyse the
different expression patterns of D epitopes and NeRh50 loop 1,
C-terminus. These antibodies were used in conjunction with a
FITC assay and a FACS ARIA II Flow cytometer/Cell Sorter
device were used. Four different constructs; pETNeRh50”6,
pET NeRh50”4, 6, pET NeRh50”3, 4, 6, pET NeRh50”2, 3,
4, 6, RhD30 wild type and NeRh50 wild type clones were trans-
formed into BL21 (DE3) E. coli competent cells (see 2.2.2.4.4).
Two types of negative control were used: non stained samples
and samples used with secondary FITC-conjugated antibodies
(See 2.2.2.4.9.2). Moreover, negative controls were used to as-
sess the background fluorescence by comparing these reads to
the reads from the samples treated with primary and secondary
antibodies. Mean fluorescence intensity was used to measure the
antibody binding. Table 3.4 shows average mean fluorescence in-
tensity (MFI) values of screening the four different constructs;
pETNeRh50”6, pET NeRh50”4, 6, pET NeRh50”3, 4, 6, pET
NeRh50”2, 3, 4, 6, RhD30 wild type, and NeRh50 wild type.
Distinct patterns of reactivity were observed, ranging from the
complete absence of D epitope expression in the case of NeRh50
wild type sample to weak and strong reaction of constructs and
RhD30 wild type to anti-D (Figure 3.39, 3.40, 3.41).
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Human RhD30 wild type showed the highest expression when
using the BRAD-3 monoclonal anti-D while shows low expres-
sion when it reacts with 1918, which is anti-NeRh50. In con-
trast, NeRh50 wild type sample showed the highest read with
1918 and lowest expression with HAM-A, which is a monoclonal
anti-D EpD 11 (Scott, 1996).
Anti-NeRh50 1918 has the highest expression with NeRh50”4,
6 construct while it has the lowest expression with NeRh50”2,
3, 4, 6 construct.
Anti-D 2.2B9 shows the highest expression with NeRh50”2, 3, 4,
6 construct, however, it shows the lowest read with NeRh50”6.
NeRh50”3, 4, 6 construct shows the lowest expression with all
anti-D antibodies, while it shows moderate expression with anti-
NeRh50 1918.
Figures 3.37 and 3.38 illustrate the mean Fluorescence intensity
(MFI) values by three dimensional chart for anti-D antibod-
ies against constructs of a recombinant protein NeRh50 human
RhD external loops, RhD30 wild type and NeRh50 wild type.
Moreover, comparing their reads to un-stained samples and sam-
ples treated with secondary antibodies only. In these charts the
variation of the reaction of anti-D and anti-NeRh50 against con-
trol samples and constructs appear as different bar length.
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Table 3.4. Flow Cytometric Analysis of wild type RhD, wild type NeRh50 and 4 different constructs using Monoclonal Anti-D and Anti-NeRh50.
Table shows the average of triplicate mean fluorescence intensity (MFI) values of NeRh50/human RhD external loop constructs, RhD30 and
NeRh50 wild type. The epitope specificity of each anti-D is shown using the 1-37 model (Scott, 1996).
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Figure 3.37. MFI values of several Anti-D against various NeRh50/human RhD external loop constructs
3-D clustered column chart shows the average reads of mean FITC Fluorescence value for different Anti-D (2.2B9, MS-26, 2A4, BIRMA-D6,
5G9, BRAD-3, HAM-A, RUM-1, BIRMA-D10, and MAD-2) against un stain E. coli cells work as a negative control. E. coli cells treated
with only secondary-FITC conjugated antibody as a negative control. E. coli cell contain RhD30 wild type as a positive control. E. coli
cell contain NeRh50 wild type as a negative control. compared to all Recombinant constructs E. coli cell contain; NeRh50”6, NeRh50”4, 6,
NeRh50”3, 4, 6, NeRh50”2, 3, 4, 6.
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Figure 3.38. MFI values of Anti-NeRh50 (1918) against various NeRh50/human RhD external loop constructs
3-D clustered column chart shows the average reads of mean FITC Fluorescence value for of Anti-NeRh50 (1918) against un stain E. coli cells
work as a negative control. E. coli cells treated with only secondary-FITC conjugated antibody as a negative control. E. coli cell contain
RhD30 wild type as a negative control. E. coli cell contain NeRh50 wild type as a positive control. compared to all Recombinant constructs
E. coli cell contain NeRh50”6, NeRh50”4, 6, NeRh50”3, 4, 6, NeRh50”2, 3, 4, 6.
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Figure 3.39. FITC fluorescence histogram of NeRh50”human RhD external loops with Anti-D BIRMA-D10 (EpD8).
FITC fluorescence histogram of NeRh50”human RhD external loops in E. coli using Anti-D BIRMA-D10. A) Un-stainE. coli cells work as
a negative control. B) E. coli cells work as a negative control by using only secondary antibody. C) E. coli contain NeRh50 wild type
work as a negative control with Anti-D BIRMA-D10. D)E. coli contains RhD30 wild type work as a positive control with Anti-D
BIRMA-D10. E)E. coli contain NeRh50”6. F) E. coli contains NeRh50”4, 6. G) E. coli contains NeRh50”3, 4, 6. H) E. coli contains
NeRh50”2, 3, 4, 6.
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Figure 3.40. FITC fluorescence histogram of NeRh50”human RhD external loops with Anti-D RUM-1 (EpD 6/7)
FITC fluorescence histogram of NeRh50/human RhD external loops in E. coli using Anti-D RUM-1. A) Un-stainE. coli cells work as a
negative control. B) E. coli cells work as a negative control by using only secondary antibody. C) E. coli contains NeRh50 wild type work
as a negative control with Anti-D RUM-1. D)E. coli contain RhD30 wild type work as a positive control with Anti-D RUM-1. E)E. coli
contains NeRh50”6. F) E.coli contains NeRh50”4, 6. G)E. coli contains NeRh50”3, 4, 6. H)E.coli contains NeRh50”2, 3, 4, 6.
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Figure 3.41. FITC fluorescence histogram of NeRh50 human RhD external loops with Anti-D MAD-2 (EpD 19)
FITC fluorescence histogram of NeRh50 human RhD external loops in E. coli using Anti-D MAD-2. A) Un-stainE. coli cells work as a
negative control. B) E. coli cells work as a negative control by using only secondary antibody. C) E. coli contain NeRh50 wild type work
as a negative control with Anti-D MAD-2. D)E. coli contain RhD30 wild type work as a positive control with Anti-D MAD-2. E)E. coli
contain NeRh50”6. F) E. coli contains NeRh50”4, 6. G) E. coli contains NeRh50”3, 4, 6. H) E. coli contains NeRh50”2, 3, 4, 6.
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3.5.3 Transmission Electron Microscopy Results
Immuno-gold staining was also used to confirm the presence of
the recombinant RHD gene in different constructs; pETNeRh50”6,
pET NeRh50”4, 6, pET NeRh50”3, 4, 6, and pET NeRh50”2,
3, 4, 6, by detecting the expression of RhD on the E. coli mem-
brane by using anti-D 2.2B9 against loop 4 and 2A4 against loop
6. Anti-NeRh50 1918 against loop 1 and C-terminus was used
to detect wild type NeRh50 protein. Furthermore, an anti E.
coli antibody was used as a positive control. TEM was used to
visualize and image the 10 nm (colloidal gold) trace, which was
conjugated to the secondary antibodies.
There was a significant change in the level of expression between
the antibodies; 2.2B9, which should detect human RhD exter-
nal loop 4 showed no binding in NeRh50”6 construct similar
to the negative control image. While, 2.2B9 works with other
constructs pET NeRh50”4, 6, pET NeRh50”3, 4, 6, and pET
NeRh50”2, 3, 4, 6 indicate the presence of human RhD external
loop 4 in these constructs. pET NeRh50”2, 3, 4, 6 construct
shows the highest expression level for human RhD external loop
4, which appear as black dots of gold trace (Figure 3.42).
2A4, which is able to detect human RhD external loop 6 showed
a high expression level in all constructs. Moreover, the E. coli
protein showed high expression with anti- E. coli antibody in
pET NeRh50 wild type sample, which was used as a positive
control (Figure 3.43).
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Figure 3.44, all constructs reacted at a moderate level with anti-
NeRh50 1918, which detects NeRh50 external loop 1 and C-
terminus. NeRh50”6 shows the lowest level of the expression
for NeRh50 external loop1 and C-terminus compared to other
constructs.
2.2B9 (Figure 3.42) shows low levels of expression for human
RhD external loop 4 compared to 2A4 for human RhD exter-
nal loop 6 (Figure 3.43), which consistently demonstrated high
levels of expression across all constructs. 1918 demonstrated a
lower level of binding than 2A4 but more than 2.2B9 (Figure
3.44).
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Figure 3.42. Transmission electron micrograph for a thin layer of E. coli contains recombinant NeRh50”RhD by using anti-D loop 4 2.2B9.
TEM images of E. coli cells contain different constructs of NeRh50”human RhD external loops. Black dots are representing gold trace, which
conjugated to the secondary antibody to show the protein presence in the E. coli membrane. A) E. coli cells work as a negative control by
using only secondary antibody, which show no dots. B) E. coli contain NeRh50 wild type with Anti.E. coli, which work as a positive control,
it shows many black dots with different intensity. C) E. coli contains NeRh50”6, which shows no gold trace. D) E. coli contain NeRh50”4,
6, which shows gold trace. E) E. coli contain NeRh50”3, 4, 6. F) E. coli contain NeRh50”2, 3, 4, 6, which shows gold trace.
207
Figure 3.43. Transmission electron micrograph for a thin layer of E. coli contains recombinant NeRh50 RhD by using anti-D loop 6 2A4.
TEM images of E. coli cells contain different constructs of NeRh50”human RhD external loops. Black dots are representing gold trace,
which conjugated to the secondary antibody to show the protein presence in the E. coli membrane. A) E. coli cells work as a negative
control by using only secondary antibody, which show no dots. B) E. coli contain NeRh50 wild type with Anti.E. coli work as a positive
control, which shows many black dots with different intensity. C) E. coli contain NeRh50”6, which shows gold trace. D) E. coli contain
NeRh50”4, 6, which shows gold trace. E) E. coli contain NeRh50”3, 4, 6. F) E. coli contain NeRh50”2, 3, 4, 6, which shows gold trace.
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Figure 3.44. Transmission electron micrograph for a thin layer of E. coli contains recombinant NeRh50”RhD by using anti-NeRh50 loop 1 and C-
terminus 1918.
TEM images of E. coli cells contain different constructs of NeRh50”human RhD external loops. Black dots are representing gold trace,
which conjugated to the secondary antibody to show the protein presence in the E. coli membrane. A)E. coli cells work as a negative
control by using only secondary antibody, which show no dots. B) E. coli contain NeRh50 wild type with Anti.E. coli work as a positive
control, which shows many black dots with different intensity. C) E. coli contain NeRh50”6, which shows gold trace. D) E. coli contain




This chapter starts with describing the generation of differ-
ent constructs based on the NeRh50 wild type sequence as a
backbone and adding the human RhD external loops to create;
NeRh50”6, NeRh50”4, 6, NeRh50”3, 4, 6, and NeRh50”2, 3, 4,
6.
The E. coli codon usage table was used to reverse translate the
human RhD external loops to increase the chance of production
of the recombinant proteins in E. coli and expression in the E.
coli membrane. The codon usage in humans differs to the codon
usage in E. coli and if human codon usage had been used it ran
the risk of the recombinant proteins not being produced.
Due to the lack of vector map for the pESV2 expression vec-
tor provided by Prof Merrick’s lab, NGS was used to sequence
the vector and plasmid constructs. The results showed that the
pESV2 vector was not a pESV2 vector and hence the expression
vector for the constructs was changed to be pET-9a.
Following enzymatic digestion with BamHI and XbaI for the re-
combinant constructs pET-NeRh50”human RhD external loops
(Figure 3.21), the band sizes of the inserts were correct and
hence the correct constructs have been cloned; plasmid (pET
expression vector) with a band size around 3 kb and the con-
structs in each plasmid; NeRh50”6 1766 bp, NeRh50”4, 6 1275
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bp, NeRh50”3, 4, 6 1275 bp, and NeRh50”2, 3, 4, 6 1275 bp.
Moreover, Sanger sequencing data for the same colonies con-
firmed that the vector is, pET expression vector as expected by
amplifying areas around the insertion; F1 forward primer (Fig-
ure 3.23), R1 reverse primer (Figure 3.24) to cover the region
before the hybrid constructs and the alignment shows similarity
between all constructs. Furthermore, F7 forward primer (Fig-
ure 3.25) and R7 reverse primer (Figure 3.26) were cover the
region in the pET vector after the hybrid sequence. Although
other primer sets shown in Table 2.4 were not able to amplify
the interested region within the hybrid recombinant sequence
(Appendix C-I).
This project was based on the successful result of SDM work by
(Liu et al., 1999 a, b). They were able to express RHCE-RHD
recombinant; the construct was based on RHCE as backbone
and replacing its third, fourth and sixth external loop with the
human RHD corresponding external loops. D epitopes success-
fully resulted from utilising the human RHCE backbone with
the addition of human RHD external loops 3, 4 and 6. So,
a simple change in the backbone lead to produce D-epitopes,
which may prove that human RHD external predicted domains
are responsible for the production of D-epitopes. As described
above synthetic construction of NeRh50 -human RhD external
loops; pETNeRh50”6, pET NeRh50”4, 6, pET NeRh50”3, 4, 6,
and pET NeRh50”2, 3, 4, 6 has been successfully cloned in to
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the pET expression vector. In the next part, the expression of
the recombinant proteins were confirmed using specific antibod-
ies (Table 2.1) (Table 3.2), western blotting, Flow cytometry,
and TEM.
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3.6.2 Confirming the presence of constructs by testing
for proteins expression
The principle of identifying blood group specific antibodies in
human sera by using their soluble antigens was successfully es-
tablished for several blood groups such as; ABO, Lewis, P and
I (Spitalnik et al., 1983; Cowles & Blumberg, 1987; Daniels,
2002).
Recombinant proteins were successfully reported to express on
cell membranes or as a soluble form and to exhibit blood-group-
specific antigen activity. In 2007, there was a successful study
by Ridgwell et al., on the activity of the soluble recombinant
proteins with Kell, Duffy and Lutheran blood group antigens.
Moreover, Knops, Cromer, Chido/Rodgers, Indian and JMH
systems were shown to be antigenically active by haemagglu-
tination inhibition (Williams et al., 1981; Telen et al., 1994;
Moulds & Rowe, 1996; Daniels, 2002)
In spite of the clinical significance of the Rh antigens, no studies
have been published describing successful production of recombi-
nant antigens for it, due to the highly conformation-dependent
structure of the human Rh antigens which make it is difficult
to construct the recombinant Rh antigen for the Rh protein in
vitro.
The recombinant RhD may be helpful to further investigate the
molecular basis and function of human RhD protein and could
be applicable for screening anti-D in patient serum. It may also
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form the technical platform to express all Rh system antigens
including uncommon variants to be capable of detecting these
antibodies in patient serum.
Based on the successful result of SDM work on expressing the
recombinant RhCE in the K562 cell line, constructing the re-
combinant RHCE gene by replacing the human RhCE external
loops (3, 4, and 6) with the corresponding, human RhD external
loops (3, 4, and 6) sequences to construct a recombinant form of
Rh protein, which has a backbone of RhCE and external loops
from human RhD by Liu et al., (1999 a, b) we have chosen the
external loops (3, 4, and 6) of the human RhD protein to study.
Furthermore, choosing the E. coli bacterial membrane to be
the host of this experiment is because of the ease to grow it in
the laboratory. Additionally, the topology similarities between
the 12 membrane domains of the N. europaea Rh50 like protein
(Figure 1.13) and the human Rh protein was the main reason
for using this construct in this project to discover new informa-
tion about Rh protein structures, and their antigens, unlike the
E. coli AmtB protein (Figure 1.11), which has only 11 mem-
brane domains. Thus, the NeRh50 like protein could be used as
a template to express human Rh epitopes on the extracellular
surface of E. coli. Rather than express the hybrid constructs
in N. europaea they were expressed in E. coli for ease of use
(Cherif-Zahar et al., 2007).
In this study NeRh50 was used as a backbone combined with
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human RHD external loops to create recombinant constructs
in order to produce D-epitopes. This is a a fundamental dif-
ference compared to the work of Liu et al., (1999). Hence by
using NeRh50 rather than RhCE as in Liu et al., (1999), we
can determine how the recombinant protein gives rise to the D
epitopes. The assembly and expression of the NeRh50 protein
on the membrane does not require RHAG.
Furthermore, Liu et al., (1999) work was based on expressing the
recombinant construct RHCE-RHD in the K562 cell line, which
is a human myelogenous leukaemia cell line, so, in that study
they worked with cell lines naturally expressing RhAG and that
is another fundamental change because this study is based on
using E. coli, which have AmtB protein instead, to detect the
expression of the recombinant gene NeRH50”RHD using spe-
cific Anti-D (Table 2.1). The advantage of using prokaryotic
system (E. coli) over the eukaryotic system (K562 cell line) is,
to express D-epitopes in system lacking of RHAG inorder to
study the chance of being able to produce D-epitopes without
the presence of this gene.
3.6.2.1 Western blot results
As part of this project, a custom antibody against human RhD
external loop 6 (2A4/ 5G9) was produced from Dundee Cell
Products. Moreover, confirming the presence of the recombi-
nant gene NeRh50”human RhD external loop 6 by detecting
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the RhD external loop 6 protein expression on the E. coli mem-
brane in; pETNeRh50”6, pET NeRh50”4, 6, pET NeRh50”3, 4,
6, and pET NeRh50”2, 3, 4, 6, constructs using the western-
blot technique (Figure 3.31) (Figure 3.32).
Ghost membrane Rh+, Rh- phenotypes, which were used as a
control samples, they were not showing a direct reactivity with
the peptides monoclonal anti-D loop 6 and to cover this issue,
these samples were treated with the bromelain (Avent et al.,
1992) before run on the acrylamide gel to digest the external
loop 6 and open it, which be easier to detect (see 2.2.2.4.7.2).
Moreover, (2A4 and 5G9) anti-D which are able to detect the
human RhD external loop 6, was expressed in all recombinant
constructs as all constructs has the human RhD external loop 6
(Figure 3.31) (Figure 3.32).
Ghost membrane Rh+ phenotype was showed a faint single band
around 32 kDa, while all recombinant constructs showed a sin-
gle band around 37 kDa. Ghost membrane Rh- phenotype and
NeRh50 wild type showed no band as expected due to the ab-
sence of the human RhD external loop 6.
Different band intensity between 2A4 and 5G9 shows that,
2A4 is a more effective clone of this anti-RhD loop 6 antibody
than 5G9 and it is able to detect a higher expression of the
human RhD external loop 6 in the ghost membrane Rh+ phe-
notype and in all constructs.
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Anti-D loop 4 (2.2B9) was used to confirm the presence of the
human RhD external fourth loop in recombinant constructs and
control samples. It shows double bands with the positive sam-
ples the upper band is a background band and it does not re-
lated to RhD. The lower band, is the band of interest has a
size approximately 32 kDa in ghost membrane Rh+ phenotype
and the RhD30 wild type samples, while it has a size of 36 kDa
in constructs samples (Figure 3.30). Furthermore, ghost mem-
brane Rh- phenotype showed a single band around 34 kDa, while
NeRh50 wild type and NeRh50”6 showed a single band close to
37 kDa, which represent the background bands due to the ab-
sence of human RhD external loop 4.
NeRh50 wild type is a glycoprotein, which contains an oligosac-
charide chain attached to the external loop 1 and this give it
a higher molecular weight than human RhD, which does not
contain the carbohydrate chain. The difference in protein struc-
ture between ghost membrane sample with an Rh- phenotype
vs NeRh50 wild type leads to the variation seen in band size
when the 2.2B9 antibody was used for Western blotting. The
difference between the 37 kDa band size for NeRh50 wild type
and 34 kDa band size for the Rh- ghost membrane sample is due
to the additional oligosaccharide chain in the former protein.
Anti-D loop 3, 4, 6 (MS-26) (Figure 3.34), shows no reaction
with all constructs or controls in the western blot technique. The
lack of an obvious band reflects that this MAb may recognise
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a conformation- dependent antibody, not detectable by western
blotting.
Anti-NeRh50 (1918, and 1917) (figure 3.35) (figure 3.36) both of
these antibodies gave negative results with human ghost mem-
brane Rh+, Rh- phenotyped samples due to the absence of the
NeRh50 protein, while they show a clear band around 37 kDa for
the NeRh50 wild type sample as well as in NeRh50”6, NeRh50”4,
6, NeRh50”3, 4, 6, and NeRh50”2, 3, 4, 6. These results clearly
demonstrate that the E. coli pET expression system works well
and all constructs are successfully integrated into the E. coli in-
ner membrane.
The variation between the positive band size between the hu-
man ghost membrane Rh+ phenotype sample (32 kDa) and all
constructs (37 kDa) is due to the difference in protein struc-
ture backbone of the construct NeRh50 protein, a glycoprotein,
which contains an oligosaccharide chain attached to the external
loop 1 and this give it a higher molecular weight than human
RhD, which does not contain the carbohydrate chain.
Furthermore, human RhD30 wild type and NeRh50 wild type
samples were used as controls to detect NeRh50 external loop
1/ C-terminus and human RhD external loops.
According to Roudkenar et al., (2008) they successfully detected
the expression of cord RhD with Human anti-Rh (D) polyclonal
antibody (Immunodiagnostika, USA) around 35 kDa, which con-
firm the band size was shown with anti-D antibodies against
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human RhD external loops 4 and 6 in the ghost membrane Rh+
phenotype and in four constructs.
According to Cherif-Zahar et al., (1991) they have His- tagged
the C-terminus of NeRh50 protein to able to detect NeRh50 ex-
pression in the E. coli membrane with anti-His tag antibody by
western blot at 37 kDa.
According to Apoil et al., (1997) they were successfully blot the
RhD protein with 33 kDa band size by using LOR15C9 Mab,
which is an important antibody to distinguish between RhD and
RhCE proteins.
3.6.2.2 Flow cytometry results
In 1999 a, Liu et al., used monoclonal anti-D, anti-E, and anti-c
antibodies, which were available through the Third International
Workshop against human red blood cells and related antigens.
Moreover, they successfully constructed a hybrid recombinant
protein based on RhCE as a backbone and replaced the third,
fourth, and sixth external loops with the corresponding exter-
nal loops from the human RhD. Then, were able to screen the
expression of all constructs with monoclonal anti-D, anti-E, and
anti-c antibodies by the flow cytometry technique on the K562
cell line.
In this study, sample preparation and staining protocol took a
long time and several repeat trials to optimize the correct mod-
ified method. Additionally, all construct samples were lysozyme
219
treated prior to staining them with the primary anti-D or anti-
NeRh50 antibodies (see 2.2.2.4.9.2) in order to make some holes
in the E. coli membrane, and this also required optimisation of
the centrifugation time (Soriano et al., 2002) moreover, assess
detecting the expression of the recombinant protein, which lo-
cated on the inner E. coli membrane.
Table 3.2 shows monoclonal anti-D antibodies were used to de-
tect the expression of human RhD external loops (2, 3, 4, and
6). Moreover, anti-NeRh50 antibody were used to detect the
expression of NeRh50 external loop 1 and C-terminus.
In this study, all constructs show variation in FITC fluorescence
values among different antibodies. The disadvantage of using
NeRh50 over human RhCE as a back bone in Liu et al., 1999,
is the difference in the expression pattern, it shows a higher ex-
pression pattern with using the human RhCE backbone.
NeRh50”3, 4, 6 construct (Table 4.3) showed the lowest expres-
sion with anti-D while it shows a moderate mean FITC fluores-
cence value with the anti-NeRh50 comparing to control samples.
Anti-D BRAD-3, which is specific for EpD 13 shows the high-
est value with RhD30 wild type control. Furthermore, in Liu et
al., 1999 BIRMA-D6 gave the highest mean value with recombi-
nant RhCE protein with human RhD fourth and sixth external
loop, while in this study BIRMA-D6 show the highest value with
NeRh50”2, 3, 4, 6 construct.
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3.6.2.3 TEM results
Thin layer of E. coli cells containing one of four constructs;
pETNeRh50”6, pET NeRh50”4, 6, pET NeRh50”3, 4, 6, and
pET NeRh50”2, 3, 4, 6, were used in immuno-gold staining tech-
nique. The human RhD external loop 4 and loop 6 expression
were detected by anti-D (Table 3.2) 2.2B9 (Figure 3.42)/ 2A4
(Figure 3.43). There was a considerable change in the expression
level between the antibodies used (Table 3.2); NeRh50”6 con-
struct showed no binding and no gold trace with anti-D 2.2B9
(Figure 3.42), due to the absence of human RhD external loop
4 in this construct.
Moreover, all constructs showed high expression level with anti-
D loop 6 2A4 (Figure 3.43), as was expected because loop 6 was
present in all constructs, similar to the expression on the sample
was stained with anti. E. coli (positive control) and higher than
the expression of the samples were stained with anti-D 2.2B9.
Furthermore, all constructs showed intermediate expression level
anti-NeRh50 1918 (Figure 3.44) comparing to the positive con-
trol and to other anti-D antibodies.
Different dot size and intensity in images taken by TEM was due
to the variation of the protein concentration in each sample: big
and dark gold trace shows higher protein concentration.
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To summarize this chapter, the recombinant NeRh50”RHD
gene was successfully cloned and expressed. The expected size
of recombinant NeRh50”human RhD external loops protein was
detected and confirmed by western blot.
Flow cytometry and TEM imaging confirmed the existence of
the human RhD external loops in the recombinant protein Ne
Rh50”human RhD external loops. RhD antibody reacted with






Early in 1901, blood groups were discovered (Landsteiner, 1901;
Landsteiner & Levine, 1927; Anstee et al ., 2010; Avent, 2016),
and there have been considerable number of studies published in
this field, reflecting the importance of this science in Immuno-
haematology. The difference in blood group phenotype remains
a significant question and it is still attracting many researchers
to study and discover more about different blood groups and
their relationship to transfusion and /or transplantation rejec-
tion.
The principle of using the blood group antigens to identify blood
group antibodies in human serum, is well established, although,
this is limited by the rare occurrence of some blood group anti-
gens. Blood group antigens can be replaced by recombinant
forms replacing the requirement for the use of human cells, ad-
ditionally it offers the ability to generate a rare blood group
antigens. Furthermore, this has been achieved for many blood
group systems: recombinant antigens were successfully produced
for MNS blood group system by constructing a recombinant
glycophorin A (GPA) carrying blood group M and N antigens,
which were able to detect anti-GPA antibodies (Blackall et al.,
1992; Blackall et al.,1994). In 2000, Yazdanbakhsh et al., were
able to express Knops, Kell and Duffy blood group antigens in
a mouse erythroleukaemic cell line (MEL) and used them to
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detect and identify human antibodies. In 2002, Jaskiewicz et
al., succeeded in expressing a recombinant Gerbich blood group
antigen on the surface of wild type Chinese hamster ovary cells
(CHO) and a monkey kidney cell line (COS 7) by using anti-
GPC murine monoclonal antibodies.
Furthermore, Ridgwell et al., (2007) looked at the activity of
soluble recombinant proteins with Kell, Duffy and Lutheran
blood group antigens and concluded that the soluble recombi-
nant proteins can mimic the blood group antigens, and these
proteins can react with the human-specific antibodies. More-
over, these kinds of proteins can be used to develop solid-phase,
high-throughput blood group antibody screening and identifi-
cation platforms. The RH blood group system has a vital im-
portance as the second most important blood group system in
transfusion medicine (Levine et al., 1941; Avent, 2018). Anti-
Rh system antibodies are major causes of transfusion reactions
and haemolytic disease of the fetus and newborn (Landsteiner &
Wiener, 1941; Race & Sanger, 1975; Mollison et al., 1987; Van
Kim et al., 2006). The rapid detection of anti-Rh is of significant
clinical relevance and is only performed using appropriate phe-
notyped red cells (Chang & Siegel, 1998). This has significant
drawbacks in that certain Rh antigens are very rare and require
the storage of a diminishing supply of red cells that must be
stored in liquid nitrogen and are scarcely available (Chaudhari,
2007; Avent, 2018).
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In spite of the clinical significant RH antigens and the consider-
able knowledge of their proteins (Levine et al., 1941; Matassi et
al., 1999; Avent et al., 2006; Van Kim et al., 2006; Avent et al.,
2012; Mustafa et al., 2014) efforts to produce recombinant Rh
antigens have to date been unsuccessful in prokaryotes (Huang
& Peng, 2005), due to the highly conformation-dependent struc-
ture of the human Rh protein which makes it difficult to con-
struct.
Liu et al., (1999 b), showed successful production of a human re-
combinant gene RHCE-RHD and a successful expression in the
K562 cell line, a eukaryotic tissue culture system, taking into
consideration the homology between RHCE and RHD, which
are both are located on the same locus on chromosome 1p34-
1p36 (Cherif-Zahar et al., 1991; Matassi et al., 1999). Both
genes share comparable exon/intron organisation (Matassi et
al., 1999; Westhoff, 2004) (Figure 1.3). This similarity raised the
probability of these recombinant constructs to successfully pro-
duce human D-epitopes, moreover, they detected the expression
of human recombinant gene RHCE-RHD on eukaryotic system
which is able to express RhAG, which is not the case with using
a prokaryotic expression system (Huang & Peng, 2005) and as
previously mentioned that the expression of RhD/RHCE anti-
gens is depend on the presence of RHAG (Chérif-Zahar et al.,
1996; Avent et al., 2000).
However, the knowledge about Rh proteins would transform the
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ability to test for particular rare Rh antigens (of which there
are 50 known) (Conroy et al., 2005). Furthermore, a suitable
expression system would yield significant new information re-
garding the topology of Rh epitopes (Mollison et al., 1987; Eyers
et al., 1994). Recombinant Rh antigens could be used to rapidly
and reliably detect anti-Rh in serum, and mono-specific anti-
gens would greatly help resolve complex mixtures of antibodies
in multi-transfused patients.
Therefore, the aim of the project was to construct a hybrid N.
europaea-human RHD gene that is capable of being transcribed,
translated and correctly inserted into the E. coli membrane, in
order to develop novel diagnostic assays able to detect Rh anti-
gens. N. europaea possesses an Rh50 protein which is similar
in the transmembrane domain structure to human RhD and
RhCE, with twelve transmembrane domains. Different regions
of the human RhD and RhCE proteins were utilised to create
these hybrids.
The topology similarities in membrane domains between the 12
transmembrane domains of the N. europaea Rh50 like protein
(Figure 1.13) and the human Rh protein was the main reason
of using this type of bacteria in this project to discover new
information about Rh protein structures, and their antigens,
unlike the E. coli AmtB protein (Figure 1.11), which only has
11 membrane domains. Thus the NeRh50 like protein was used
as a backbone for the human Rh epitopes as NeRh50 can be
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expressed in E. coli (Cherif-Zahar et al., 2007).
Furthermore, the objective of this research was to use the NeRh50
human RhD external loops protein as a template to express hu-
man RhD epitopes on the bacterial membrane. Coupled with
considerable knowledge regarding the predicted molecular topol-
ogy of Rh antigen epitopes as defined by site directed mutagen-
esis (SDM) (Liu et al., 1999 b), recombinant Ne-human Rh pro-
teins may provide a suitable alternative to produce vast amounts
of recombinant Rh antigens in a bacterial system.
Based on the successful result of SDM work in constructing the
recombinant RHCE gene by Liu et al., 1999 b, we chose the
external loops (6, 4, and 3) of the human RhD protein to study.
Loop 6 was chosen to start with because of its location between
two highly conserved transmembrane domains (11-12), which
increased the probability of this sequence being expressed suc-
cessfully by N. europaea. Following working with loop 6 , loops
2, 3, and 4 were also chosen.
Using recombinant antigens to detect the anti-D in patient serum
will be a useful tool in cases such as, pregnant women carrying
an RhD positive fetus, in multi-transfused patient, in individu-
als with partial D and or weak D.
Moreover, it possible to follow the same method and construct
a hybrids mimicking partial D in order to accurately phenotype
individuals carrying variant antibodies and hence reduce mis-
matching. Although the importance of this approach, there are
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some limitations such as the possibility of the carbohydrate parts
of E. coli membrane could copy human A/ B antigens, which can
show some false positive results. This limitation can be solved
by using the L-form bacteria (Kujau et al., 1998; Rippmann et
al., 1998; Errington, 2017). Moreover, other limitation is hav-
ing a variation in the expression pattern of different batches by
using flow-cytometry.
4.2 Expression of D-epitope in E. coli
E. coli was used as the expression system due to the simplic-
ity of using E. coli in the laboratory and it is widely used as a
model and host organism in biotechnology and microbiology,
especially when working with recombinant DNA (Lee, 1996;
Makrides 1996).
In this study, the idea was that the bacteria express just one
Rh-D antigen, which has many epitopes, although bacterial car-
bohydrate structures may mimic red cell antigens. Thus, the
need of having recombinant antigen was developed in this field
to cover these problems.
The recombinant NeRH50”RHD gene with different human RhD
external loops (2, 3, 4, 6) to create: NeRh50”6, NeRh50”4, 6,
NeRh50”3, 4, 6, and NeRh50”2, 3, 4, 6, were successfully cloned
in to the pET expression vector and D epitope was successfully
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expressed in E. coli. Western blotting, flow cytometry analysis,
and TEM techniques were used to determine the expression of
human D-epitopes in the E. coli membrane by using anti-D and
anti-NeRh50 antibodies (Table 2.1).
The expected size of recombinant NeRh50”human RhD external
loops protein was 32-37 kDa. According to some studies on hu-
man RhD, they were able to detect it by western blotting at 30-
35 kDa using monoclonal anti-D (Moore et al., 1982; Gahmberg,
1982, 1983). That concludes, D-epitopes in the recombinant pro-
tein have been successfully detected and confirmed by western
blotting by use the anti-D in this study (Figure 3.30 - 3.36).
The expected size range of recombinant NeRh50”human RhD
protein was higher than 30-35 kDa, which is the range of human
D-epitope. This was due to the backbone of the recombinant
protein used in this study being NeRh50 wild type is a glyco-
protein, which contains an oligosaccharide chain attached to the
external loop 1 and this gives it a higher molecular weight than
human RhD, which does not contain the carbohydrate chain.
Different FITC- Fluorescence flow cytometry mean values anal-
ysis, and TEM imaging confirmed the existence of the human
RhD external loops in the recombinant protein (NeRh50”human
RhD external loops). RhD antibody reacted with recombinant
NeRh50”RhD antigen as well as with RhD30 wild type, con-
firming the presence of the D-epitopes in the recombinant pro-
tein. Furthermore, a specific antibody raised against the ex-
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ternal loop1 and C-terminus peptides of NeRh50 protein was
ordered from Dundee Cell Product. This antibody was used to
confirm the existence of the NeRh50 protein in E. coli.
This project has a significantly advanced from the Liu et al.,
1999a and b studies. In their study they used the human RHCE
as a backbone, while in this study NeRH50 was used to be the
backbone of the recombinant construct. Moreover, this study
showed successful detection of D-epitopes from the recombinant
protein NeRh50”human RhD external loops, which proves that
the recombinant protein expresses D epitopes even though only
the second, third, fourth, and sixth human RhD external do-
mains have been added to the NeRh50 backbone.
RhD was successfully expressed in K562 cell line (Yan et al.,
2005) moreover, recombinants RHCE-RHD were expressed in
K562 cell line (Liu et al., 1999). The K562 cell line is a eukary-
ote expression system and dependent on the presence of RhAG.
Although the prokaryotic expression system represented in E.
coli does not require the presence of RhAG, it successfully ex-
pressed D-epitopes from the recombinant NeRh50”human RhD
external loops.
Finally, so far, no study has been published describing a success-
ful expression of a recombinant RhD in a bacterial system and
this project seems to be the first one. Furthermore, the anti-
genicity of the recombinant protein NeRh50”human RhD ex-
ternal loops was confirmed by western blotting, flow cytometry
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analysis and TEM by using anti-D and anti-NeRh50 antibodies.
Moreover, this study proved some points; firstly, D-epitope ex-
pression does not require the presence of RhAG and the external
predicted domains on the RhD protein can alone be responsible
for expression. Secondly, using the correct expression system,
Rh antigens can be expressed. A false positive and/or a false
negative reaction could be seen from using a recombinant anti-
gens with human sera and for that many trials and modification
should be required.
Moreover, using a recombinant of the bacterial membrane do-
mains coupled with humanized extracellular regions will help
to discover new features about RhD protein and to investigate
the molecular basis of RhD protein also to discover the main
function of this protein.
4.3 Conclusions
In this project different techniques, western blots, flow cytom-
etry and transmission electron microscopy have been used to
detect expression of recombinant constructs of NeRh50”human
RhD external loops in the E. coli inner membrane combined
with the using of different antibodies (Table 3.2 ).
2.2B9 which is a mAb used to detect the expression of human
RhD external loop 4, has been used in all techniques and it
shows negative results with the recombinant NeRh50”6 as ex-
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pected, as this construct is missing the human 4 th external loop.
Moreover, this mAb showed positive results with the other re-
combinant constructs.
2A4 is a mAb used to detect the expression of human RhD ex-
ternal loop 6 showed positive results with all constructs in three
techniques. Moreover, it shows the highest number of black
dots comparing to other antibodies with all constructs. MS26
is a mAb used to detect the expression of human RhD external
loop 3, 4, 6. Although it was not able to detect any expression
in either constructs or control samples by western blots but it
was showed different expression pattern with flow cytometry.
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4.4 Future Work
Firstly, the sequence of the human RhD external loops needs to
be confirmed by designing new primer sets and resequencing all
constructs using Sanger sequencing or NGS.
Secondly, it would be valuable to generate a custom antibody
against human RhD second external loop. There have been no
studies working with this loop before and the antibody would
help to detect the second loop and distinguish between the re-
combinant constructs; NeRh50”6, NeRh50”4, 6, NeRh50”3, 4,
6, and NeRh50”2, 3, 4, 6 .
Thirdly, grow a stable L-form E. coli cell strains, which are a
wall-less, or wall deficient cells (Kujau et al., 1998; Rippmann
et al., 1998; Errington, 2017) to use as an expression system for
the recombinant gene (NeRh50”RhD) and that is because Rh
antigens are expressed on the E.coli inner membrane, and thus
any recombinant antigen system would need to remove E. coli
external membrane.
Knocking down the AmtB gene in the L-form E. coli and put the
recombinant construct and try to grow them with the expression
from the recombinant protein, thus will able to investigate more
about the RhD function.
There are over 100 monoclonal anti-D and some of them are
commercially available. Some of them have been used in this
study (Table 2.1) to detect the human D-antigens and so, more
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anti-D need to be used to screen all colonies to confirm the pres-
ence of D-epitopes in each construct. Furthermore, LOR-15C9
human mAbs anti-D (Zhu et al., 1999), which is a loop 6 depen-
dent Ab and can distinguish between RhD and RhCE, could be
used to confirm if the RhD and RhCE proteins are expressed
successfully on the E. coli membrane. Furthermore, wild type
RhD30 clone would be used as a reference in the expression pat-
tern because this clone should express all D-epitopes.
After the successful work in expressing recombinant Rh antigens
in this project, which were confirmed with Western blotting, flow
cytometry analysis, and TEM techniques; it extends the possi-
bility of having more mutant Rh clones by using CE-epitopes
and try to express Rh (C, c, E, e) antigens in prokaryotic sys-
tem, using anti-E and anti-C antibodies. Moreover, testing these
recombinants in human sera will be one of the most practical
procedures to investigate the efficiency of these recombinants.
Finally, enzyme-linked immunoassays (ELISA) technique could
be used to assess the antigenicity of the expressed recombinant
protein. Moreover, make it possible to detect anti-D in patient
serum by immobilized E. coli membrane, which contain Rh anti-
gens on a solid surface, then add the patient serum to detect
their Rh antibodies. The most important element of the detec-
tion strategy is a highly specific antibody-antigen interaction.
Recently, there are progression and improvement in the genetic
tools that lead to more understanding of the E. coli organism,
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which leads to raise the importance of using E. coli as expression
system of complex eukaryotic proteins. Moreover, it increases
the ability to express and purify the desired recombinant pro-
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Sanger sequencing data with electropherogram of all constructs
cDNAs: NeRh50”6, NeRh50”4, 6, NeRh50”3, 4, 6, and NeRh50”2,
3, 4, 6 were aligned by CLC Genomics Workbench 12.0 pro-
gramme against: F5 forward primer/ R5 reverse primer which
























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Sanger sequencing data with electropherogram of all constructs
cDNAs: NeRh50”6, NeRh50”4, 6, NeRh50”3, 4, 6, and NeRh50”2,
3, 4, 6 were aligned by CLC Genomics Workbench 12.0 pro-
gramme against: F6 forward primer/ R6 reverse primer which
























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Sanger sequencing data with electropherogram of all constructs
cDNAs: NeRh50”6, NeRh50”4, 6, NeRh50”3, 4, 6, and NeRh50”2,
3, 4, 6 were aligned by CLC Genomics Workbench 12.0 pro-
gramme against: F7 forward primer/ R7 reverse primer which
cover the sequence in the pET expression vector after the inser-
tion.
316
1
G
G
G
G
G
G
C
A
A
A
T
G
G
C
T
G
C
T
G
C
-
C
C
G
C
T
G
A
G
C
A
A
T
A
A
C
T
-
-
-
-
-
-
-
-
-
A
G
C
A
T
A
A
-
-
C
C
C
C
T
T
G
G
G
G
C
C
T
C
T
A
A
A
C
G
G
G
T
C
T
G
G
G
G
A
G
C
A
C
C
C
C
G
T
C
C
T
G
T
G
G
A
T
A
T
C
C
G
G
A
T
A
T
A
G
T
T
C
C
T
C
C
T
T
T
C
A
G
C
A
A
A
A
A
A
C
C
C
C
T
C
A
A
G
A
C
C
C
G
T
T
T
A
G
A
G
G
C
C
C
T
G
G
G
G
G
C
A
A
A
T
G
G
-
T
G
C
T
G
C
A
C
C
G
C
T
G
A
G
C
A
A
T
A
A
C
T
-
-
-
-
-
-
-
-
-
A
G
C
A
T
A
A
-
-
C
C
C
C
T
T
G
G
G
G
C
C
T
C
T
A
A
A
C
G
G
G
T
C
T
G
G
G
G
G
G
C
A
A
A
T
G
G
C
T
G
C
T
G
C
A
C
C
G
C
T
G
A
G
C
A
A
T
A
A
C
T
-
-
-
-
-
-
-
-
-
A
G
C
A
T
A
A
-
-
C
C
C
C
T
T
G
G
G
G
C
C
T
C
T
A
A
A
C
G
G
G
T
C
T
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
G
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
T
G
A
G
G
G
G
T
T
T
T
-
-
-
-
-
-
-
-
T
T
G
C
T
G
A
A
A
G
G
A
G
G
A
A
C
T
A
-
-
-
-
-
-
-
-
-
-
-
-
-
-
T
A
T
C
C
G
G
A
T
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
A
T
C
C
C
A
A
G
G
G
G
T
T
A
T
G
C
T
A
G
T
T
A
T
T
G
C
T
C
A
G
C
G
G
T
G
G
C
A
G
C
A
G
C
C
A
A
C
T
C
A
G
C
T
T
C
C
T
T
T
C
G
G
G
C
T
T
T
G
T
T
A
G
C
A
G
C
C
G
G
A
T
C
C
T
G
A
G
G
G
G
T
T
T
T
-
-
-
-
-
-
-
-
T
T
G
C
T
G
A
A
A
G
G
A
G
G
A
A
C
T
A
-
-
-
-
-
-
-
-
-
-
-
-
-
-
T
A
T
C
C
G
G
A
T
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
A
T
C
C
T
G
A
G
G
G
G
T
T
T
T
-
-
-
-
-
-
-
-
T
T
G
C
T
G
A
A
A
G
G
A
G
G
A
A
C
T
A
-
-
-
-
-
-
-
-
-
-
-
-
-
-
T
A
T
C
C
G
G
A
T
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
A
T
C
C
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
A
C
A
G
G
A
C
G
G
G
T
G
T
G
G
T
C
-
-
-
-
-
G
C
C
A
T
G
A
T
C
G
C
G
T
A
G
T
C
G
A
T
A
G
T
G
G
C
T
C
C
A
A
G
T
A
G
C
G
A
A
G
C
G
A
G
-
-
C
A
G
G
A
C
T
G
G
G
C
G
G
C
G
A
C
C
C
A
T
T
T
G
C
T
G
T
C
C
A
C
C
A
G
T
C
A
T
G
C
T
A
G
C
C
A
T
A
T
G
T
A
T
A
T
C
T
C
C
T
T
C
T
T
A
A
A
G
T
T
A
A
A
C
A
A
A
A
T
T
A
T
T
T
C
T
A
G
A
G
G
A
C
A
G
G
A
C
G
G
G
T
G
T
G
G
T
C
-
-
-
-
-
G
C
C
A
T
G
A
T
C
G
C
G
T
A
G
T
C
G
A
T
A
G
T
G
G
C
T
C
C
A
A
G
T
A
G
C
G
A
A
G
C
G
A
G
-
-
C
A
G
G
A
C
T
G
G
G
C
G
A
C
A
G
G
A
C
G
G
G
T
G
T
G
G
T
C
-
-
-
-
-
G
C
C
A
T
G
A
T
C
G
C
G
T
A
G
T
C
G
A
T
A
G
T
G
G
C
T
C
C
A
A
G
T
A
G
C
G
A
A
G
C
G
A
G
-
-
C
A
G
G
A
C
T
G
G
G
C
G
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
317
2
G
C
G
G
C
C
A
A
A
G
C
G
G
T
C
G
G
-
-
-
A
C
A
G
T
G
C
T
C
C
G
A
G
A
A
C
G
G
G
T
G
C
G
C
-
-
-
A
T
A
G
A
A
A
T
T
G
C
A
-
-
-
-
T
C
A
A
C
G
C
-
-
-
A
T
A
T
A
G
C
G
A
A
A
C
C
G
T
T
G
T
G
G
T
C
T
C
C
C
T
A
T
A
G
T
G
A
G
T
C
G
T
-
A
T
T
A
A
T
T
T
C
G
C
G
G
G
A
T
C
G
A
G
A
T
C
T
C
G
A
T
C
C
T
C
T
A
C
G
C
C
G
G
A
C
G
C
A
T
C
G
C
G
G
C
C
A
A
A
G
C
G
G
T
C
G
G
-
-
-
A
C
A
G
T
G
C
T
C
C
G
A
G
A
A
C
G
G
G
T
G
C
G
C
-
-
-
A
T
A
G
A
A
A
T
T
G
C
A
-
-
-
-
T
C
A
A
C
G
C
-
-
-
A
T
A
T
A
G
C
G
C
G
G
C
C
A
A
A
G
C
G
G
T
C
G
G
-
-
-
A
C
A
G
T
G
C
T
C
C
G
A
G
A
A
C
G
G
G
T
G
C
G
C
-
-
-
A
T
A
G
A
A
A
T
T
G
C
A
-
-
-
-
T
C
A
A
C
G
C
-
-
-
A
T
A
T
A
G
C
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
G
C
T
A
G
C
A
G
C
A
-
-
-
-
-
-
-
C
G
C
C
A
T
A
G
T
G
A
C
T
G
G
C
G
A
T
G
C
T
G
T
C
G
G
A
A
T
G
G
A
C
G
A
T
A
T
C
C
C
G
C
A
A
G
A
G
G
C
C
C
G
G
C
A
G
T
A
C
C
G
G
T
G
G
C
C
G
G
C
A
T
C
A
C
C
G
G
C
G
C
C
A
C
A
G
G
T
G
C
G
G
T
T
G
C
T
G
G
C
G
C
C
T
A
T
A
T
C
G
C
C
G
A
C
A
T
C
A
C
C
G
A
T
G
G
G
G
A
A
G
A
T
C
G
G
G
C
T
C
G
G
C
T
A
G
C
A
G
C
A
-
-
-
-
-
-
-
C
G
C
C
A
T
A
G
T
G
A
C
T
G
G
C
G
A
T
G
C
T
G
T
C
G
G
A
A
T
G
G
A
C
G
A
T
A
T
C
C
C
G
C
A
A
G
A
G
G
C
C
C
G
G
C
A
G
T
A
C
C
G
G
C
T
A
G
C
A
G
C
A
-
-
-
-
-
-
-
C
G
C
C
A
T
A
G
T
G
A
C
T
G
G
C
G
A
T
G
C
T
G
T
C
G
G
A
A
T
G
G
A
C
G
A
T
A
T
C
C
C
G
C
A
A
G
A
G
G
C
C
C
G
G
C
A
G
T
A
C
C
G
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
G
C
A
T
A
A
C
C
A
A
G
C
C
T
A
T
G
C
C
T
A
C
A
G
C
A
T
C
C
A
G
G
G
T
G
-
-
-
A
C
G
G
T
G
C
C
G
A
G
G
A
T
G
A
C
G
A
T
G
A
G
C
G
C
A
T
T
G
T
T
A
G
A
-
-
-
-
-
-
-
C
C
A
C
T
-
T
C
G
G
G
C
T
C
A
T
G
A
G
C
G
C
T
T
G
T
T
T
C
G
G
C
G
T
G
G
G
T
A
T
G
G
T
G
G
C
A
G
G
C
C
C
C
G
T
G
G
C
C
G
G
G
G
G
A
C
T
G
T
T
G
G
G
C
G
C
C
A
T
C
G
C
A
T
A
A
C
C
A
A
G
C
C
T
A
T
G
C
C
T
A
C
A
G
C
A
T
C
C
A
G
G
G
T
G
-
-
-
A
C
G
G
T
G
C
C
G
A
G
G
A
T
G
A
C
G
A
T
G
A
G
C
G
C
A
T
T
G
T
T
A
G
A
-
-
-
-
-
-
-
G
C
A
T
A
A
C
C
A
A
G
C
C
T
A
T
G
C
C
T
A
C
A
G
C
A
T
C
C
A
G
G
G
T
G
-
-
-
A
C
G
G
T
G
C
C
G
A
G
G
A
T
G
A
C
G
A
T
G
A
G
C
G
C
A
T
T
G
T
T
A
G
A
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
318
3
-
-
-
T
T
T
C
A
T
A
C
A
C
G
G
T
G
C
C
T
G
A
C
T
G
C
G
T
T
A
G
C
A
A
T
T
T
A
A
C
T
G
T
G
A
T
A
A
A
C
T
A
C
C
G
C
A
T
T
A
A
A
G
C
T
T
A
T
C
G
A
T
G
A
T
A
A
G
C
T
T
C
C
T
T
G
C
A
T
G
C
A
C
C
A
T
T
C
C
T
T
G
C
G
G
C
G
G
C
G
G
T
G
-
C
T
C
A
A
C
G
G
C
C
T
C
A
A
C
C
T
A
C
T
A
C
T
G
G
G
C
T
G
C
T
T
C
C
T
A
A
T
G
C
A
G
G
A
G
T
-
-
-
T
T
T
C
A
T
A
C
A
C
G
G
T
G
C
C
T
G
A
C
T
G
C
G
T
T
A
G
C
A
A
T
T
T
A
A
C
T
G
T
G
A
T
A
A
A
C
T
A
C
C
G
C
A
T
T
A
A
A
G
C
T
T
A
T
C
G
A
T
G
A
T
A
A
G
C
T
-
-
-
T
T
T
C
A
T
A
C
A
C
G
G
T
G
C
C
T
G
A
C
T
G
C
G
T
T
A
G
C
A
A
T
T
T
A
A
C
T
G
T
G
A
T
A
A
A
C
T
A
C
C
G
C
A
T
T
A
A
A
G
C
T
T
A
T
C
G
A
T
G
A
T
A
A
G
C
T
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
G
T
C
A
A
A
C
A
T
G
A
G
A
A
T
T
C
T
T
A
G
A
A
A
A
A
C
T
C
A
T
C
G
A
G
-
-
C
A
T
C
A
A
A
T
G
A
A
A
C
T
G
C
A
A
T
T
T
-
-
-
-
-
-
-
A
T
T
C
A
T
A
T
C
A
G
G
A
T
T
C
G
C
A
T
A
A
G
G
G
A
G
A
G
C
G
T
C
G
A
C
C
G
A
T
G
C
C
C
T
T
G
A
G
A
G
C
C
T
T
C
A
A
C
C
C
A
G
T
C
A
G
C
T
C
C
T
T
C
C
G
G
T
G
G
G
C
G
C
G
G
G
G
C
A
T
G
A
C
T
G
T
C
A
A
A
C
A
T
G
A
G
A
A
T
T
C
T
T
A
G
A
A
A
A
A
C
T
C
A
T
C
G
A
G
-
-
C
A
T
C
A
A
A
T
G
A
A
A
C
T
G
C
A
A
T
T
T
-
-
-
-
-
-
-
A
T
T
C
A
T
A
T
C
A
G
G
A
T
T
G
T
C
A
A
A
C
A
T
G
A
G
A
A
T
T
C
T
T
A
G
A
A
A
A
A
C
T
C
A
T
C
G
A
G
-
-
C
A
T
C
A
A
A
T
G
A
A
A
C
T
G
C
A
A
T
T
T
-
-
-
-
-
-
-
A
T
T
C
A
T
A
T
C
A
G
G
A
T
T
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
A
T
C
A
A
T
A
C
C
A
T
A
T
T
T
T
T
G
A
A
A
A
A
G
C
C
G
T
T
T
C
T
G
T
A
A
T
G
A
A
G
G
A
G
A
A
A
A
C
T
C
A
C
C
G
A
G
G
C
A
G
T
T
C
C
A
T
A
G
G
A
T
G
G
C
A
A
G
A
T
A
T
C
G
T
C
G
C
C
G
C
A
C
T
T
A
T
G
A
C
T
-
-
G
T
C
T
T
C
T
T
T
A
T
C
A
T
G
C
A
A
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
C
T
C
G
T
A
G
G
A
C
-
-
-
-
A
G
G
T
A
T
C
A
A
T
A
C
C
A
T
A
T
T
T
T
T
G
A
A
A
A
A
G
C
C
G
T
T
T
C
T
G
T
A
A
T
G
A
A
G
G
A
G
A
A
A
A
C
T
C
A
C
C
G
A
G
G
C
A
G
T
T
C
C
A
T
A
G
G
A
T
G
G
C
A
A
G
A
T
A
T
C
A
A
T
A
C
C
A
T
A
T
T
T
T
T
G
A
A
A
A
A
G
C
C
G
T
T
T
C
T
G
T
A
A
T
G
A
A
G
G
A
G
A
A
A
A
C
T
C
A
C
C
G
A
G
G
C
A
G
T
T
C
C
A
T
A
G
G
A
T
G
G
C
A
A
G
A
T
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
c
c
t
t
c
c
c
c
a
t
t
a
t
g
a
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
C
A
A
C
A
A
C
A
T
G
A
A
T
G
G
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
319
4
C
C
T
G
G
T
A
T
C
G
G
T
C
T
G
C
G
A
T
T
C
C
G
A
C
T
C
G
T
C
C
A
A
C
A
T
C
A
A
T
A
C
A
A
C
C
T
A
T
T
A
A
T
T
T
C
C
C
C
T
C
G
T
C
A
A
A
A
A
T
A
A
G
G
T
T
A
T
C
A
G
C
C
G
G
C
A
G
C
G
C
T
C
T
G
G
G
-
-
T
C
A
T
T
T
T
C
G
G
C
G
A
G
G
A
C
C
G
C
T
-
-
-
-
-
-
-
-
T
T
C
G
C
T
G
G
A
G
C
G
C
G
A
C
G
A
T
G
A
T
C
G
G
C
C
T
G
T
C
G
C
C
T
G
G
T
A
T
C
G
G
T
C
T
G
C
G
A
T
T
C
C
G
A
C
T
C
G
T
C
C
A
A
C
A
T
C
A
A
T
A
C
A
A
C
C
T
A
T
T
A
A
T
T
T
C
C
C
C
T
C
G
T
C
A
A
A
A
A
T
A
A
G
G
T
T
A
T
C
A
C
C
T
G
G
T
A
T
C
G
G
T
C
T
G
C
G
A
T
T
C
C
G
A
C
T
C
G
T
C
C
A
A
C
A
T
C
A
A
T
A
C
A
A
C
C
T
A
T
T
A
A
T
T
T
C
C
C
C
T
C
G
T
C
A
A
A
A
A
T
A
A
G
G
T
T
A
T
C
A
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
A
G
T
G
A
G
A
A
A
T
C
A
C
C
A
T
G
A
G
T
G
A
C
G
A
C
T
G
A
A
T
C
C
G
G
T
G
A
G
A
A
-
T
G
G
C
A
A
A
A
G
C
T
T
A
T
G
C
A
T
T
T
C
T
T
T
C
C
-
-
-
-
-
-
-
-
A
G
A
C
C
T
T
G
C
G
G
T
A
T
T
-
-
-
-
-
-
-
-
-
-
-
-
-
-
C
G
G
A
A
T
C
T
T
G
C
A
C
G
C
C
C
T
C
G
C
T
C
A
A
G
C
C
T
T
C
G
T
C
A
C
T
G
G
T
C
C
C
G
C
C
A
C
C
A
A
A
C
G
T
A
G
T
G
A
G
A
A
A
T
C
A
C
C
A
T
G
A
G
T
G
A
C
G
A
C
T
G
A
A
T
C
C
G
G
T
G
A
G
A
A
-
T
G
G
C
A
A
A
A
G
C
T
T
A
T
G
C
A
T
T
T
C
T
T
T
C
C
-
-
-
-
-
-
-
-
A
G
A
C
A
G
T
G
A
G
A
A
A
T
C
A
C
C
A
T
G
A
G
T
G
A
C
G
A
C
T
G
A
A
T
C
C
G
G
T
G
A
G
A
A
-
T
G
G
C
A
A
A
A
G
C
T
T
A
T
G
C
A
T
T
T
C
T
T
T
C
C
-
-
-
-
-
-
-
-
A
G
A
C
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
t
t
c
t
t
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
T
C
T
T
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
T
T
G
T
T
C
A
A
C
A
G
G
C
C
A
G
C
C
A
T
T
A
C
G
C
T
C
G
T
C
A
T
C
A
A
A
A
T
C
A
C
T
C
G
C
A
T
C
A
A
C
C
A
A
A
C
C
G
T
T
A
T
T
C
A
T
T
C
G
T
G
A
T
T
G
C
G
C
C
T
T
T
C
G
G
C
G
A
G
A
A
G
C
A
G
G
C
C
A
T
T
A
T
C
G
C
C
G
G
C
A
T
G
G
C
G
G
C
C
G
-
-
-
-
-
A
C
G
C
G
C
T
G
G
G
C
T
A
C
G
T
C
T
T
G
C
T
G
G
C
G
T
T
C
G
C
G
A
C
-
T
T
G
T
T
C
A
A
C
A
G
G
C
C
A
G
C
C
A
T
T
A
C
G
C
T
C
G
T
C
A
T
C
A
A
A
A
T
C
A
C
T
C
G
C
A
T
C
A
A
C
C
A
A
A
C
C
G
T
T
A
T
T
C
A
T
T
C
G
T
G
A
T
T
G
C
G
C
C
T
T
T
G
T
T
C
A
A
C
A
G
G
C
C
A
G
C
C
A
T
T
A
C
G
C
T
C
G
T
C
A
T
C
A
A
A
A
T
C
A
C
T
C
G
C
A
T
C
A
A
C
C
A
A
A
C
C
G
T
T
A
T
T
C
A
T
T
C
G
T
G
A
T
T
G
C
G
C
C
T
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
320
5
G
A
G
C
G
A
G
A
C
G
A
A
A
T
A
-
C
G
C
G
A
T
C
G
C
T
G
T
T
A
A
A
A
G
G
A
C
A
A
T
T
A
C
A
A
A
C
A
G
G
A
A
T
C
G
A
A
T
G
C
A
A
C
C
G
G
C
G
C
A
G
G
A
A
C
A
C
T
G
C
-
-
G
C
G
A
G
G
C
T
G
G
A
T
G
G
C
C
T
T
C
C
C
A
T
T
A
T
G
A
T
T
C
T
T
C
T
C
G
C
T
T
C
C
G
G
C
G
G
C
A
T
C
G
G
G
A
T
G
C
C
C
G
C
G
T
T
G
C
A
G
G
C
A
T
G
C
T
G
T
G
A
G
C
G
A
G
A
C
G
A
A
A
T
A
-
C
G
C
G
A
T
C
G
C
T
G
T
T
A
A
A
A
G
G
A
C
A
A
T
T
A
C
A
A
A
C
A
G
G
A
A
T
C
G
A
A
T
G
C
A
A
C
C
G
G
C
G
C
A
G
G
A
A
C
A
C
T
G
C
G
A
G
C
G
A
G
A
C
G
A
A
A
T
A
-
C
G
C
G
A
T
C
G
C
T
G
T
T
A
A
A
A
G
G
A
C
A
A
T
T
A
C
A
A
A
C
A
G
G
A
A
T
C
G
A
A
T
G
C
A
A
C
C
G
G
C
G
C
A
G
G
A
A
C
A
C
T
G
C
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
C
A
G
C
G
C
A
-
-
T
C
A
A
C
A
A
T
A
T
T
T
T
C
A
C
-
-
C
T
G
A
A
T
C
A
G
G
A
T
A
T
T
C
T
-
-
-
T
C
T
A
A
A
C
C
T
G
G
A
A
T
G
C
T
G
T
T
T
C
C
C
G
G
G
G
A
T
C
G
C
C
C
A
G
G
C
A
G
G
T
A
G
A
T
G
A
C
G
A
C
A
T
C
A
G
G
A
C
A
G
C
T
T
C
A
G
G
A
T
C
G
T
C
G
C
G
G
T
C
T
A
C
A
G
C
C
T
A
A
T
T
C
A
T
C
T
T
G
G
A
C
G
C
T
G
A
T
C
G
T
C
A
G
C
G
C
A
-
-
T
C
A
A
C
A
-
T
A
T
T
T
T
C
-
C
-
-
C
T
G
A
A
T
C
A
G
G
A
T
A
T
T
C
T
-
-
-
T
C
T
A
T
A
C
C
T
G
G
A
A
T
G
C
T
G
T
T
T
T
C
C
G
G
G
G
A
T
C
G
C
C
A
G
C
G
C
A
-
-
T
C
A
A
C
A
A
T
A
T
T
T
T
C
A
C
-
-
C
T
G
A
A
T
C
A
G
G
A
T
A
T
T
C
T
-
-
-
T
C
T
A
T
A
C
C
T
G
G
A
A
T
G
C
T
G
T
T
T
C
C
C
G
G
G
-
A
T
C
G
C
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
A
G
G
G
G
T
G
A
G
T
A
A
C
C
T
G
C
A
T
C
A
T
C
A
G
A
A
T
A
C
G
G
A
T
A
A
A
T
G
C
T
T
G
A
G
G
T
C
G
A
A
A
A
G
C
T
A
A
A
T
T
C
C
T
C
A
G
C
C
G
T
T
A
A
T
C
T
G
-
-
C
C
G
G
G
-
-
-
-
-
A
T
T
A
T
G
C
C
G
C
T
C
G
G
G
A
A
C
A
T
G
G
A
A
G
G
G
T
G
G
A
G
G
A
T
G
G
A
G
G
C
C
G
C
C
T
A
A
C
T
G
T
T
G
C
C
C
C
C
C
G
T
G
G
C
C
G
G
G
G
A
G
-
G
G
T
G
A
G
T
A
A
C
C
T
G
C
A
T
C
T
C
A
G
G
A
G
T
A
C
G
G
A
T
A
A
A
T
G
C
T
-
G
A
T
G
T
C
G
G
A
A
G
A
G
C
T
A
A
T
T
C
G
T
C
A
G
C
A
G
T
T
A
G
C
T
G
A
C
A
A
G
T
G
G
T
G
A
G
T
A
-
C
C
T
G
C
A
T
C
A
T
C
A
G
G
A
G
T
C
G
G
A
T
A
A
A
T
G
C
T
-
G
A
G
G
T
C
G
A
G
A
A
G
C
A
A
A
A
T
T
C
C
G
C
A
G
C
A
G
T
T
A
G
C
T
G
A
C
A
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
321
6
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
A
T
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
G
A
A
C
G
G
C
C
C
C
A
C
-
-
-
-
T
C
T
C
A
T
T
G
A
A
A
T
C
T
T
G
G
C
A
C
C
T
A
C
T
T
G
C
A
G
T
T
C
A
G
A
A
C
A
T
C
T
G
G
G
G
A
T
G
G
G
T
T
C
-
-
-
-
-
-
T
T
C
A
T
C
G
G
A
A
A
T
C
T
T
G
G
A
A
C
C
T
C
C
T
T
G
C
A
G
T
T
C
A
A
A
A
A
-
-
T
T
G
G
G
G
A
C
G
G
G
T
C
C
A
A
A
A
T
A
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
322
